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1. Overview 
 
Polysubstituted heterocycles belong to the most important organic compounds both in 
view of their mere production quantity and of their economic importance. The methods for 
their synthesis form the bedrock of modern medicinal chemical and pharmaceutical research. 
For instance, N-heterocyclic organic compounds are extensively applied to modify the 
reactivity profile of antitumor compounds. Pyrroles, pyrimidines, indoles, quinolines, and 
purines are the heterocycles known to show interesting cytotoxicity profiles.  
The search for a new drug often begins with the identification of a particular class of 
heterocycles having a potential for the desired biological activity. The second step is the 
functionalization of this class of heterocycle in order to obtain several candidates. The 
synthetic approaches towards polyfunctionalized heterocycles can be crudely divided into two 
categories. The first approach aims at the construction of a heterocyclic core after the 
substituents have been installed and functionalized. As an illustration of this approach, a 
transition-metal catalyzed Biginelli heterocyclization reaction for the synthesis of monastrol,1 
a potentially important chemotherapeutic for cancer, is shown in Scheme 1. 
 
OH
O
EtO
O O
H2N NH2
S
N
H
NH
S
OH
EtO2C+ +
Yb(OTf)3
THF, reflux
95%
1: monastrol
H
 
 
Scheme 1: The modern variant of Biginelli reaction for the synthesis of monastrol (1). 
 
The second approach is based on a preformed heterocycle to which different substituents are 
attached in successive order. This approach is more flexible concerning the choice of the 
substituents and gives an easy access to various analogs. It may include traditional aromatic 
substitution chemistry, directed metalation methods, halogen–metal exchange reactions as 
well as cross-coupling reactions. The methods used should be reliable in terms of reactivity, 
functional tolerance and selectivity. To address these requirements, the organometallic 
                                                 
1
  (a) Dondoni, A.; Massi, A.; Sabbatini, S. Tetrahedron Lett. 2002, 43, 5913. 
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chemistry proved to be an excellent tool with a broad applicability. 2   Over the years, 
organometallic compounds, especially Grignard, copper and zinc reagents, facilitated the 
development of an arsenal of synthetic methods for efficient and selective reactions and have 
found numerous applications in industrial processes. In order to perform efficient C-C and C-
N bond formations in heterocycle chemistry, there is still a need of new organometallic 
methods and reagents, which have to be chemo- and regioselective and as inexpensive and 
environmentally friendly as possible. 
 
                                                 
2
 For general review, see: (a) Knochel, P.; Leuser, H.; Gong, L.-Z.; Perrone, S.; Kneisel, F. F in Handbook of 
Functionalized Organometallics; Knochel, P., Ed.; Wiley-VCH, Weinheim 2005: 251; (b) Knochel, P.; Millot, 
P.; Rodriguez, A. L.; Tucker, C. E. in Organic reactions; Overman, L. E., Ed.; Wiley & Sons Inc., New York, 
2001. 
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2. Direct Preparation and Use of Organomagnesiated Aryl and Heteroaryl 
Compounds 
 
2.1. Introduction 
Since their first preparation in ethereal solution in 1901 by Victor Grignard, 3 
organomagnesium reagents have obtained a key role in organic synthesis.  Their easy 
synthesis, good stability and their excellent reactivity make Grignard reagents one of the most 
powerful tools for carbon-carbon formation used in industry4 and academic laboratories. As 
an example, the Grignard reaction, using phenyl magnesium bromide, is a key step of the 
industrial production of Tamoxifen (2), 5 currently the world's largest selling drug for breast 
cancer (Scheme 2).  
 
O
O
MgBr
THF
O
HO
O
(Z)-Tamoxifen (2)
N
N
N
 
 
Scheme 2: Key step of the total synthesis of the drug Z-Tamoxifen (2) 
 
Furthermore, organomagnesium reagents are also useful reactants for C-N bond formation6 
leading to polyfunctionalized amines, useful for pharmaceutical applications. Finally, 
transmetalations to more chemoselective organometallic species such as zinc, copper,7 or 
titanium, allow additional fine-tuning of their reactivity pattern. 
 
                                                 
3
 Grignard, V. Ann. Chim. 1901, 24, 433. 
4
 Bush, F. R.; De Antonis, D. M. Grignard Reagents- New Developments; Richey, H. G., Jr., Ed.; Wiley, New 
York, 2000, pp.165-183. 
5
 (a) Harper, M. J. K.; Walpole, A. L. Nature 1966, 212, 87; (b) Bedford, G. R.; Richardson, D. N. Nature 1966, 
212,733; for a review of the pharmacology, see: (c) Heel, R. C.; Brogdon, R. N.; Speight, T. M.; Avery, G. S. 
Drugs 1978, 16, 1; (d) Harper, M. J. K.; Richardson, D. N.; Walpole, A. L.GB1013907, 1965, Imperial 
Chemical Industries, Ltd.; (e) Robertson, D. W.; Katzenellenbogen, J. A. J. Org. Chem. 1982, 47, 2387; (f) 
McCague, R. J. Chem. Soc., Perkin Trans. 1 1987, 1011. 
6
 For a review on recent amination procedures see: Kienle, M.; Dubbaka, S. R.; Brade, K.; Knochel. Eur. J. Org. 
Chem.  2007, 25, 4166.  
7
 Lipshutz  B. H.; Sengupta S. Org. Reactions  1992, 41, 135. 
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2.2. Direct oxidative addition of magnesium to organic halides 
The most common used method for the preparation of Grignard reagents is the direct 
oxidative addition of magnesium metal to organic halides in an aprotic solvent like THF or 
diethyl ether (Scheme 3, Eq. 1).  
2 RMgX
RX RMgX
R2Mg MgX2
       Mg
THF or Et2O
(1)
(2)
 
Scheme 3: Synthesis of Grignard reagents by oxidative addition (Eq. 1) and Schlenk-
equilibrium (Eq. 2). 
The detailed mechanism of this reaction is still not clear, although a radical pathway is 
generally accepted.8 In solution, a Grignard reagent (RMgX) is in equilibrium with R2Mg and 
MgX2 (Schlenk equilibrium, Scheme 3, Eq. 2), depending on temperature, solvent and the 
anion X−.9 Usually, magnesium metal is covered with an 'oxide layer' which mainly consists 
of Mg(OH)2. 10  Thus, in order to shorten the induction period and obtain a better 
reproducibility of the reaction, the activation of the magnesium surface with reagents like 1,2-
dibromoethane prior to reaction is normally desired.11 For the synthesis of functionalized 
Grignard reagents bearing sensitive functional groups, highly reactive Rieke magnesium 
(Mg*)12 can be used (Scheme 4). The direct trapping of Grignard reagent with an electrophile 
(Barbier-reaction) 13 can sometimes be used to overcome the stability problems. 
                                                 
8
 (a) Walborsky, H. M. Acc. Chem. Res. 1990, 23, 286; (b) Garst, J. F. Acc. Chem. Res. 1991, 24, 95; (c) Rogers, 
H. R.; Hill, C. L.; Fujuwara, Y.; Rogers, R. J.; Mitchell, H. L.; Whitesides, G. M. J. Am. Chem. Soc. 1980, 102, 
217; (d) Garst, J. F.; Ungvary, F. Grignard Reagents (Ed.: H. G. Richey, Jr.), Wiley, Chichester, 2000, 185; (e) 
Kharasch, M. S.; Reinmuth, O. Grignard Reactions of Nonmetallic Substances, Prentice-Hall, New York, 1954; 
(f) Hamdouchi, C.; Walborsky, H. M. Handbook of Grignard-Reagents (Eds: Silverman, G. S.; Rakita, P. E.), 
Marcel Dekker, New York, 1995, 145; (g) Oshima, K. Main Group Metals in Organic Synthesis (Eds.: 
Yamamoto, H.; Oshima, K.), Wiley-VCH, Weinheim, 2004. 
9
 Schlenk, W.; Schlenk Jr., W. Chem. Ber. 1929, 62, 920. 
10
 Garst, J. F.; Seriaga, M. P. Coord. Chem. Rev . 2004, 248, 623. 
11
 For relevant parameters controlling Grignard reagent formation, see: Lindsell, W. E. Comprehensive 
Organometallic Chemistry I (Eds. G. Wilkinson, F. G. S. Stone and G. E. Ebel), Vol. 1 , Chap. 3, Pergamon 
Press, Oxford, 1982, pp. 155-252 and references therein. 
12
 (a) Rieke, R. D.; Hanson, M. V. Tetrahedron 1997, 53, 1925; (b) Rieke, R. D. Aldrichim. Acta 2000, 33, 52; 
(c) Rieke, R. D.; Sell, M. S.; Klein, W. R.; Chen, T.-A.; Brown, J. D.; Hansen, M. U. Active Metals. 
Preparation, Characterization, Application, Fürstner, A. (Ed.), Wiley-VCH, Weinheim (Germany), 1996, p.1. 
13
  Blomberg, C. The Barbier Reaction and Related One-Step Processes Springer, Berlin, Heidelberg, New York, 
1993. 
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Br
FG FG
MgBr
FG
EMg*
THF
-78 C, 15 min
E+
53-86%
FG = CO2Bu-t, OC(O)Bu-t, CN, etc.
E+ = PhCHO, PhCOCl, allyl bromide
E = PhCH(OH), PhCO, CH2=CHCH2
 
Scheme 4: Preparation of functionalized Grignard reagents using Rieke-magnesium (Mg*). 
 
Interestingly, low reactive aryl chlorides can be converted to the corresponding 
organomagnesium species through transition metal catalysis using 2 mol% FeCl2 (Scheme 
5).14 
NMeO Cl
Mg
NMeO MgCl
+
MgCl2 (5 mol%)
FeCl2 (2 mol%)
EtBr (1 mol%)
THF, 1-3 h
96 %
 
Scheme 5: Direct oxidative insertion of activated magnesium into aryl chloride. 
 
2.3. The halogen/magnesium exchange reaction 
The direct oxidative addition of magnesium has been used successfully for the preparation of 
organomagnesium compounds. However, the use of magnesium metal leads also to the 
reduction of electrophilic functional groups and involves exothermic reactions, which are not 
easy to control during industrial processes.4 These limitations can be considerably reduced by 
using a halogen/magnesium exchange reaction. The first example was briefly reported in 1931 
by Prévost. 15  The reaction of cinnamyl bromide (3) with EtMgBr furnished 
cinnamylmagnesium bromide 4 in a low yield. Urion reported the preparation of 
cyclohexylmagnesium bromide 5 in a similar way (Scheme 6). 16 
 
 
                                                 
14
 Bogdanović, B.; Schwickardi, M. Angew. Chem. Int. Ed. 2000, 39, 4610. 
15
 Prévost, C. Bull. Soc. Chim. Fr. 1931, 49, 1372. 
16
 Urion, E. Comp. Rend. Acad. Sci. Paris 1934, 198, 1244. 
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Br
Br
MgBr
MgBr
+  EtMgBr +  EtBr
3 4: 14%
+  EtMgBr +  EtBr
5: 12%
 
Scheme 6: First examples of a Br/Mg exchange. 
 
The halogen/magnesium exchange is a reaction favoring the formation of the more stable 
organomagnesium compound (sp > sp2(vinyl) > sp2(aryl) > sp3(prim.)> sp3(sec.)). The 
mechanism of the exchange reaction is not yet fully clarified,17a,b,c but calculations show that 
it proceeds via a concerted 4-centered mechanism, 17 d in contrast to the halogen-lithium 
exchange that goes via the formation of a halogenate complex. In 1971, Tamborski showed 
that not only the electronic properties of the organic molecule play an important role in the 
formation-rate of the new Grignard reagent, but also the nature of the halogen atom.18 The 
reactivity order (I > Br > Cl >> F) is influenced by the carbon-halogen bond strength and by 
the electronegativity and polarizability of the halide. In recent years, the halogen/magnesium 
exchange has been found to be the method of choice for the preparation of new 
polyfunctionalized organomagnesium reagents of considerable synthetic utility. 19  The 
reactivity of organomagnesium reagents is strongly dependent of the temperature: only 
reactive electrophiles such as aldehydes and most ketones react rapidly at temperature below 
0 °C. Thus, performing the halogen/magnesium exchange at temperatures below 0 °C has the 
potential for the preparation of magnesiated reagents that bear reactive functional groups. In 
1998, Knochel showed excellent functional group tolerance during a low-temperature I/Mg 
exchange reaction used for the preparation of functionalized aromatic Grignard reagents 
(Scheme 7, 6a and 6b).20  
 
                                                 
17
 (a) Bailey W. F.;  Patricia, J. J. J. Organomet. Chem. 1988, 352, 1; (b) Reich, H. J.; Phillips, N. H.;  Reich, I. 
L. J. Am. Chem. Soc. 1985, 107, 4101; (c) Farnham, W. B.; Calabrese, J. C. J. Am. Chem. Soc. 1986, 108, 2449;  
(d) Krasovskiy, A.; Straub, B. F.; Knochel, P. Angew. Chem., Int. Ed. 2006, 45, 159. 
18
 Tamborski, C.; Moore, G. J. J. Organomet. Chem. 1971, 26, 153. 
19
 For a review on functionalized organomagnesium reagents see: Knochel, P.; Dohle, W.; Gommermann, N.; 
Kneisel, F. F.; Kopp, F.; Korn, T.; Sapountzis, I.; Vu, V. A. Angew. Chem., Int. Ed. 2003, 42, 4302. 
20
 (a) Boymond, L.; Rottländer, M.; Cahiez, G.; Knochel, P. Angew. Chem. 1998, 110, 1801; Angew. Chem. Int. 
Ed. 1998, 37, 1701; (b) Varchi, G.; Jensen, A. E.; Dohle, W.; Ricci, A.; Knochel, P. Synlett 2001, 477. 
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FG
X
I
MgBr
CN
MgBr
CO2Et
FG
X
N
Me
OTf
EtO2C
MgCl
MgBr
NHMgCl
MgCl
CN
FG
X
NO2
O2N
MgCl
E
   RMgX
       THF
−50 to −20 °C
E
6
6a 6b 6c
R  = i-Pr, Ph
X = C, N
6d 6e
 
Scheme 7: Functionalized arylmagnesium halides of type 6 prepared via an I/Mg exchange. 
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    80 °C, 16 h
 85 %
-40 °C, 0.5 h
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Scheme 8: I/Mg exchange using for the synthesis of functionalized heterocycles. 
 
Many applications19 have confirmed that the halogen/magnesium exchange proceeds under 
mild conditions and that various sensitive functional groups such as esters (6c,21 Scheme 8), 
nitriles (6d), 22  iodides, imines, or even nitro group (6e) 23  are tolerated during the 
organomagnesium reagent formation. One interesting example is the preparation of the 
                                                 
21
 Staubitz, A.; Dohle, W.; Knochel, P. Synthesis 2003, 223. 
22
 Varchi, G.; Kofink, C.; Lindsay, D. M.; Ricci, A.; Knochel, P. Chem. Commun. 2003, 396. 
23
 Sapountzis, I.; Knochel, P. Angew. Chem. Int. Ed. 2002, 41, 1610. 
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functionalized α,β-unsaturated lactam 7 (Scheme 8).24 The halogen/magnesium exchange is 
an attractive method for the generation of stable functionalized heteroarylmagnesium 
compounds. A variety of functionalized heteroarylmagnesium compounds bearing electron-
withdrawing groups can be readily prepared by using I/Mg or Br/Mg exchange between -
30 °C and -20 °C within few hours.25 The electronic density of the heterocycle influences the 
halogen/magnesium-exchange rate: electron-poor heterocycles react faster and electron-
withdrawing substituents strongly accelerate the exchange rate. Likewise, heteroaryl iodide 
such as 2-chloro-4-iodopyridine (8a)26 or protected iodouracils (8b),27 react very fast with i-
PrMgBr in THF giving the corresponding magnesium compounds in high yields (Scheme 8).  
Polyhalogenated substrates usually undergo a single halogen-magnesium exchange (Schemes 
9 and 10). After the first magnesiation, the electron density of the heterocycle increases and 
the subsequent second exchange reaction proceeds much slower. This very general behavior 
allows a high chemoselectivity for the Br/Mg exchange reaction of polyhalogenated 
compounds. Chelating groups, such as an ester or an ether, strongly influence the 
regioselectivity of the exchange reaction, as demonstrated by the reaction of i-PrMgBr with 
the tribromoimidazole 9 and the dibromothiazole 10 (Scheme 9).28 Chemo and regio-selective  
Br/Mg exchange have also been observed in the dihalogenated thiophenes 11 and 12, using  
EtMgBr at 25 °C (Scheme 10).29 
 
NNEtOH2C
Br Br
Br
NS
Br CO2Et
Br
i-PrMgBr
NNEtOH2C
BrMg Br
NS
BrMg CO2Et
Br
Me3SiCl
NS
TMS CO2Et
Br
NNEtOH2C
EtO2C Br1) i-PrMgBr
    -40 °C, 1.5 h
2) NC-CO2Et
    -40 to 25 °C
    2 h
1) i-PrMgBr, ether
    25 °C, 30 min
2) CuCN·2LiCl
    allyl bromide
9  57 %  55%
67%10
-40 °C
 
Scheme 9: Regioselective Br/Mg exchanges induced by chelating effect 
                                                 
24
 Dohle, W. PhD thesis, LMU München, 2002. 
25
 For review concerning the halogen/magnesium exchange on heterocycles, see: Hiriyakkanavar, I.; Baron, O.; 
Wagner, A. J.; Knochel, P. Chem. comm. 2006, 583. 
26
 (a) Marzi, E.; Bigi, A.; Schlosser, M. Eur. J. Org. Chem. 2001, 7, 1371; (b) Rocca, P.; Cochennec, C.; 
Marsais, F.; Thomas-dit-Dumont, L.; Mallet, M.; Queguiner, G. J. Org. Chem. 1993, 58, 7832. 
27
 Abarbri, M.; Knochel, P. Synlett 1999, 1577. 
28
 (a) Lipshutz, B. H.; Hagen, W. Tetrahedron Lett. 1992, 33, 5865; (b) Abarbri, M.; Thibonnet, J.; Bérillon, L.; 
Dehmel, F. ; Röttlander, M. ; Knochel, P. J. Org. Chem. 2000, 65, 4618. 
29
 Christophersen, C.; Begtrup, M.; Ebdrup, S.; Petersen H.; Vedsø,  P. J. Org. Chem. 2003, 68, 9513. 
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Scheme 10: Regioselective I/Mg and Br/Mg exchange on dihalogenated thiophenes. 
 
Inactived aryl bromides do not react with i-PrMgBr at a sufficient rate even at 25 °C. In some 
cases, the use of trialkylmagnesiate reagents (R3MgLi) according to the work of Oshima 
allowed the magnesiation of less active system, such as 3-bromobenzonitrile.30 However, a 
catalyzed version of the Br/Mg exchange, recently developed by Knochel, using 1 equivalent 
of LiCl, significantly broadered the range of suitable substrates for this process. 31 The mixed 
organometallic iPrMgCl·LiCl (13), allowed a fast Br/Mg exchange leading to the desired 
Grignard reagents of type 14 in high yields under mild conditions (Scheme 11). 
 
FG
Br
i-PrMgCl·LiCl (13)
N
S MgCl
Br
MgClBr
THF
NC
N
MgClBr
FG
MgCl
MgCl·LiCl
MgCl
CO2t-Bu
N
Br MgCl
OTs
FG
E
FG = F, Cl, Br, CN, CO2R, OMe
 14b:o, m, p : 0 °C, 1 -3 h
 14d: 25 °C, 30 min
 14a: -50 °C, 2 h  14c: -10 °C, 3 h
 14e: -10 °C, 15 min
E+
(- i-PrBr)
 14f: -30 °C, 2 h
14: >95%
 
 
Scheme 11: LiCl-mediated Br/Mg exchange reaction of brominated aryls and heteroaryls.31, 32 
                                                 
30
 (a) Oshima, K. J. Organomet. Chem. 1999, 575, 1; (b) Kitagawa, K.; Inoue, A.; Shinokubo, H.; Oshima, K. 
Angew. Chem. 2000, 112, 2594; Angew. Chem. Int. Ed. Engl. 2000, 39, 2481; (c) Inoue, A.; Kitagawa, K.; 
Shinokubo, H.; Oshima, K. J. Org. Chem. 2001, 66, 4333; (d) Inoue, A.; Kitagawa, K.; Shinokubo, H.; Oshima, 
K. Tetrahedron 2000, 56, 9601; (e) Yousef, R.I.; Rüffer, T.; Schmidt, H.; Steinborn, D. J. Organomet. Chem. 
2002, 655, 111. 
31
 Krasovskiy, A.; Knochel, P. Angew. Chem. 2004, 116, 3369; Angew. Chem. Int. Ed. 2004, 43, 3333. 
32
 Ren, H.; Knochel, P. Chem. Commun. 2006, 726. 
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The necessity to use the stoichiometric complex 13, leads to the postulate that the addition of 
LiCl breaks the aggregates of i-PrMgCl producing a highly reactive Grignard reagent 
(Scheme 12). Knochel has presented model calculations to correlate the structure of 
magnesium reagents with their reactivity in Br/Mg exchange reaction in the presence of 
LiCl.17d 
 
Mg
Cl
Cl
Mg
2 LiCl
Mg
Cl
Cl
Li
2 ArBr Ar Mg
Cl
Li
Cl-2 i-PrBr
2 2
 
 
Scheme 12: Catalysis of the Br/Mg-exchange reaction with LiCl. 
 
 
Using this catalyzed version of the Br/Mg exchange reaction, Knochel and Mayr33  have 
recently reported the use of 3,3´,5,5´-tetra-tert-butyldiphenoquinone (15, Scheme 13) as an 
electron acceptor to allow the simple preparation of functionalized biaryls, diynes and dienes 
through coupling reactions of organomagnesiated reagents which are complexed with LiCl. 
As an example, the 5-bromopyridin-3-ylmagnesium chloride (14e) was coupled using 15 to 
lead to the corresponding bipyridine (16) in 80% yield (Scheme 13).  
 
N
Br MgCl·LiCl
OO
N
Br
N
Br
16: 80%
THF, -20 to 25 °C, 2 h
14e
15
 
 
Scheme 13: Coupling of the organomagnesium reagent 14e. 
 
As an extension of the LiCl-mediated Br/Mg exchange reaction, the synthesis of the new 
Grignard reagent i-Pr2Mg·LiCl (17)17d offered a new class of highly reactive exchange 
reagents. Using additives such as dioxane to shift the Schlenk equilibria, the reaction of 17 on 
electron rich aryl bromides undergo a fast conversion as shown in Scheme 14. 
 
                                                 
33
 Krasovskiy, A.; Tishkov, A.; del Amo, V.; Mayr, H.; Knochel, P. Angew. Chem. Int. Ed. 2006, 45, 5010. 
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i-Pr2Mg·LiCl   +   MgCl2·additive
MeO Br +  i-Pr2Mg·LiCl MeO Mg·LiCl
additives: 15-crown-5, PEG250, 1,4-dioxane, TMEDA, DMPU
17
2
2
additive, THF
2  i-PrMgCl   +    LiCl
THF, 25 °C, 10 h,
1,4-dioxane
- 2 i-PrBr
> 98%
 
 
Scheme 14: Preparation of i-Pr2Mg·LiCl (17) and his reaction on 4-bromoanisole. 
 
 
 
2.4. Metalation reactions with magnesium amide bases 
The preparation of aryl and heteroaryl organometallics via directed metalations has found 
many applications in recent years, especially via the directed ortho-lithiation using lithium 
bases such as sec-BuLi or lithium 2,2,6,6-tetramethylpiperidide (TMPLi). 34 However, the use 
of lithium bases is often complicated by the undesired side reactions due to high reactivity of 
the products and therefore the low tolerance towards sensitive functional groups. These 
limitations reduce the scope of useful directing group. Magnesium amides of type R2NMgCl, 
R2NMgR or (R2N)2Mg, were developed as metalating reagents 35  to overcome these 
limitations, but their low kinetic basicity and low solubility have hampered more general 
applications. Nevertheless, interesting examples of the metalation of N-heterocyclic 
                                                 
34
 (a) Schlosser, M. Angew. Chem. 2005, 117, 380; Angew. Chem. Int. Ed. 2005, 44, 376; (b) Turck, A.; Plé, N., 
Mongin, F.; Quéguiner,G. Tetrahedron 2001, 57, 4489 (c)  Schlosser, M. Eur. J. Org. Chem. 2001, 21, 3975; (d) 
Hodgson, D. M.; Bray, C. D.; Kindon, N. D. Org. Lett. 2005, 7, 2305; (e) Plaquevent, J.-C.; Perrard, T. ; Cahard, 
D. Chem. Eur. J. 2002, 8, 3300; (f) Chang, C.-C.; Ameerunisha,  M. S. Coord. Chem. Rev. 1999, 189, 199; (g) 
Clayden, J. Organolithiums: Selectivity for Synthesis (Hrsg.: J. E. Baldwin, R. M. Williams), Elsevier, 2002; 
(h)”The Preparation of Organolithium Reagents and Intermediates“: Leroux, F., Schlosser, M.; Zohar, E.; 
Marek, I. Chemistry of Organolithium Compounds (Hrsg.: Z. Rappoport, Marek, I.), Wiley, New York, 2004, 
Chapt.1, S. 435; (i) Whisler, M. C.; MacNeil, S.; Snieckus, V.; Beak, P. Angew. Chem. 2004, 116, 2256; Angew. 
Chem. Int. Ed. 2004, 43, 2206; (j) Queguiner, G.; Marsais , F.; Snieckus, V.; Epsztajn, J. Adv. Heterocycl. Chem. 
1991, 52, 187; (k) Veith, M.; Wieczorek, S.; Fries, K.; Huch, V. Z. Anorg. Allg. Chem. 2000, 626, 1237.  
35
 (a) Mulvey, R. E.; Mongin, F.; Uchiyama, M.; Kondo, Y. Angew. Chem. Int. Ed. 2007, 46, 3802; (b) 
Henderson, K. W.; Kerr, W. J. Chem. Eur. J. 2001, 7, 3430; (c) Hauser, C. R.; Walker, H. G. J. Am. Chem. Soc. 
1947, 69, 295; (d) Kobayashi, K.; Kitamura, T.; Nakahashi, R.; Shimizu, A.; Yoneda, K.; Konishi, H. 
Heterocycles 2000, 53, 1021; (e) Westerhausen, M. Dalton Trans. 2006, 4768. (f) Zhang M.-X. ; Eaton, P. E. 
Angew. Chem. Int. Ed. 2002, 41, 2169; (g) Kondo, Y.; Akihiro Y.; Sakamoto, T.  J. Chem. Soc., Perkin 
Trans.1996, 1, 2331; (h) Eaton, P. E.; Lee, C. H.; Xiong, Y. J. Am. Chem. Soc.1989, 111, 8016; (i) Eaton, P. E.; 
Zhang, M.-X.; Komiya C.-G. N.; Yang, Steele, I.; Gilardi, R. Synlett. 2003, 1275; (j) Eaton, P. E.; Martin, R. M. 
J. Org. Chem. 1988, 53, 2728; (k) Shilai, M.; Kondo, Y.; Sakamoto, T. J. Chem. Soc., Perkin Trans. 1. 2001, 
442. 
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compounds, using excess (2-3 equiv) of Hauser bases (R2NMgCl), showed selective 
deprotonations tolerating an ester function (Scheme 15).36 
 
N
SO2Ph
SEtO2C
N
SO2Ph
SEtO2C
OH
Ph
1) i-Pr2NMgCl (2 equiv)
    THF, rt, 10 min
2) PhCHO
60%
1) i-PrMgCl (3 equiv.)
    5 mol% i-Pr2NH
    THF, rt, 10 min
2) allyl bromide
52%
(1)
(2)
 
 
Scheme 15: Selective magnesiation of N-heterocycles. 
 
Recently, a major improvement of this chemistry was achieved in our group when 
Krasovskiy, Krasovskaya and Knochel discovered the mixed Mg/Li-bases of type 
R2NMgCl·LiCl (18a and 18b, Scheme 16).37  This new generation of bases possesses an 
excellent kinetic basicity, a very good solubility and excellent thermal stability allowing their 
long term storage in THF solution. TMPMgCl·LiCl (18a) used in nearly stoichiometric 
amounts permits the magnesiation of various aromatics and heteroaromatics with excellent 
regioselectivity at practical temperatures (Scheme 17). 
 
i-PrMgCl·LiCl
i-PrMgCl·LiCl
i-Pr2NH
TMPH
N MgCl·LiCl
N MgCl·LiCl
18b (ca. 0.6 M in THF)
18a (ca. 1.2 M in THF)
25 °C, 1h
25 °C, 24 h
13
13
 
 
Scheme 16: Preparation of Mg/Li amide bases of type R2NMgCl·LiCl. 
 
                                                 
36
 (a) Kondo, Y.;  Yoshida, A.; Sakamoto, T.  J. Chem. Soc., Perkin Trans. 1 1996, 2331; (b) Dinsmore, A.; 
Billing, D. G.; Mandy, K. ; Michael, J. P.; Mogano, D.; Patil, S. Org. Lett. 2004, 6, 293. 
37
 Krasovskiy, A.; Krasovskaya, V.; Knochel, P. Angew. Chem. 2006, 118, 3024; Angew. Chem. Int. Ed. 2006, 
45, 2958. 
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Scheme 17: Direct magnesiation of functionalized aryls and heteroaryls using 18a.37,38  
 
The successive direct magnesiations of highly functionalized aromatics bearing an ester, a 
nitrile or a ketone has been achieved using TMPMgCl·LiCl (18a, Scheme 18). 39   After 
quenching with electrophiles, highly functionalized and polysubstituted benzenes were 
obtained (Scheme 18). 
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CO2Et
CN
Cl
CN
Cl
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EtO2C
COPh
76%
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1) TMPMgCl·LiCl
    (1.2 equiv)
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2) TsCN 
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    1 h
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2) EtOCOCN 
    (1.7 equiv)
    -40 °C to 25 °C 
    1 h
1) TMPMgCl·LiCl (1.2 equiv)
    -50 °C, 0.5 h
2) ZnCl2 (1.2 equiv)
    -50 °C to -30 °C, 0.5 h
3) Pd(PPh3)4 (2 mol %)
    EtOCOCl (1.5 equiv)
    -30 °C to 25 °C, 24 h
1) TMPMgCl·LiCl
    (1.2 equiv)
    -50 °C, 1.5 h
2) PhCOCl
    (CuCN·LiCl)
 
 
Scheme 18: Successive magnesiations of 3-chlorobenzoate. 
                                                 
38
 Kienle, M.; Dubbaka, S. R.; del Amo, V.; Knochel, P. Synthesis 2007, 1272. 
39
 Lin, W.; Baron, O. Org. Lett. 2006, 8, 5673. 
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After the discovery of TMPMgCl·LiCl (18a), the chemistry of the corresponding magnesium 
bisamides complexed with lithium chloride, TMP2Mg·2LiCl (19), was further developed by 
Clososki, Rohbogner and Knochel.40 This new class of bases displays a superior metalation 
power allowing the magnesiation of various polyfunctional aromatic or heteroaromatic 
reagents bearing functional groups such as an ester, a nitrile or a ketone. The efficiency of 
TMP2Mg·2LiCl (19) was demonstrated by the ortho-deprotonation of dimethyl-1,3-
benzodioxan-4-one (20, Scheme 19) which led after the Negishi cross-coupling and 
hydrogenation, followed by the cleavage of the dioxanone, to 6-hexylsalicylic acid (21), a 
natural product found in essential oil of Pelargonium sidoides DC. 
 
O
O
O TMP2Mg·2LiCl O
O
O
MgTMP
I
HO
HO
O
O
O
O
1. ZnCl2, -40 °C, 15 min
    Pd(PPh3)4 (5 mol%)
-40 °C to rt, 12 h
2.
> 98% 77%
(19, 1.1 equiv)
-40 °C, 10 min
20
1. H2, Pd/C,
MeOH, 24 h
2. KOH, THF,
water, reflux, 12 h
then HCl
21: 89%
 
 
Scheme 19: Preparation of 6-hexylsalicylic acid (21) via the regioselective deprotonation 
using TMP2Mg·2LiCl (19). 
 
 
2.5. Recent applications of Grignard reagents for a C-N bond formation 
Functionalized aromatic and heteroaromatic amines are important building blocks for the 
synthesis of pharmaceuticals.41 Beside, the transition metal-catalyzed amination protocols6 
using palladium, copper or nickel, the reaction of aromatic nitro compounds with Grignard 
reagents have proven to be a versatile alternative for the synthesis of functionalized 
                                                 
40
 Clososki, G. C.; Rohbogner, C. J.; Knochel, P. Angew. Chem. 2007, 119, 7825; Angew. Chem. Int. Ed. 2007, 
46, 1. 
41
 Czarnik, A. W. Acc. Chem. Res. 1996, 29, 112 and references cited therein. 
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diarylamines.42 In this reaction the aromatic organometallic species acts as a nucleophile, 
while the nitroarene plays the role of an electrophile. Even heterocycles bearing a nitro group 
can be transformed successfully to the corresponding heterocyclic amines (Scheme 20). 
Alternatively, arylazo tosylates can be used in such electrophilic amination reactions (Scheme 
21).43 
 
MgCl
EtO2C
O2N
N
+
1) –20 °C, 2 h, THF
2) FeCl2, NaBH4
      
–20 to 25 °C,2 h(2 equiv.) 59%
H
N
NEtOOC
 
 
Scheme 20: Electrophilic amination using a nitroarene and a Grignard reagent. 
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1) Ar2MgX
   –20 °C, 1 h
    NMP, 20 °C, 3 h
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   (5 : 1)
2)
71% 83%
 
 
Scheme 21: Electrophilic amination using an aryzalo tosylate and a Grignard reagent. 
 
The oxidative amination reaction of amidocuprates is a further complement to transition 
metal-catalyzed and electrophilic amination reactions. Previous studies by H. Yamamoto, K. 
Maruoka 44  and A. Ricci 45  focused on the oxidative coupling of lithium amidocuprates, 
leading to amines by molecular oxygen. Since the use of gaseous oxygen is not convenient for 
large-scale industrial reactions, del Amo, Dubbaka, Krasovskiy and Knochel developed a 
                                                 
42
 (a) Sapountzis, I.; Knochel, P. J. Am. Chem. Soc. 2002, 124, 9390; (b) Ono, A.; Sasaki, H.; Yaginuma, F. 
Chem. Ind. (London) 1983, 480. 
43
 (a) Sapountzis, I.;  Knochel, P. Angew. Chem. Int. Ed. 2004, 43, 897; (b) Sinha, P.; Knochel, P. Synlett 2006, 
3304.  
44
 Yamamoto, H.; Maruoka, K. J. Org. Chem. 1980, 45, 2739. 
45
 (a) Casarini, A.; Dembech, P.; Lazzari, D.; Marini, E.; Reginato, G.; Ricci, A.; Seconi, G. J. Org. Chem. 1993, 
58, 5620; (b) Alberti, A.; Canè, F.; Dembech, P.; Lazzari, D.; Ricci, A.; Seconi, G. J. Org. Chem. 1996, 61, 
1677; (c) Canè, F.; Brancaleoni, D.; Dembech, P.; Ricci, A.; Seconi, G. Synthesis 1997, 545; (d) Bernardi, P.; 
Dembech, P.; Fabbri, G. ; Ricci, A.; Seconi, G. J. Org. Chem. 1999, 64, 641. 
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preparation of amines via the oxidative coupling of polyfunctional aryl and heteroaryl 
amidocuprates mediated by solid tetrachlorobenzoquinone (chloranil (22), Scheme 22).38, 46 
The transmetalation of Grignard reagent 23 with CuCl·2LiCl,47 soluble in THF, provided the 
copper reagent 24, which after treatment with a lithium amide resulted in the lithium 
amidocuprate of type 25. This intermediate could be oxidized with chloranil (22) affording 
desired amines 26 (Scheme 22). 
 
Li N
R2
R3 Ar1 Cu N
R2
R3CuCl·2LiCl Ar1 Cu.LiClAr1 MgCl Li
O
O
Cl
ClCl
Cl
LiO O
Cl Cl
ClCl
Ar1 Cu
N
R2R3
CuO OLi
Cl Cl
ClCl
Ar1 N
R2
R3
22
R2  or R3  = alkyl, aryl, TBS, TMS
26
23 24 25
 
 
Scheme 22: Preparation of amines of type 26 via an oxidative coupling of amidocuprates 
using chloranil (22). 
 
This method is well-suited for the preparation of primary, secondary and tertiary aromatic and 
heterocyclic amines.  It tolerates a broad range of functional groups such an ester, a cyanide, a 
halide, and is not hampered by steric hindrance (Schemes 23 and 24). Using LiHMDS as 
lithium amide, a primary arylamine could be prepared as shown by the synthesis of the 
aminated isophtalic diester 26b (Scheme 24). 
                                                 
46
 del Amo, V.; Dubbaka, S. R.; Krasovskiy, A.; Knochel, P. Angew. Chem. Int. Ed. 2006, 45, 7838. 
47
 (Et2NCH2CH2)2O was added to CuCN·2LiCl. This additive was found to improve the yield of the amination 
reaction. 
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Scheme 23: Preparation of the sterically hindered tertiary amine 26a through an oxidative 
amination with TMP-Li using chloranil (22). 
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Scheme 24: Preparation of the primary arylamine 26b through an oxidative amination with 
the cuprated polyfunctional aryl derivative 24b and LiHMDS using chloranil (22). 
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3. Direct Preparation and Use of Organozincated Aryl and Heteroaryl 
Compounds. 
 
3.1 Introduction 
Organozinc reagents are known for more than 150 years, since the preparation of diethylzinc 
by Frankland in 1849 in Marburg (Germany).48 These organometallic reagents were used to 
form new carbon-carbon bonds until Grignard 3 discovered in 1900 a convenient preparation 
of organomagnesium compounds. Over the years, some reactions were conventionally 
performed with zinc organometallics such as the Reformatsky reaction49 or the Simmons-
Smith cyclopropanation.50 The intermediate organometallics (zinc enolate and zinc carbenoid) 
were more easy to handle and more selective than the corresponding magnesium species. In 
1943, Hunsdiecker has shown that organozinc reagents bearing a long carbon chains 
terminated by an ester function can be prepared, 51 but it was only recently that Knochel has 
demonstrated the synthetic potential of these reagents.52 Organozinc compounds are prone to 
undergo a broad range of transmetalations. This is due to the presence of empty low-lying p-
orbitals which readily interact with the d-orbitals of many transition metal salts, leading to 
highly reactive intermediates such as organocopper53 or palladium compounds54 (Scheme 25). 
 
YZn
R
X
RZnY     +      XMLn MLn RMLn      +       ZnXY
 
 
Scheme 25: Transmetalation of organozincs reagents 
 
Moreover, the highly covalent character of the carbon-zinc bond makes organozinc species 
stable at the temperatures where the corresponding organomagnesiums and organolithiums 
                                                 
48
 Frankland, E. Liebigs Ann. Chem. 1849, 71, 171 and 173. 
49
 (a) Reformatsky, S. Chem. Ber. 1887, 20, 1210; 1895, 28, 2842; (b) Fürstner, A. Angew. Chem. Int. Ed. 1993, 
32, 164. 
50
 Simmons, H. E.; Smith, R. D. J. Am. Chem. Soc. 1958, 80, 5323; (b) Nakamura, M.; Hirai, A.; Nakamura, E. 
J. Am. Chem. Soc. 2003, 125, 2341. 
51
 Hunsdiecker, H.; Erlbach, H., Vogt, E. 1942, German patent 722467; Chem. Abstr. 1943, 37, 5080. 
52
 (a) Knochel, P.; Singer, R. D. Chem. Rev. 1993, 93, 2117; (b) Knochel, P.; Almena, J.; Jones, P. Tetrahedron 
1998, 54, 8275. 
53
 (a) Knochel, P. Synlett 1995, 393; (b) Knochel, P.; Vettel, S.; Eisenberg, C. Applied Organomet. Chem. 1995, 
9, 175; (c) Knochel, P.;  Jones, P. Organozinc reagents. A Practical Approach, Oxford University Press, 1999; 
(d) Knochel, P.; Millot, N.; Rodriguez, A. L.; Tucker, C. E. Org. React. 2001, 58, 417; (e) Boudier, A.; Bromm, 
L. O.; Lotz, M.; Knochel, P. Angew. Chem. Int. Ed. 2000, 39, 4415. 
54
 (a) Negishi, E.; Valente, L. F.; Kobayashi, M. J. Am. Chem. Soc. 1980, 102, 3298; (b) Kobayashi, M.; Negishi, 
E. J. Org. Chem. 1980, 45, 5223. (c) Negishi, E. Acc. Chem. Res. 1982, 15, 340. 
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undergo decomposition. Such combination of the high tolerance toward functionalities, facile 
transmetalation to many transition metal complexes and an excellent stability makes 
organozincs extremely valuable reagents for organic synthesis. The reactivity of organozinc 
halides strongly depends on the electronegativity of the carbon attached to zinc (alkynyl < 
alkyl < alkenyl ≤ aryl <benzyl< allyl). A stabilization of the negative carbanionic charge by 
inductive or mesomeric effects leads to a more ionic carbon-zinc bond and to a higher 
reactivity. The direct preparation of organozinc compounds can be achieved by an insertion of 
zinc dust into organic halides or by an I/Zn exchange of iodinated alkyl and aryl substrates. 
 
 
3.2 The direct insertion of zinc metal into aryl and heteroaryl halides 
The oxidative addition of zinc dust into organic halides is an usual method for the preparation 
of functionalized organozinc halides, especially iodides (28, Scheme 26). This method of 
preparation tolerates several functionalities and is sensitive to the reaction conditions (solvent, 
concentration, and temperature), the nature of the halide and the method of zinc activation 
(Scheme 26).  
 
N
H
ZnI
ZnBr
CN
O
ZnI
N
AcO
N
N
N
OAcO
OAc
ZnI
FG-R-X
Zn dust 
THF
FG-R-ZnX
FG = CO2R, enoate, CN, halide, (RCO)2N, RNH, NH2, RCONH, 
RCONH, (RO)3Si, (RO)2PO, RS, RSO, RSO2, PhCOS
R = alkyl, aryl, benzyl, allyl
X = I, Br
28
28a: 90%
(THF, 30 °C, 2 h)
28b: >98%,
(THF, 5 °C, 2 h)
28c: >98%
(THF, 25 °C, 1 h)
28d: >98%
(THF, 25 °C, 3h)
 
 
Scheme 26: Direct insertion of zinc into functionalized organic halides. 
 
As magnesium, zinc slowly oxidizes in air and is covered by an oxide layer. An efficient 
activation procedure consists of treating zinc with 1,2-dibromoethane in THF (reflux, 1-2 
min), followed by the addition of TMSCl (1-2 mol%; reflux, 1 min).2a, 52a, 53d Rieke zinc 
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(Zn*)55 prepared by the reduction of zinc chloride with lithium naphthalenide in THF, offers a 
second alternative to obtain highly reactive zinc. Over the last 20 years, using these two 
methods, a wide range of functionalized organozinc iodides was obtained including 
functionalized alkyl, allylic or benzylic compounds. 2 For instance, using activated zinc dust 
in THF, Knochel described the successful insertion into a non protected 3-(2-
iodoethyl)indole,56 functionalized benzylic57 and alkenyl58 iodides and, interestingly, into an 
iodinated nucleoside59 (28a-d, Scheme 26). In general, the zinc insertion into a sp2 C-I(Br) 
bond is more difficult than into a sp3 C-I(Br) bond and requires either the use of polar 
solvents60 or the use of Rieke zinc (Zn*). Knochel described the insertion into a 5-iodouridine 
derivative 28e using activated zinc in the presence of DMA (Scheme 27). Fürstner, Singer 
and Knochel showed direct insertion into a reactive aryl bromide such as p-
bromobenzonitrile61 using Zn* (28f, Scheme 27). 
 
O
AcO
AcO OAc
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N
O
O
Me I
O
AcO
AcO OAc
N
N
O
O
Me ZnI
I
CN
ZnI
CN
CuCN·2LiCl
PhCOCl
COPh
CN
O
AcO
AcO OAc
N
N
O
O
Me
CF3
Zn, DMA
70 °C, 3 h
Pd(dba)2 (1 mol%)
P(furyl-o)3 (2 mol%)
THF, 70 °C, 4 h
Zn/Ag-graphite
THF, 25 °C, 3 h
89%
58%
28f
28e: > 98%
 
 
Scheme 27: Zinc insertion into sp2 C-iodine bond. 
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 (a) Organozinc Reagents, Editors: P. Knochel, P. Jones, Oxford University Press, New York, 1999; (b) Rieke, 
R. D.;  Li, P. T.; Burns, T. P.; Uhm, S. T. J. Org. Chem. 1981, 46, 4323; (c) Arnold, R. T.; Kulenovic, S. T.; 
Synth. Commun. 1977, 7, 223.  
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 Knoess, H. P.; Furlong, M. T.; Rozema, M. J.; Knochel, P. J. Org. Chem. 1991, 56, 5974. 
57
 Knochel, P.; Yeh, M. C. P.; Berk, S. C.; Talbert, J. J. Org. Chem. 1988, 53, 2390. 
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 Knochel, P.; Rao, C. J. Tetrahedron 1993, 49, 29. 
59
 (a) Stevenson, T. M.; Prasad, A. S. B.; Citineni, J. R.; Knochel, P. Tetrahedron Lett. 1996, 37, 8375; (b) 
Prasad, A. S. B.; Stevenson, T. M.; Citineni, J. R.; Nyzam, V.; Knochel, P. Tetrahedron 1997, 53, 7237. 
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 (a) Tagaki, K.; Hayama, N.; Inokawa, S. Bull. Chem. Soc. Jpn. 1980, 53, 3691; (b) Tagaki, K. Chem. Lett. 
1993, 469; (c) Tagaki, K.; Shimoishi, Y.; Sasaki, K. Chem. Lett. 1994, 2055; (d) Majid, T. N.; Knochel, P. 
Tetrahedron Lett. 1990, 31, 4413.  
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Since the activity of Rieke Zn decreases with time, a new practical zinc insertion procedure 
was invented by Krasovskiy, Malakhov, Gavryushin and Knochel in 2006.62 They found that 
the addition of LiCl during the insertion of zinc dust into organic bromides or iodides leads to 
a spectacular rate increase as shown by the example of ortho-trifluoromethylphenyl iodide 
(29a) providing the corresponding organozinc iodide at 25 °C (30a, Scheme 28). This method 
allows a simple, high-yielding preparation of a broad range of functionalized aryl and 
heteroarylzinc reagents such as the zincated diester 30b and the furylzinc reagent 30c 
(Scheme 29). 
 
I
CF3
Zn·LiCl
THF
ZnI·LiCl
CF3
by using Zn (2 equiv.) at 70 °C, 24 h : 70%
by using Zn·LiCl (1.4 equiv.) at 25 °C, 18 h : 96%
29a 30a
 
 
Scheme 28: The effect of LiCl on the zinc insertion into ortho-trifluoromethylphenyl iodide 
(29a). 
 
 
 
 
EtO2C
Br
CO2Et
Zn·LiCl ZnBr·LiCl
CO2Et
EtO2C
CuCN·2LiCl
CO2Et
EtO2C
25 °C, 12 h
allyl bromide
(1.1 equiv.)
(0.4 mol %)
30b: 91 %  90 %
CNI
Pd(PPh3)4OEtO2C ZnBr·LiCl
Zn·LiCl
OEtO2C Br
CN
OEtO2C
1 mol %
25 °C, 12 h
30c: 92 %  89 %
 
 
Scheme 29: Direct zinc insertion in the presence of LiCl into aromatic and heterocyclic 
bromides. 
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3.3  The iodine/zinc exchange reaction 
The halide/zinc exchange allows the preparation of diorganozincs, which are more reactive 
than organozinc halides and are extensively used in asymmetric synthesis.52a, 63  The I/Zn 
exchange reaction is a practical way for preparing polyfunctional diorganozincs (FG–R)2Zn.64 
A wide range of polyfunctional primary alkyl iodides undergo this exchange if treated neat 
with diethyl zinc in the presence of a catalytic amount of copper(I) iodide or copper(I) 
cyanide (Scheme 30).65 This reaction can also be catalyzed by Pd-complexes.66 
 
FG-I
Et2Zn (1.5 equiv)
CuI cat. (0.3 mol%)
(FG-R)2Zn
 
 
Scheme 30: Copper-catalyzed I/Zn exchange.  
 
This method provides a general access to functionalized dialkylzincs but fails in the case of 
aromatic iodides. For performing an I/Zn exchange on aryl iodides, Knochel showed in 200467  
that the addition of catalytic amounts of Li(acac) to an aryl iodide and i-Pr2Zn allows the I/Zn 
exchange with the formation of Ar2Zn and i-PrI. The “ate” intermediate 31 (Scheme 31) is 
similar to the one during the Br/Mg exchange catalyzed by LiCl.17d, 31 This method affords an 
easy synthesis of functionalized diarylzinc derivative such as 32 bearing an aldehyde function 
(Scheme 32). 
 
2 Ar I
i-PrI
Li
i-Pr2Zn
ArZni-Pr
ArI
Zn(acac)
i-Pr
Ar ArI
Ar2Zn
i-PrI
Li(acac) (10mol%)
NMP/ether
   25°C
+ + 2 i-PrI
Li(acac)
31
 
 
Scheme 31: Li (acac) catalyzed synthesis of diarylzincs. 
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A: General Introduction  24 
  
  
 
OAc
MeO
CHO
I i-Pr2Zn (0.55 equiv)
Li(acac) (10 mol%)
NMP, 0 °C, 2 h
OAc
MeO
CHO
Zn
OAc
MeO
CHO
O
2
Pd(dba)2 (2.5 mol%)
P(furyl-o)3 (5 mol%)
c-Hex-COCl (1.5 equiv)
THF, 25 °C, 5 h
75%32
 
 
Scheme 32. Functionalized diarylzinc bearing an aldehyde function. 
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4. Objectives 
 
We plan in this work to apply the newly developed preparations of organomagnesium and 
zinc reagents for the synthesis of various N-heterocyclic magnesium and zinc intermediates. 
Our aim was to perform successive selective functionalizations of N-heterocycles, and apply 
our methodology for the synthesis of biologically active compounds. 
 
In a first project, our research was mainly focused on the functionalizations of quinolines, 
protected uracils, and purines, which are the classes of N-heterocycles where metalation and 
subsequent functionalization are still unexplored.   
More precisely, our objectives were:  
• The magnesiations and functionalizations of quinoline cores by the combination of 
selective Br/Mg exchanges as well as direct deprotonations (Scheme 33).  
 
N
 FGs
N
FG
FG
FG
FG
Regioselective magnesiations using
RMgX , R2Mg, R2NMgX or 
(R2N)2Mg
FG= -Br, -COOR, COR, -CN, -CHOHR, -OR, -NR2, -SR, -Ar
FGs
 
 
Scheme 33: Multiple regioselective functionalizations of quinolines via magnesiations. 
 
 
• The selective magnesiation of 2,4-dimethoxypyrimidine as a synthetic route to 
polyfunctionalized protected uracils (Scheme 34). 
 
N
N
OCH3
OCH3 NH
NH
O
O
X
FG or E = -Br, -I,  -COOR, COR, -CN, -CHOHR, -OR, -NR2, -SR, -Ar
X = H, I, Br, Cl
1. Selective magnesiations
using RMgX and R2NMgX reagents
2. E+
3. Deprotection
FGs
 
 
Scheme 34: Chemo- and regio-selective functionalization of uracil derivatives. 
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• The aminations of DNA and RNA units such as protected uracils, pyrimidines and 
purines, via selective magnesiations and cupration followed by the addition of lithium 
amides and the oxidative coupling with chloranil (Scheme 35). 
 
Li N
R2
R3
N
N
X = I, Br, H
1) RMgX
2) CuCl·2LiCl
3)
4) chloranil
N
N
R2R1NX
 
 
Scheme 35: Amination of DNA and RNA units via cuprated purine and pyrimidine 
derivatives. 
 
In the second project, it was planned to study the insertion of zinc dust in the presence of LiCl 
into polyhalogenated aryls and N-heterocycles, in order to access new zincated aromatic and 
heterocyclic compounds (Scheme 36). 
 
Directing group (DG)
Zn, LiCl
A
DG
ZnXX
A
DG
XX X= I, Br
A: aryl or N-heteroaryl
 
 
Scheme 36: LiCl-mediated regioselective zinc insertion of aryl and heteroaryl compounds. 
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1. Functionalizations of Quinoline Moieties via Chemo- and 
 Regioselective Magnesiations. 
 
1.1 Introduction 
The functionalization of quinoline and its derivatives is a matter of great interest, since the 
basic structure of many antimalarial drugs is derived from quinine 33a (Scheme 37). Quinine 
is the active ingredient of the bark of Cinchona tree, which has been used against malaria 
since the early 17th century. In 1820, quinine (33a) was isolated and replaced the crude bark 
for the treatment of malaria. It was of the first pure chemical compounds used as a drug. In 
the next century, various antimalarial drugs have been developed, including chloroquine 33b 
and mefloquine 33c (Scheme 37).68  
 
N
N
HO
H
O
N
CF3
CF3
N
H
HO
H
NCl
HN N
33a: quinine 33c: mefloquine33b: chloroquine
 
 
Scheme 37: Quinine derived antimalarial drugs. 
 
There is still an urgent need for the rapid development of an effective, safe and affordable 
chemotherapeutics against malaria in which the functionalization of quinoline and its 
derivatives would play an important role. Nowadays, the quinoline moiety is not only present 
as a substructure of the drugs for treatment of parasitic infections, but is also present in 
antitumor agents such as irinotecan (33d),69 in P-selectin antagonists like luotonin A (33e),70 
or in potential NK3 receptor antagonists such as talnetant (33f)71 (Scheme 38).72 
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 Wiesner, J.; Ortmann, R.; Jomaa, H.; Schlitzer, M. Angew. Chem. Int. Ed. 2003, 42, 5274. 
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Scheme 38:  Drugs containing the quinoline skeleton. 
 
 
1.2 Functionalization of quinolines using selective Br/Mg exchange reactions 
 
1.2.1  Functionalization of quinolines using halogen/metal exchanges 
Quéguiner73  has studied an exchange on 3-bromoquinoline (34) with reagents such as i-
PrMgCl, t-BuMgCl, i-Pr2Mg and i-PrTMPMg, but the corresponding 3-quinolylmagnesium 
derivatives could not be obtained. Due to the low LUMO energy, quinoline is prone to a 
nucleophilic attack, and the addition of a Grignard reagent to the quinoline ring was favoured  
 
N
Br Bu3MgLi (0.35 eq.), THF,
-10 °C, 2.5 h
35
N
Mg
-
N
N
N
E
 Electrophile
36: E = CH(OH)Ph: 65 % 
             CHO: 75 %
             I: 76 %
             SPh: 44 %
Li+
34
 
 
Scheme 39: Functionalization via lithium tri(quinolyl)magnesates shown for 3-
bromoquinoline (34). 
 
over the exchange reaction. Quéguiner could overcome these problems by treating the 
monobrominated quinoline 34 with Bu3MgLi in THF at –10 °C to generate the corresponding 
lithium tri(quinolyl)magnesates 35 (Scheme 39). The resulting organomagnesium derivative 
                                                 
73
 Dumouchel, S.; Mongin, F.; Trécourt, F.; Quéguiner, G. Tetrahedron Lett., 2003, 44, 2033. 
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was quenched with various electrophiles, furnishing monofunctionalized quinolines of type 
36. Using the same method, the functionalizations at C4 and C2 positions were also studied 
by this group, providing monofunctionalized quinolines in moderate yields.73 Comins 
achieved the functionalization at the C4-position by a regioselective Br/Li exchange reaction 
of 2,4-dibromoquinoline (37a).74 When 37a is treated with n-BuLi at –78 °C only the 4-
lithiated species is observed (Scheme 40).  
 
N
Br
Br
1) n-BuLi 1.1 eq., 
Et2O/THF, -78 °C
2) Electrophile N
E
Br
E = H: 76 %
      I: 87%
      CHO: 74 %
37a
 
 
Scheme 40: Regioselective bromine/lithium exchange on 2,4-dibromoquinoline (37a). 
 
 
1.2.2 Regioselective Br/Mg exchange on di- and tribrominated quinolines 
The Br/Mg exchange reactions using i-PrMgCl·LiCl (13) allows an efficient functionalization 
of brominated substrates,31 so we focused first our attention on the regioselectivity of the 
Br/Mg exchange on the polybrominated quinolines of type 37 (Scheme 41). A similar study 
was performed by Quéguiner in 2000 on polybrominated pyridines and the obtained 
regioselectivity using i-PrMgCl was C3>C4>>C2.75, 76 We have tested several magnesiation 
reagents on quinolines of type 37 in order to obtain a complete regioselective exchange. Thus, 
starting from 2,4-dibromoquinoline (37a)77, the addition of i-PrMgCl·LiCl (13; 1.1 equiv, -
78 °C, 2 h) gave quantitatively78 and regioselectively79 the corresponding 4-magnesiated 2-
bromoquinoline (38a, Scheme 42). Similarly, the reaction of 2,3-dibromoquinoline (37b) with 
i-PrMgCl·LiCl (13;1.1 equiv, -50 °C, 2 h, Scheme 42) provided the corresponding 3-
magnesiated 2-bromoquinoline (38b, Scheme 42).  
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2747.  
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 The completion of the Br/Mg exchange reaction was checked by GC analysis of reaction of aliquots quenched 
with saturated NH4Cl (aqueous).  
79
 The regioselectivity of the Br/Mg exchange reaction was checked by 1H NMR of the crude product quenched 
with saturated NH4Cl (aqueous). 
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Scheme 41: Polybrominated quinolines of type 37 as substrates for the regioselective Br/Mg 
exchange reactions. 
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Scheme 42: Regioselective Br/Mg exchanges on 2,4- and 2,3-dibromoquinolines (37a and 
37b). 
 
In contrast, the reactions of 3,4-dibromoquinoline (37c) or 2,3,4-tribromoquinoline (37d) with 
i-PrMgCl·LiCl (13) were not selective, giving a regioisomeric mixture (C3 and C4 positions) 
of Grignard reagents. Moreover, as the main side reaction, the addition of the Grignard at the 
C2 position was observed. Related selectivity problems have been observed with 
dibromopyridines. 59, 60 Starting from 3,4-dibromoquinoline (37c), more sterically hindered 
magnesiation reagents were tried such as sec-BuMgCl·LiCl (39a, Scheme 43), PhMgCl·LiCl 
(39b), 1-naphtylmagnesium chloride (39c), MesMgBr·LiBr (39d), and 1,3,5-
triisopropylphenylmagnesium bromide (39e) (Scheme 44 and Table 1). The regioselectivity 
and the conversion of the reaction between 37c and the Grignard reagents 39a-d were 
checked by 1H NMR of the crude product, obtained after quenching the reaction mixture with 
allyl bromide (1.5 equiv) in the presence of catalytic amount of CuCN·2LiCl (cat.)57 (Scheme 
44). Unfortunately, the lack of reactivity of the Grignard reagents 39a-d led to long time 
reactions and a moderate selectivity (mixture of isomers C3 (40a) and C4 (40b), entries 1-6, 
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Table 1). The best regioselectivity (C3/C4, 6.5:1) was obtained with MesMgBr·LiBr (39d, 
entry 5). 
 
MgCl·LiCl Me Me
Me
MgBr·LiCl
i-Pri-Pr
i-Pr
MgBr·LiCl
MgCl·LiClMe
Me
MgCl·LiCl
39a 39b 39c 39d 39e
 
 
Scheme 43: Sterically hindered Grignard reagents. 
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Scheme 44: Br/Mg exchange on 37c. 
 
 
Table 1: Br/Mg exchange on 3,4-dibromoquinoline (37c) 
entry Grignard reagent 
 (1.1 equiv) 
T/t 
[°C]/[h] 
conv. 
(%)a isomer 40a : isomer 40b
a
 
1 i-PrMgCl·LiCl -78 / 2 98 1.6 : 1 
2 sec-BuMgCl·LiCl(39a) -78 / 3 91 3.3 : 1 
3 PhMgCl·LiCl(39b) 0 / 12 90 1.2 : 1 
4 C10H7MgCl·LiCl (39c) 0 / 24 56 2.5 : 1 
5 MesMgBr·LiBr (39d) 0 / 24 95 6.5 : 1 
6 C15H23MgCl·LiCl (39e) 0-25 / 30 85 6 : 1 
7 Mes2Mg·2LiBr(39f) -10 / 3 95 19 : 1 
8 
Mes2Mg·2LiBr (39f) 
+ TMEDA (1.1 equiv) 
-10 / 6 96 >19 :1 
a
 The regioselectivity and the conversion were checked by 1H NMR of the crude product obtained after 
quenching the reaction mixture with allyl bromide (1. 5 equiv) in presence of cat. amount of CuCN·2LiCl (cat.) 
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To overcome this problem, we have performed the synthesis of the corresponding 
dimesitylmagnesium·2LiBr complex 39f (Mes2Mg·2LiBr, Scheme 45). Diaryl or dialkyl 
Grignard are more reactive than their corresponding mono Grignard species.17d Starting from 
commercially available mesityl bromide (41), the addition of t-BuLi (1.95 equiv, Et2O, -
78 °C) provided the corresponding lithiated compound 42 in quantitative yield, which after 
evaporation of the solvent reacted with one equivalent of MesMgBr to furnish Mes2Mg·2LiBr 
(39f). The use of this new diaryl Grignard was found to be more effective, and a 19 : 1 
mixture of the isomers  C3 (40a)/C4 (40b) was obtained at -10 °C after 3 h (entry 7).80 We 
have improved the regioselectivity by adding 1.1 equiv of TMEDA. This led to the complex 
39f·TMEDA of reduced reactivity, and furnished selectively the C3-magnesiated quinoline 
(entry 8, Table 1 and Scheme 46).  
 
MeMe
Me
Br
MeMe
Me
Li
THF
Me
Me
Mg·2LiBrMe
 t-BuLi  (1.95 equiv.) 
 Et2O, -78 °C
MesMgBr (1 equiv.)
2
+ LiBr
41 42 39f
 
 
Scheme 45: Preparation of the diaryl Grignard reagent Mes2Mg·2LiBr (39f) 
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Scheme 46: Regioselective Br/Mg exchanges on 3,4-di- and 2,3,4-tri-bromoquinolines (37c 
and 37d). 
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 1.1 equivalent of Mes2Mg·2LiBr (39f) was necessary to obtain a complete conversion of the 3,4-
dibromoquinoline. 
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Concerning the Br/Mg exchange on 2,3,4-tribromoquinoline (37d), the reaction of  
MesMgBr·LiCl (39d (1.1 equiv), -10 °C, 3 h) led to a completely regioselective magnesiation 
at C3 position providing the corresponding intermediate 38d (Scheme 46). Compared to 3,4-
dibromoquinoline, the presence of the bromine at C2 position increases the reactivity of the 
C3 position for the Br/Mg exchange, and MesMgBr·LiCl appeared to be sufficiently selective. 
The Grignard compounds 38a-d (Schemes 42 and 46) were trapped with various electrophiles 
as shown in Scheme 47 and Table 2. Thus, the Grignard intermediate 38a afforded after 
quenching with PhSO2SPh81  or tosyl cyanide the corresponding phenylsulfanyl quinoline 
(43a, 91%) or 4-cyano-2-bromoquinoline (43b, 85%) (entries 1 and 2). The transmetalation of 
the C4-magnesiated 2-bromoquinoline 38a using CuCl·2LiCl (1.2 equiv, -50 °C, 1 h) 
followed by the addition of LiHMDS (2 equiv, -60 °C, 1 h) provided the corresponding 
amidocuprate which was oxidized using chloranil (1.2 equiv, -78 °C, 12 h) 46 and then 
deprotected with TBAF (2.0 equiv, 25 °C, 15 min) leading to the 4-amino-2-bromoquinoline 
(43c, entry 3) in 75% yield. The C3-magnesiated 2-bromoquinoline 38b was quenched with 
tosyl cyanide or propionaldehyde and gave 3-cyano-2-bromoquinoline (43d, 84%) or the 
corresponding alcohol (43e, 76%) (entries 4 and 5 of Table 2). The C3-magnesiated 4-
bromoquinoline (38c) provided after trapping with PhSO2SMe82 the thioether 43f (entry 6, 
79% yield). Interestingly, the diarylmagnesium reagent 38c underwent after transmetalation 
with ZnCl2 a Pd-catalyzed Negishi cross-coupling54 with 4-iodobenzonitrile, and furnished 
the coupling product (43g) in 71% yield (entry 7). The reaction with C4-magnesiated 2,3-
dibromoquinoline (38d) and tosyl cyanide afforded the corresponding quinoline 43h (88%, 
entry 8). The Grignard intermediate 38d was also quenched with ethyl cyanoformate giving 
the quinoline ester 43i (90%, entry 9). 
 
 
N
MgX
Br
N
E
Br
38a-d 43
E+
 
 
 
Scheme 47: Functionalization of the magnesiated quinolines of type 38a-d. 
 
 
                                                 
81
 Fujiki, K.; Tanifuji, N.; Sasaki, Y.; Yokoyama, T. Synthesis 2002, 343. 
82
 Stoll, A. H.; Krasovskiy, A.; Knochel, P. Angew. Chem. Int. Ed. 2006, 45, 606.  
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Table 2: Bromoquinolines of type 43 obtained by the reaction of brominated quinolines with 
an exchange Grignard reagent and an electrophile 
 
entry magnesium species of type 38 a electrophile product of type 43 
yield 
(%)b 
 
 
N Br
MgX
 
38a 
 
N Br
E
 
  
1 38a PhSO2SPh 43a: E=SPh 91 
2 38a TsCN 43b: E=CN 85 
3 38a LiHMDS; chloranil 43c: E=NH2 75c 
 
N
MgX
Br
 
38b 
 
N
E
Br
 
 
 
4 38b TsCN 43d: E=CN 84 
5 38b C2H5CHO 43e: E=CH(OH)C2H5 76 
 
N
Br
MgAr
 
38cd 
 
N
Br
E
 
 
 
6 38c d PhSO2SMe 43f: E= SMe 79 
7 38c d NC I
 
43g: E= 
NC
 71e,f 
 
N
Br
MgX
Br
 
38d 
 
N
Br
E
Br
 
  
8 38d TsCN 43h: E=CN 88 
9 38d NC-CO2Et 43i: E=CO2Et 90 
a X = Cl·LiCl or Br·LiCl . b Isolated yield of analytically pure product. c Reaction performed after transmetalation 
with CuCl·2LiCl (1.2 equiv). d Ar = Mes·2LiBr. e Reaction performed after transmetalation with ZnCl2. f 2 mol% 
of Pd(dba)2 and 4 mol% of P-(o-furyl)3 were added. 
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1.2.3 Successive regioselective Br/Mg exchanges on 2,3,4-tribromoquinoline (37d) 
Remarkably, multiple selective exchanges can also be performed starting with the 
tribromoquinoline 37d. Thus, the reaction of MesMgBr·LiCl (39e, 1.1 equiv, -10 °C, 3 h) 
with 37d provided after quenching with benzyl bromide the corresponding benzylated 
quinoline 43j in 89% yield (Scheme 48). This product 43j underwent a second Br/Mg 
exchange reaction using 13 (1.1 equiv,  -50 °C, 12 h) and led after quenching with PhSO2SMe  
 
 
N
Br
Br
Ph
N
SMe
CH2Ph
EtO2C
N
SMe
CH2Ph
BrN
Br
Br
Br
43j : 89% 44: 87%
45: 70%
1) MesMgBr·LiCl (39d), 
   THF, -10 °C, 3 h
2) PhCH2Br, 
   -10 to 25 °C, 10 h
1) i-PrMgCl·LiCl (13), 
   THF, -50 °C, 12 h
2) PhSO2SMe,
   -50 to 25 °C, 12 h
44
1) Mes2Mg·2LiBr (39f), 
   0 °C, 12 h
2) 
   CuCN·2LiCl (cat.), 
   -20 to 25 °C, 12 h
37d
CO2Et
Br
 
 
Scheme 48: Successive regioselective Br/Mg exchange reactions at the C3, C4 and C2 
positions. 
 
to 3,4-difunctionalized-2-bromoquinoline 44 in 87% yield. The third Br/Mg exchange was 
performed on 44 using Mes2Mg·2LiBr (39f, 1.2 equiv, 0 °C, 12 h) and a copper-catalyzed 
allylation with ethyl (2-bromomethyl)acrylate83 afforded the highly functionalized quinoline 
45 in 70% yield. This last exchange reaction completed the sequence of successive 
functionalization at C4, C3 and C2 positions.  
 
 
                                                 
83
 Villieras, J.; Rambaud, M. Org. Synth. 1988, 66, 220. 
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1.3 Functionalization of quinolines using a combination of selective magnesiations 
 
1.3.1 Metalations of quinolines using lithium amide bases 
Strong bases like lithium amide reagents (LDA) can be used for the ortho-directed lithiation 
of 2-bromoquinoline.84 Schlosser studied the “regioflexibility”85 in the functionalization of 
polyhalogenated quinolines using LDA or LiTMP. As an example, the sequential treatment of 
4-bromo-2-(trifluoromethyl)quinoline (46) with LDA and carbon dioxide provided the 
quinoline 3-carboxylic acid 47 in 88% yield (Scheme 49). 
 
 
N
Br
CF3 N CF3
Br
CO2H
1) LDA,
    THF, -78 °C
2) CO2
3) Hydrolysis
47: 88%46
 
 
Scheme 49: C3 lithiation of 4-bromo-2-(trifluoromethyl)quinoline. 
 
Quéguiner described the functionalization of the 4-position of 3-fluoroquinoline (48, Scheme 
50) achieved by an intricate sequence of deprotonation reactions with LDA at –78 °C. The 
first deprotonation is followed by the trapping with iodine and leads to 3-fluoro-4-
iodoquinoline (49) which can be then deprotonated in the 2-position and quenched with 
electrophiles, leading to 4-substituted dihalogenated quinoline derivatives 50 via a “halogen-
dance” rearrangement (Scheme 50).86 
 
 
N
N N
F I
F
E
F
I
1) LDA, THF,
 -78 °C, 4 h
2) I2
3) hydrolysis
1) LDA, THF, 
-78 °C, 2 h
2) electrophile
3) hydrolysis
50: 74 - 98 %
E = H, I, Cl, CH(OH)Me, 
CH(OH)Ph, CHO
49: 94 %48
 
Scheme 50: Functionalization of the 4-position of 48 via two deprotonations and a halogen-
dance. 
                                                 
84
 Comins, D. L.; Hong, H.; Saha, J. K.; Jianhua, G. J. Org. Chem. 1994, 59, 5120. 
85
 (a) Marull , M. ; Schlosser, M. Eur. J. Org. Chem. 2004, 1008; (b) Marull , M. ; Schlosser, M. Eur. J. Org. 
Chem. 2003, 8, 1576.  
86
 a) Arzel, E.; Rocca, P.; Marsais, F.; Godard, A.; Quéquiner, G. Tetrahedron Lett. 1998, 39, 6465; b) Arzel, E.; 
Rocca, P.; Marsais, F.; Godard, A.; Quéquiner, G. Tetrahedron 1999, 55, 12149.  
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1.3.2 Magnesiations of quinolines using deprotonations and Br/Mg exchanges 
Recently, our group developed the new mixed Mg/Li amide bases TMPMgCl·LiCl (18a)37 
and TMP2Mg·2LiCl (19)40 which allowed the direct magnesiation of some heteroaryl 
compounds such as 3-bromoquinoline (34) leading to the 2-functionalized quinoline 51 
(Scheme 51).37 
 
N
N
Br
Br
1) TMPMgClLiCl,
    THF, -25 °C, 0.3 h
2) I2
3) Hydrolysis
51: 87 %34
I
 
 
Scheme 51: Direct C2-magnestion of 3-bromoquinoline (34). 
 
We focused our attention on the direct magnesiation of quinolines using TMPMgCl·LiCl 
(18a), and TMP2Mg·2LiCl (19), which further enhanced both the scope of regioselective 
magnesiations as well as the tolerance toward sensitive functional groups, such as ketones or 
esters. Using the combination of this metalation reaction with the regioselective Br/Mg 
exchange on polybrominated quinolines, we may thus choose different pathways for 
polyfunctionalization and obtain a complete “regioflexibility”.  
 
 
N
Br Br
BrN N
CO2Et
Br
Br
COt-Bu
CO2Et
N
37a: 65% 43k: 92%
52: 84%
34
1) TMPMgCl·LiCl (18a), 
   THF, -20 °C, 2 h
2) (Cl2BrC)2, 
   -20 to 25 °C, 12 h
1) i-PrMgCl·LiCl (13), 
   THF, -50 °C, 2 h
2) NC-CO2Et, 
   -50 to 25 °C, 5 h
43k
1) TMPMgCl·LiCl (18a), 
   THF, 0 °C, 3 h
2) CuCN·2LiCl, THF, 
   -40 °C, 10 min
3) t-BuCOCl, 
  -40 to 25 °C, 6 h
 
 
Scheme 52: Successive regioselective magnesiations at the C2, C3 and C4 positions.  
 
Thus, a successive magnesiations in position C2, C3 and C4 could be achieved. Commercially 
available 3-bromoquinoline (34, Scheme 52) underwent a C2-deprotonation using 
TMPMgCl·LiCl (18a, 1.1 equiv, -20 °C, 2 h) and was quenched with 1,2-dibromo-1,1,2,2-
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tetrachloroethane giving the 2,3-dibromoquinoline 37a in 65% yield. The treatment of 37a 
with iPrMgCl·LiCl (13), provided after the reaction with ethyl cyanoformate 2-
bromoquinoline-3-carboxylic acid ethyl ester (43k) in 92% yield. Addition of TMPMgCl·LiCl 
(18a) to 43k gave regioselectively the C4-magnesiated intermediate under mild conditions 
(0 °C, 3 h). Then, a smooth carboxylation in the presence of CuCN·2LiCl led to the quinoline 
52 in 84% yield. Thus, the sequence of functionalization C2-C3-C4 was accomplished 
(Scheme 52).  
The pertinent combination of Br/Mg exchanges and direct metalations allowed a 
regioselective functionalization of up to three new positions of the 2,4-dibromoquinoline 
(37a). Performing a Br/Mg exchange on 37a with i-PrMgCl·LiCl (13, -78 °C, 2 h, Scheme 53) 
led after the reaction with ethyl cyanoformate, to the quinoline 43l in 92% yield. Then, the 
regioselective deprotonation of 43l at the C3-position using 18a (-10 °C, 3 h) followed by a 
copper-mediated acylation57 using pivaloyl chloride gave the quinoline derivative 53 in 81% 
yield. Remarkably, a second regioselective deprotonation on the quinoline 53 was performed 
at the position C8 (N-coordination), using the magnesium bisamide TMP2Mg·2LiCl 40, 87 
under mild conditions (0 °C, 20 h). After the transmetalation with ZnCl2, the Pd-catalyzed 
Negishi cross-coupling with ethyl 4-iodobenzoate furnished the highly functionalized 
quinoline 54 in 71% yield (Scheme 53). 
 
BrN
Br
IEtO2C
N
CO2Et
Br
CO2Et
N
CO2Et
Br
COt-Bu
N
CO2Et
Br
COt-Bu
53: 81%
54: 71%
37a 43l: 92%
1) i-PrMgCl·LiCl (13),
   THF, -78 °C, 2 h
2) NC-CO2Et, 
   -78  to 25 °C, 12 h
1) TMPMgCl·LiCl (18a), 
   THF, -10 °C, 3 h
2) CuCN·2LiCl, THF, 
   -20 °C, 30 min
3) t-BuCOCl,
 -40  to 25 °C, 12 h
53
1) TMP2Mg·2LiCl (19), 
   THF, 0 °C, 20 h
2) ZnCl2, 0  to 25 °C, 0.5 h
3) 
   Pddba2, P-(o-furyl)3, 
   THF, reflux, 4 h.
 
 
Scheme 53: Successive regioselective magnesiations at the C4, C3 and C8 positions.  
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 TMPMgCl·LiCl (18a) was found to be ineffective for this metalation. 
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1.3.3 An application to the synthesis of the NK3 receptor antagonist talnetant (33f) 
As an application of our methodology, the total synthesis of talnetant (33f) was performed 
(Scheme 54). Talnetant is a neurokinin-3 receptor antagonist, it is under development by 
GlaxoSmithKline for the potential treatment of several disorders, including urinary 
incontinence, irritable bowel syndrome and schizophrenia.  
 
N
CO2Et
Br B
O
O
EtO
N
CO2H
OH
N
EtO2C
Br
B O
O
N
EtO2C
B O
O
N
OH
O NH
EtPh
57: 89%
56: 76%55: 71%
talnetant 33f: 84%
43l
56
1) TMPMgCl·LiCl (7), 
   THF, -10 °C, 3 h 
2) 
   -10  to 25 °C, 12 h
   HCl, Et2O
PhZnCl, THF,
 Pd(PPh3)4,
 25 °C, 1 h
LiOH, 
H2O2 (32 % aq), 
MeOH, 25 °C, 15 h
1) NEt3, Im2CO (CDI), 
CH3CN, 50 °C, 5 h
2) (S)-1-phenyl-propylamine,
 CH3CN, 50  to 25 °C, 12 h
 
Scheme 54: Successive regioselective functionalizations of quinolines at the C4, C3 and C2 
positions.  
 
The treatment of 4-carbethoxy-2-bromoquinoline (43l) with TMPMgCl·LiCl (18a, -10 °C, 
3 h), followed by quenching with ethyl pinacol borate88 (1.5 equiv, -10 °C to 25 °C, 12 h) and 
acidic workup (1.2 equiv HCl in Et2O) 89  furnished the corresponding pinacol boronic ester 
55 in 71% yield (Scheme 54). Its Pd(0)-catalyzed cross-coupling with PhZnCl gave the 
corresponding functionalized boronic ester 56 in 76% yield. A basic oxidation using LiOH (6 
equiv) and 30% aq H2O2 (3 equiv) in MeOH (25 °C, 15 h) afforded the acid 57 in 89% yield. 
Treatment90 of 57 with NEt3 (25 °C, 30 min), CDI (1.1 equiv, 50 °C, 5 h) and (S)-1-phenyl-
propylamine (1.1 equiv, 50 °C to 25 °C, 12 h) in acetonitrile gave talnetant (33f) in 84% 
yield. By this method, we obtained a new sequence of functionalization, C4-C3-C2, and have 
found an alternative method to the Pfitzinger synthesis, the common method to obtain 
                                                 
88
 Ethyl pinacol borate was preferentially used instead of commercially isopropyl pinacol borate because of a 
transesterification side reaction.  
89
 Brown, H. C.; Bhat, N. G.; Srebnik, M. Tet. Lett. 1988, 29, 2631. 
90
 Labaw, C. S.; Liu, P. PCT Int. Appl. 2007, WO 2007016609.  
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quinoline salicylic acid series used as clinical candidate for P-selectin antagonists (Scheme 
55). 91, 92  
 
R
N
H
O
O Ar
O
OR1
R N
CO2H
OH
Arn+
1) KOH, EtOH, H2O, ∆
2) 1M HCl
 R1 = OH; OAc
n
 
 
 
Scheme 55: Pfitzinger reaction used for the synthesis of quinoline salicylic acid. 
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 Pfitzinger, W. J. Prakt. Chem. 1886, 33, 100. 
92 Kaila, N.; Janz, K.; Huang, A.; Moretto, A.; DeBernardo, S.; Bedard, P. W.; Tam, S.; Clerin, V.; Keith, J. C. 
Jr.; Tsao, D. H. H.; Sushkova, N.; Shaw, G. D.; Camphausen, R. T.; Schaub, R. G.; Wang, Q.  J. Med. Chem. 
2007, 50, 21. 
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2.  Functionalizations of Protected Uracils via Chemo- and Regioselective 
Magnesiations 
 
2.1. Introduction 
Uracil derivatives are present among the natural products, like the marine alkaloid rigidin 5893  
(Scheme 56), are mainly privileged structures in drug discovery 94  and display a broad 
spectrum of biological activities. For example, 5-fluorouracil (59)95 is an important anticancer 
agent. Oxypurinol (60),96 is a xanthine oxidase inhibitor, the active metabolite of the drug 
allopurinol. In recent years, several pathways were developed for the synthesis of analogues 
of emivirine (61), belonging to non-nucleoside reverse transcriptase inhibitors (NNRTIs) 97 
that targets the retrovirus HIV-1 (Scheme 56). 
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Scheme 56: Uracil derivatives as pharmacological agents. 
 
                                                 
93
 (a) Sakamoto, T.; Kondo, Y.; Sato, S.; Yamanaka, H. J. Chem. Soc., Perkin Trans. 1. 1996, 5, 459; (b) Lagoja, 
I. M. Chemistry & Biodiversity 2005, 2, 1. 
94
 Newkome, G. R.; Pandler, W. W.; Contemporary Heterocyclic Chemistry, Wiley, New York, 1982. 
95
 Cai, T. B.; Tang, X.; Nagorski, J.; Brauschweiger, P. G.; Wang, P. G. Bioorganic & Medicinal Chemistry 
2003, 11, 4971. 
96
 Nagamatsu, T.; Fujita, T.; Endo, K. J. Chem. Soc., Perkin Trans. 1. 2000, 33. Allopurinol is a well known 
drug clinically used for the treatment of gout and hyperuricemia. Oxypurinol is currently being developed by 
Cardiome Pharma for the treatment of allopurinol-intolerant hyperuricaemia (gout) and is in phase III trials for 
the treatment of congestive heart failure. 
97
 (a) Tanaka, H.; Takashima, H.; Ubasawa, M.; Sekiya, K.; Inouye, N.; Baba, M.; Shigeta, S.; Walker, R. T.; De 
Clercq, E.; Miyasaka, T. J. Med. Chem. 1995, 38, 2860; (b) Pedersen, O. S.; Pedersen, E. B. Antiviral Chem. 
Chemother. 1999, 10, 2860. 
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2.2. Chemo and regioselective Br/Mg exchanges on protected uracils 
 
2.2.1. Functionalization of protected uracils using halogen/metal exchange 
The functionalization of uracil derivatives at C4 or C5 generally requires the protection of the 
carbonyl groups.98 Two ways of the amide group protection are often used. The N-alkylation 
(as with the uracil 62) protected the nitrogens with benzyl or methyl groups, or the O-
alkylation protected the oxygens such as in the 2,4-dialkylpyrimidine derivatives 63 and 64 
(Scheme 57). 
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67: 56%
1) i-PrMgBr, THF, 
    -40 °C, 0.5 h
2) TsCN
65: 57%
1) n-BuLi,
   -70 °C, THF, 5 min
2) benzaldehyde, Et2O
-70 °C, 1 h
66: 70%
1) EtMgCl (1 equiv),
    25 °C, THF, 1.5 h
2) benzaldehyde, THF
25 °C, 12 h
64 (4 equiv) 68: 80%
conc. HCl
68a: 96%
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(1)
(2)
(3)
(4)
 
 
 
Scheme 57: Halogen/metal exchange on protected uracils. 
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 For a recent functionalization of unprotected uracil, see: Kopp, F.; Knochel, P. Org. Lett. 2007, 9, 1639. 
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Knochel described the I/Mg exchange on the protected uracil 62 which led to compound 65 
after quenching with tosyl cyanide (Scheme 57, Eq. 1). 99  The harsh conditions for 
deprotection have limited the use of this route. 2,4-Dialkoxypyrimidine was first used as a 
starting material for the preparation of protected uracil by Binkley in 1963,100 which described 
the Br/Li exchange on 5-bromo-diethoxypyrimidine (63) using n-BuLi. After quenching with 
benzaldehyde, the corresponding product 66 was obtained in high yield (Scheme 57, Eq. 2). 
Later, Br/Mg exchanges were studied by Yokohama on 5-bromo-2,4-di-t-butoxypyrimidine 
(64) using n-BuMgCl under ultrasonic irradiation to perform the synthesis of nucleoside 
derivatives (67, Eq. 3)101  or using EtMgCl in the presence of a large excess of starting 
material (Eq. 4) to synthesize the alcohol uracil derivative 68. 102  Interestingly, the 
corresponding product 68 was easily deprotected using conc. HCl affording the uracil 68a in 
96% yield. These methods allowed the preparation of various uracil derivatives but required 
low temperatures, activation and non-stoichiometric conditions, precluding the presence of 
sensitive functional groups. Recently, we have found a LiCl-catalyzed Br/Mg exchange 
reaction using i-PrMgCl·LiCl (13).31 This reagent considerably accelerates the Br/Mg 
exchange reaction on aryl and heteroaryl bromides. We focused our studies on the general 
preparation of uracils, functionalized at C4 and C5 positions, starting from readily available 
protected uracils, which easily undergo deprotection. We chose 5-bromo-4-chloro-2,6-
dimethoxypyrimidine (69a, Scheme 58) and 4,5-dibromo-2,6-dimethoxypyrimidine (69b) as 
starting materials, prepared respectively by bromination 103  of commercially available 4-
chloro-dimethoxypyrimidine (70a), and readily available 4-bromo-dimethoxypyrimidine 
(70b).104 
 
Br2
MeOH/H2O
5 h,rtN
N
X
OMe
OMe N
N
X
OMe
OMe
Br
70a: X = Cl
70b: X = Br
69a: X = Cl, 92%
69b: X = Br, 96%
 
 
Scheme 58: Preparation of starting materials 69a and 69b. 
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 Abarbri, M.; Thibonnet, J.; Bérillon, L.; Dehmel, F. ; Rottländer, M. ; Knochel, P. J. Org. Chem. 2000, 65, 
4618. 
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 Rajkumar, T. V.; Binkley, S. B. J. Med. Chem. 1963,  6,  550.   
101
 Momotake, A.; Mito, J.; Yamaguchi, K.; Togo, H.; Yokohama, M. J. Org. Chem. 1998, 63, 7207. 
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 Shimura, A.; Momotake, A.; Togo, H.; Yokoyama, M. Synthesis 1999, 495. 
103
 Okafor, C. J. Org. Chem. 1973, 38, 4386. 
104
 4-Bromo-2,6-dimethoxypyrimidine (70b) was prepared following the literature procedure: White, J. D.; 
Hansen, J. D. J. Org. Chem. 2005, 70, 1963. 
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2.2.2. Chemoselective Br/Mg exchange on 5-bromo-4-chloro-2,6-dimethoxy-
pyrimidine 
The addition of i-PrMgCl·LiCl (13) to 5-bromo-4-chloro-2,6-dimethoxypyrimidine (69a) at 
25 °C in THF furnished within 15 min quantitatively105 the magnesiated N-heterocycle 71 
(Scheme 59, Table 3). This magnesium reagent reacts with a wide range of electrophiles 
providing new 5-functionalized 4-chloro-2,6-dimethoxypyrimidines of type 72a-g in high 
yields (Scheme 59, Table 3). Thus, the addition of benzaldehyde or 2-methoxy-benzaldehyde 
 
N
N
OCH3
OCH3Cl
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N
N
OCH3
OCH3Cl
LiCl·ClMg
N
N
OCH3
OCH3Cl
E1i-PrMgCl·LiCl, 
THF, 25 °C, 
15 min
E1+
69a 71 72a-g
 
 
Scheme 59: Chemoselective functionalizations of 5-bromo-4-chloro-2,6-dimethoxy-
pyrimidine (69a) at C5 position. 
 
to the magnesiated species 71 led to the corresponding alcohols 72a and 72b respectively in 
91 and 83% yield (entries 1 and 2 of Table 3). The reaction with acid chlorides like PhCOCl 
or a carbamoyl chloride provided the ketone 72c in 86% yield and the amide 72d in 85% 
yield (entries 3-4). Treatment of the magnesiated derivative 71 with TsCN afforded the 
heterocyclic nitrile 72e in 89% yield (entry 5). The introduction of an ester group was best 
performed by the reaction with NC-CO2Et leading to the ester 72f in 87% yield (entry 6). The 
reaction with an activated bromide like benzyl bromide provided the expected product 72g in 
75% yield (entry 7). 
                                                 
105
 The completion of Br-Mg exchange was checked by GC analysis of reaction aliquots quenched with saturated 
NH4Cl (aq.). 
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Table 3: Products of type 72 
 
entry Grignard 
reagent a electrophile product of type 72 yield (%)
b 
1 
N
N
OCH3
OCH3Cl
XMg
 
71 
PhCHO N
N
OCH3
OCH3Cl
OH
 
72a 91 
2 71 
OHC
MeO
 
N
N
OCH3
OCH3Cl
OHCH3O
 
72b 83 
3 71 
PhCOCl 
N
N
OCH3
OCH3Cl
O
 
72c 86 
4 71 
O
N
O
Cl
 
N
N
OCH3
OCH3
O
N
ClO
 
72d 85 
5 71 
TsCN 
N
N
OCH3
OCH3Cl
NC
 
72e 89 
6 71 
NC-CO2Et N
N
OCH3
OCH3Cl
O
EtO
 
72f 87 
7 71 
PhCH2Br N
N
OCH3
OCH3Cl
 
72g 75 
a X = Cl·LiCl. b Isolated yield of analytically pure product.  
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2.2.3. Application to the synthesis of annelated heterocycles and the xanthine 
oxidase inhibitor oxypurinol. 
The pyrimidine 72c can be easily converted into annelated heterocycles. Thus, the reaction 
between the chloroketone 72c and hydroxylamine hydrochloride in a 1:1 mixture of 
H2O/MeOH gave within 4 h the desired product 73 in 83% yield (Scheme 60). Interestingly, 
the addition of methyl mercaptoacetate to 72c in the presence of triethylamine106 provided the 
bicyclic S,N-heterocycle 74 in 69% yield (Scheme 60). 
 
N
N
OCH3
OCH3
SO
MeO
N
N
OCH3
OCH3
O
N
N
N
OCH3
OCH3
Cl
O
NH2OH·HCl,
AcONa,
H2O, MeOH
4 h, reflux
HSCH2CO2Me,
Et3N, EtOH,
12 h, reflux
74: 69%
73: 83%
72c
 
 
Scheme 60: Synthesis of annelated heterocycles starting from the acyluracil derivative (72c). 
 
As an application, we also used an intramolecular cyclization to prepare the drug oxypurinol 
60 (Scheme 61). Thus, the reaction of pyrimidine 69a with i-PrMgCl·LiCl (13 (1.05 equiv), 
25 °C, 15 min) followed by the reaction with N-formylmorpholine provided the aldehyde 72h  
in 83% yield. Treatment of 72h with an excess of hydrazine monohydrate 107  led to 
pyrazolopyrimidine 75 in 91% yield (80 °C, 0.5 h). Deprotection using conc. HCl led to 
oxypurinol (60) in 81% yield. 
 
                                                 
106
 Rahman, L. K. A.; Scrowston, R. M. J. Chem. Soc., Perkin Trans. 1. 1984, 3, 385. 
107
 Nagamatsu, T. ; Fujita, T. ; Endo, K. J. Chem. Soc., Perkin Trans. 1. 2000, 33. 
B: Results and Discussion  48 
  
  
N
N
OCH3
OCH3
Br
Cl
N
H
NH
O
O
N
N
H N
N
OCH3
OCH3
N
N
H
N
N
OCH3
OCH3Cl
H
O
 conc. HCl,
 reflux, 2 h
72h: 83%
75: 91%oxypurinol (60): 81%
(overall yield: 58%)
1) i-PrMgCl·LiCl, 
THF, 25 °C, 15 min
2) -35 °C, 5 h
69a
NH2NH2.H2O
EtOH, reflux,
30 min
NO
O
H
 
 
Scheme 61: Synthesis of oxypurinol (60). 
 
 
2.2.4. Regioselective Br/Mg exchange on 4,5-dibromo-2,6-dimethoxypyrimidine 
(69b). 
The Br/Mg exchange on 4,5-dibromo-2,6-dimethoxypyrimidine (69b), using i-PrMgCl·LiCl 
(13 (1.05 equiv), 25 °C, 15 min) occurred regioselectively at C5, providing the corresponding 
magnesium species 76 (Scheme 62, Table 4). The reaction of 76 with various electrophiles 
gave the expected products 77i-m in 70-91% yield (Table 4). The silylation and the direct 
allylation of the magnesium derivative 76 can be accomplished respectively with TMSCl and 
allyl bromide, leading to pyrimidines 77i and 77j in 91% yield (entries 1-2 of Table 4). 
Trapping the magnesium species 76 with ethyl cyanoformate, benzaldehyde or 4-morpholine-
carbonyl chloride furnished the corresponding functionalized products 77k-m in 70-95% 
yields (entries 3-5). 
 
N
N
OCH3
OCH3Br
Br
N
N
OCH3
OCH3Br
LiCl·ClMg
N
N
OCH3
OCH3Br
E1i-PrMgCl·LiCl, 
THF, 25 °C, 15 min
E1+
69b 76 77
 
 
Scheme 62: Regioselective functionalizations of 4,5-dibromo-2,6-dimethoxypyrimidine (69b) 
at C5 position. 
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Table 4: Products of type 77 
 
entry Grignard 
reagent a electrophile product of type 72 yield (%)
b 
1 
N
N
OCH3
OCH3Br
XMg
 
76 
TMSCl 
N
N
OCH3
OCH3Br
Me3Si
 
77a 91 
2 76 
allyl bromide 
N
N
OCH3
OCH3Br
 
77b 91 
3 76 
NC-CO2Et N
N
OCH3
OCH3Br
O
EtO
 
77c 81 
4 76 
PhCHO 
N
N
OCH3
OCH3Br
OH
 
77d 95 
5 76 
O
N
O
Cl
 
N
N
OCH3
OCH3Br
O
N
O
 
77e 70 
a X = Cl·LiCl. b Isolated yield of analytically pure product.  
 
 
2.2.5. Successive Br/Mg exchanges on 4,5-dibromo-2,6-dimethoxypyrimidine (69b) 
and his application the synthesis of the anti-HIV drug emivirine. 
A successive introduction of two different electrophiles in positions C4 and C5 of 4,5-
dibromo-2,6-dimethoxypyrimidine (69b) can be performed. Thus, the reaction of 4-bromo-
2,6-dimethoxy-5-(trimethylsilyl)pyrimidine (77d) with i-PrMgCl·LiCl (13 (1.1 equiv), -15 °C, 
12 h) furnished the corresponding Grignard reagent, which could be trapped with allyl 
bromide to give the expected product 78 in 81% yield (Scheme 63). Interestingly, 
difunctionalizations with two successive Br/Mg-exchange reactions using a “one-pot” 
procedure could also be performed. Thus, by using successively c-HexCHO and N-
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morpholinecarbonyl chloride as electrophiles, the desired product 79a was obtained in 69% 
overall yield. Similarly, by using allyl bromide and MeI, the 4,5-disubstituted pyrimidine 79b 
was prepared in 81% yield (Scheme 64).  
 
N
N OCH3
OCH3
Me3Si
N
N
OCH3
OCH3Br
Me3Si
1) i-PrMgCl·LiCl,
    THF, -15 °C, 12 h
2) allyl bromide,
   CuCN·2LiCl (cat.),
   6 h, -15 to 25 °C 78: 81%77a
 
 
Scheme 63: Br/Mg exchange of 4-bromo-5-(trimethylsilyl)-2,6-dimethoxypyrimidine (77a). 
 
 
 
N
N
OCH3
OCH3Br
Br
N
N
OCH3
OCH3E2
E1
N
N
OCH3
OCH3Me
N
N
OCH3
OCH3
OH
O
N
O
1) i-PrMgCl·LiCl, THF, 
    25 °C, 15 min
2) (E1)+
3) i-PrMgCl·LiCl, THF 
4) (E2)+
79a: 69% 79b: 81%
69b
79
 
 
Scheme 64: Difunctionalizations of 4,5-dibromo-2,6-dimethoxypyrimidine via successive 
“one-pot” Br/Mg exchange reactions. 
 
To illustrate the versatility of this method, a synthesis of the anti-HIV drug emivirine (61) was 
performed (Scheme 65). Treatment of 4,5-dibromo-2,6-dimethoxypyrimidine (69b) with i-
PrMgCl·LiCl (13) followed by the reaction with acetone in the presence of a solution of 
LaCl3·2LiCl in THF,108 led to the corresponding alcohol (77f) in 87% yield. This compound 
was partly reduced using triethylsilane and trifluoroacetic acid.109 A mixture of the expected 
4-bromo-5-isopropyl-2,6-dimethoxypyrimidine (80) and the corresponding unsaturated 
                                                 
108
 Krasovskiy, A.; Kopp, F.; Knochel, P. Angew. Chem. Int. Ed. 2006, 45, 497. 
109
 Albert, J. S.; Aharony, D.; Andisik, D.; Barthlow, H.; Bernstein, P. R.; Bialecki, R. A.; Dedinas, R.; 
Dembofsky, B. T.; Hill, D.; Kirkland, K.; Koether, G. M.; Kosmider, B. J.; Ohnmacht, C.; Palmer, W.; Potts, 
W.; Rumsey, W.; Shen, L.; Shenvi, A.; Sherwood, S.; Warwick, P. J.; Russell, K. J. Med. Chem. 2002, 45, 3972. 
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product was obtained110. The product mixture was directly hydrogenated using PtO2111 (1 bar, 
30 min) to obtain 80 in 91% yield. The second Br/Mg exchange was performed at 25 °C 
within 5 h, followed by the benzyl bromide addition, leading to the 4,5-dialkylated-2,6-
dimethoxypyrimidine species (81) (20 h, 25 °C, 87%). An acidic hydrolysis in aqueous 
MeOH gave the corresponding uracil 82 in 92% yield after the recrystallization. Compound 
82 was transiently silylated using BSA in MeCN and then N-alkylated 112  with 
diethoxymethane to furnish 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (61, emivirine) in 
90% yield (Scheme 65). 
 
N
N
OCH3
OCH3
Br
Br
N
N
OCH3
OCH3
Br
HO
N
N
OCH3
OCH3
N
NH
O
O
O
N
N
OCH3
OCH3
Br
N
H
NH
O
O
1) i-PrMgCl·LiCl,
    THF, 25 °C, 15 min
2) LaCl3·2LiCl, (CH3)2CO,
    THF, 0 °C, 4 h
1) Et3SiH, TFA,
    CH2Cl2, 25 °C, 12 h
2) H2, 1 bar, PtO2
    EtOH, 30 min
77f: 87% 80: 91%
1) i-PrMgCl·LiCl,
    THF, rt, 5 h
2) PhCH2Br, 25 °C, 20 h
CuCN·2LiCl (cat.)
HCl conc.,
MeOH, reflux, 4 h
1) BSA, MeCN
2) TMSOTf
    CH2(OEt)2
emivirine (61): 91%
81: 87% 82: 92%
69b
80
82
 
 
Scheme 65: Synthesis of the anti-HIV drug emivirine (61). 
                                                 
110 A mixture of 17% of 80 and 83% of the corresponding dehydrated product was obtained by 1H NMR analysis 
of the crude product. 
111
 Tilley, J. W.; LeMahieu, R. A.; Carson, M.; Kierstead, R. W. J. Med. Chem. 1980, 23, 92.  
112
 Therkelsen, F. D.; Hansen, A-L. L.; Pedersen, E. B.; Nielsen, C. Org. Biomol. Chem. 2003, 1, 2908. 
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2.3. Direct magnesiation of protected uracils 
 
2.3 Deprotonation of 2,4-dimethoxypyrimidine (83a) using lithium amide bases 
Using the amide base TMPMgCl·LiCl (18a),37 we have investigated the deprotonation of 
commercially available 2,4-dimethoxypyrimidine (83a, Scheme 66). Our aim was to access 
regioselectively polyfunctionalized protected uracils. J. Yamamoto described the use of strong 
bases such as the lithium amide TMPLi which led to the ortho-directed lithiation of 2,4-
dimethoxypyrimidine (83a) in order to obtain the 5-functionalized 2,4-dimethoxypyrimidine 
84 (Scheme 66). 113 The chelating effect of the methoxy group in the intermediate 85 led to 
the thermodynamically most stable metal species.114 With the use of lithium reagents, the 
range of potential electrophiles was strongly limited, and the 5-functionalized 2,4-
dimethoxypyrimidines were obtained in moderate to low yields (4-65%). Very low yields 
were obtained using LDA, with recovery of the starting material.113 
 
N
N
OCH3
OCH3
N
OCH3
OCH3
Li
N N
N
OCH3
OCH3
Ph
OH
ElectrophileTMPLi (1.2 eq.), 
Et2O, 0 ºC, 1 h
84: 65 %83a 85
 
 
Scheme 66: Ortho-directed lithiation of 2,6-dimethoxypyrimidine. 
 
 
2.3.1 Deprotonation of 2,4-dimethoxypyrimidine using TMPMgCl·LiCl (18a) 
Surprisingly, through the treatment of commercially available 2,4-dimethoxypyrimidine (83a) 
with TMPMgCl·LiCl (18a) at –40 °C we easily got an access to the 6-magnesiated 2,4-
dimethoxypyrimidine (86). Trapping of the resulting Grignard reagent 86 with benzaldehyde 
furnished the corresponding alcohol 87a in 88 % yield (Scheme 67a). By the comparison of 
1H NMR115 of the products 87a and 84 (synthesized by Yamamoto using TMPLi (Scheme 66), 
we could show that we obtained the kinetic product, C6-isomer product (87a) and not the C5 
product (84). Starting from 83a, the reaction with TMPMgCl·LiCl at various temperatures 
such as -20 °C, 0 °C or 25 °C, and the quenching with several electrophiles, led to a 
regioisomeric C6/C5 mixture.  
 
                                                 
113
 (a) Wada, A.;Yamamoto, J.; Kanatomo, S. Heterocycles 1987, 3, 585; (b) Wada, A.; Yamamoto, J.; 
Hamoaka, Y.; Ohki, S.; Nagai, S.; Kanamoto, S. J. Heterocycl. Chem. 1990, 27, 1831. 
114
 Turck, A. ; Plè, N.; Quéguiner, G. Heterocycles 1994, 3, 2149. 
115
 1H-NMR (CDCl3):  84: δ = 8.16 ppm (s, 1H at C6 position); 87a: δ = 6.21 ppm (s, 1H at C5 position). 
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N
N
OCH3
OCH3
N
N
OCH3
OCH3
N
N
OCH3
OCH3
OH
N
N
OCH3
OCH3
ClLi·ClMg
86
N
OCH3
OCH3
OH
N
TMPMgCl·LiCl (18a),
THF, -40 °C, 12 h
1) TMPMgCl·LiCl (18a),
   THF, -40 ºC, 12 h
2) PhCHO
+
84: no traces87a: 88%
83a
83a
 
 
Scheme 67a: First regioselective 6-functionalization of 2,4-dimethoxypyrimidine (83a). 
 
 
Remarkably, the reaction of 2,4-dimethoxypyrimidine (83a), in presence of TMSCl (1.5 
equiv) in THF at -100°C (Barbier conditions reaction), with TMPLi (1.0 M in Et2O) led after 
0.5 h to a regioisomeric mixtures of the corresponding products C6/C5 = 15:1116 (Scheme 
67b). This result proved that using TMPLi a kinetic deprotonation of 2,4-
dimethoxypyrimidine (83a) is also possible to occur at C6 position, but at lower temperature 
compared with TMPMgCl·LiCl. 
 
N
N
OCH3
OCH3 N
N
OCH3
OCH3TMS N
N
OCH3
OCH3
1) TMSCl (1.2 equiv),  
THF,  -100 ºC, 5 min    
2) TMPLi (1.2 equiv),
THF, -100 ºC, 0.5 h
83a
+
TMS
15                       :                        1
 
 
Scheme 67b: Deprotonation of 2,4-dimethoxypyrimidine (83a) at C6 position using TMPLi 
under Barbier conditions. 
 
Keeping carefully the temperature at -40 °C during the deprotonation, we could quench the 
C6-magnesiated 2,4-dimethoxypyrimidine (86, Scheme 67) at low temperature with several 
electrophiles, obtaining the C6-functionalized protected uracils of type 87 (Scheme 68, Table 
5, entries 1-4). Thus, the reaction of the Grignard intermediate 86 with iodine produced the 4- 
iodo-2,6-dimethoxypyrimidine (87b) in 87% yield (entry 1). A transmetalation of 86 with 1.1 
equiv of CuCN·2LiCl and the treatment with pivaloyl chloride furnished the protected uracil 
                                                 
116
 The regioselectivity of the reaction was obtained by GC-MS analysis of the crude mixture obtained after 
quenching the reaction with NH4Cl and extracting with Et2O. 
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87c in 72% yield (entry 2). Starting from the Grignard intermediate 86 and using 
transmetalation with ZnCl2  (1 M in THF, 1.1 equiv, 25 °C, 15 min) and the Pd-Negishi cross-
coupling with ethyl 4-iodobenzoate we obtained the arylpyrimidine 87d in 75% yield (entry 
3). An ester function was also implemented on 83a using ethyl cyanoformate, and ester 
derivative 87e was prepared in 71% yield (entry 4).  
 
N
N
OCH3
OCH3 N
N
OCH3
OCH3ClMg N
N
OCH3
OCH3E1
TMPMgCl·LiCl (18a), 
THF, -40 ºC, 12 h
83a 86 87b-e
(E1)+
 
 
Scheme 68: C6-functionalization of 2,4-dimethoxypyrimidine (83a) using TMPMgCl·LiCl 
(18a). 
 
Table 5: Products of type 87 and 89. 
entry reagent (°C) ;
 [T] 
magnesium 
reagent 
electro-
phile product, yield (%)
a
 
1 
N
N
OCH3
OCH3
 
83a 
-40; 
[12] 
N
N
OCH3
OCH3ClMg
 
86 
I2 N
N
OCH3
OCH3I
 
87b: 87 
2 
 
83a 
-40; 
[12] 
 
86 
t-BuCOCl N
N
OCH3
OCH3
O
t-Bu
 
87c: 72[c] 
3 83a 
-40; 
[12] 86 
I
CO2Et
 
N
N
OCH3
OCH3
EtO2C
87d: 75[e,d] 
4 83a 
-40; 
[12] 86 
NC-CO2Et N
N
OCH3
OCH3EtO2C
 
87e: 71 
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5 
N
N
OCH3
OCH3I [f]
 
87b 
-30 to 
0; [2] 
N
N
OCH3
OCH3I
ClMg
 
88a 
I2 
N
N
OCH3
OCH3I
I
 
89a: 87  
6 87b 
0; 
[1] 88a 
COCl
F
 
N
N
OCH3
OCH3I
O
F
 89b: 84[c] 
7 
N
N
OCH3
OCH3EtO2C
87e 
-40; 
[2] 
N
N
OCH3
OCH3EtO2C
ClMg
88b 
PhCOCl 
N
N
OCH3
OCH3EtO2C
O
Ph
 
89c: 78[c] 
[a]
 Isolated yield of analytically pure product; [b] Catalytic amount of CuCN·2LiCl was added; [c] 1 equiv. of 
CuCN·2LiCl was added; [d] The Grignard was transmetalated with 1.2 equiv. of ZnCl2 in THF [e] 1 mol % of 
Pd(Ph3P)4 was added. [f] This reaction was made starting from 83a in a “one pot” procedure. 
 
2.3.2 Deprotonation of 6-functionalized 2,4-dimethoxypyrimidine using 
TMPMgCl·LiCl (18a) 
 
N
N
OCH3
OCH3E1 N
N
OCH3
OCH3E1
ClMg
N
N
OCH3
OCH3E1
E2
87
TMPMgCl·LiCl (18a)
            THF
88 89
(E2)+
 
 
Scheme 69: Functionalization of compounds of type 87 using TMPMgCl·LiCl (18a). 
 
 
Interestingly, contrary to the regioselectivity C5>C4, obtained on 4,5-dibromo-2,6-
dimethoxypyrimidine (69b) in the Br/Mg exchange reaction (Scheme 64), the direct 
deprotonation of 2,4-dimethoxypyrimidine (83a) with TMPMgCl·LiCl allowed us to 
introduce successively functional groups first at C6 and then at C5 positions (Scheme 69, 
Table 5, entries 5-7).  The “one pot” successive diiodination of 83a was performed using 
TMPMgCl·LiCl (-40 °C, 12 h) and iodine (1.2 equiv, -30 °C, 2 h) and provided the 4,5-
diiodo-2,6-dimethoxypyrimidine (89a) (87% yield, entry 6). Starting from 87b, the reaction 
with TMPMgCl·LiCl (0 °C, 1 h) followed by a copper(I)-catalyzed acylation with 4-
fluorobenzoyl chloride led to the ketone derivative 89b (84%, entry 7). Moreover, the use of 
this mixed Mg/Li amide base enhanced the tolerance toward sensitive functional groups such 
as an ester (entry 7). Thus, the reaction of TMPMgCl·LiCl (1.1 equiv, -40 °C, 2 h) on the 
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protected uracil ester 87e led to the C5-magnesiated intermediate 88b, which after a 
transmetalation with CuCN·2LiCl was quenched with benzoyl chloride and afforded the 
highly functionalized pyrimidine 89c in 78% yield (entry 7).  
 The use of TMPMgCl·LiCl (18a) allowed us the direct functionalization of commercially 
available 4-chloro-2,6-dimethoxypyrimidine (70a).  We used this substrate for the synthesis 
of the pyrrolopyrimidine 90, a known precursor of the marine alkaloid rigidin (58, Scheme 
70). 117  Thus, the addition of TMPMgCl·LiCl (16, 25 °C, 1 h) to 4-chloro-2,6-
dimethoxypyrimidine (70a) gave after transmetalation with ZnCl2, and the Pd-catalyzed 
coupling with iodoethynyl-trimethylsilane,118 the corresponding cross-coupling product 91 in 
79% yield (Scheme 70). A one-pot amination and deprotection of 91 using NH3 in MeOH 
furnished the 6-amino-2,4-dimethoxypyrimidine (92) in 31% yield. This product was then 
successfully cyclized using the conditions developed by Knochel119  to the pyrrolopyrimidine 
90 in yield 81 % yield. 
 
N
N
OCH3
OCH3Cl
TMS I
N
N
OCH3
OCH3NH
N
N
OCH3
OCH3Cl
TMS
N
H
NH
N
H
O
O
O
HO
HO
N
N
OCH3
OCH3H2N
H
1) TMPMgCl·LiCl, THF
    25 °C, 1 h
2) ZnBr2, THF, 25 °C, 1 h
3) Pddba2 (2 mol%)
    P(o-furyl)3 (4 mol%)
4)
    rt, 8 h
91: 79%
NH3 in MeOH,
autoclave, 
95 °C, 2 d
KH, NMP,
60 °C, 8 h
92: 31%
90: 81 %
rigidin (58)
70a
92
 
Scheme 70: Synthesis of the precursor 90 for the synthesis of rigidin (58). 
 
                                                 
117
 Sakamoto, T.; Kondo, Y.; Sato, S.; Yamanaka, H. J. Chem. Soc., Perkin Trans. 1. 1996, 5, 459. (b) Lagoja, I. 
M. Chemistry & Biodiversity 2005, 2, 1. 
118
 For the preparation of iodoethynyl-trimethyl-silane, see:  Al-Hassan, M. I. J. Organomet. Chem. 1989, 372, 
183. This reagent was distilled and stored under argon at -4 °C. 
119
 Rodriguez, A. L.; Dohle, W.; Knochel, P. Angew. Chem. Int. Ed. 2000, 39, 2488. 
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3.  Amination of DNA and RNA Units via Cuprated Pyrimidines and 
Purines Intermediates 
 
3.1. Introduction 
The chemical modification of DNA and RNA nucleotides 93a-e (Scheme 71) is an important 
synthetic task, since modified DNA and RNA bases have interesting pharmaceutical 
properties and are important for the investigations of biochemical pathways.120 Organocopper 
intermediates, due to their exceptional functional group tolerance, would be ideal reagents for 
DNA and RNA modification. 121, 122 
 
N
NN
H
N
NH2
NH
NN
H
N
O
NH2
N
N
H
NH2
O
NH
N
H
O
O
Me
NH
N
H
O
O
93d: adenine 93e: guanine93c: cytosine93b: thymine93a: uracil
 
 
Scheme 71: DNA and RNA bases of type 93. 
 
Recently, we have reported an efficient oxidative amination procedure of lithium 
amidocuprates using chloranil.46a We have applied this method to the amination of various 
pyrimidine and purine derivatives. 
                                                 
120
 For recent advance in DNA modifications:  (a) Leumann, C. J. Bioorg. Med. Chem. 2002, 10, 841; (b) Burley, 
G. A.; Gierlich, J.; Mofid, M. R.; Nir, H.; Tal, S.; Eichen, Y.; Carell, T. J. Am. Chem. Soc. 2006, 128, 1398; (c) 
Wilson, J. N.; Kool, E. T. Org. Biomol. Chem. 2006, 4, 4265; (c) Matsuda, S.; Fillo, J. D.; Henry, A. A.; Rai, P.; 
Wilkens, S. J.; Dwyer, T. J.; Geierstanger, B. H.; Wemmer, D. E.; Schultz, P. G.; Spraggon, G.; Romesberg, F. E.  
J. Am. Chem. Soc. 2007, 129, 10466; (d) McCulloch, S. D.; Kokoska, R. J.; Masutani, C.; Iwai, S.; Hanaoka, F.; 
Kunkel, T. A. Nature. 2004, 428, 97.  
121
 (a) Yang, X.; Althammer, A.; Knochel, P. Org. Lett. 2004, 6, 1665. (b) Yang, X.; Knochel, P. Synthesis 2006, 
15, 2618; (c) Piazza, C.; Knochel, P. Angew. Chem. Int. Ed. 2002, 41, 3263. 
122
 For a recent contribution in organocopper chemistry: (a) Deutsch, C.; Lipshutz, B. H.; Krause, N.   Angew. 
Chem. Int. Ed. 2007, 46, 1650; (b) Krause, N.; Morita, N. Application of Copper, Silver and Gold in Preparative 
Organic Chemistry in: “Comprehensive Organometallic Chemistry III” (Crabtree, R. H.; Mingos, D. M. P. Eds.), 
Elsevier, Oxford. 2007, 9, 501-586. (c) Lipshutz, B. H.; Taft, B. R.  Angew. Chem. Int. Ed. 2006, 45, 8235; (d) 
Geurts, K.; Fletcher, S. P.; Feringa, B. L. J. Am. Chem. Soc.  2006, 128, 15572; (e) Lopez, F.; Harutyunyan, S. 
R.; Meetsma, A.; Minnaard, A. J.; Feringa, B. L. Angew. Chem. Int. Ed. 2005, 44, 2752; (f) Palais, L.; Mikhel, I. 
S.; Bournaud, C.; Micouin, L.; Falciola, C. A.; Vuagnoux-d'Augustin, M.; Rosset, S.; Bernardinelli, G.; Alexakis, 
A. Angew. Chem. Int. Ed. 2007, 46, 7462; (g) Sulzer-Mosse, S.; Tissot, M.; Alexakis, A. Org. Lett. 2007, 9, 3749; 
(h) Isobe, H. ; Cho, K.; Solin, N.; Werz, D. B.; Seeberger, P. H.; Nakamura, E. Org. Lett. 2007, 9, 4611. 
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3.2. Selective aminations of pyrimidine derivatives 
 
3.2.1 Preliminary studies 
Thus, in preliminary experiments, we magnesiated the 5-alkynyl pyrimidine 94 with 
TMPMgCl·LiCl (18a, THF, -10 °C, 3 h)37 and performed transmetalation to the copper 
derivative 95 using CuCl·2LiCl (Et3N, -50 °C, 45 min)123 (Scheme 72).  After the additions of 
LiHMDS (96a, 2 equiv, -60 °C, 1 h) and chloranil (22, 1.2 equiv, -78 °C, 12 h), followed by a 
deprotection using TBAF (25 °C, 2 h), the desired 2,4-dimethoxypyrimidine 92 was obtained 
in 71% yield. Compared with the previous method for the synthesis of the compound 90 
(Scheme 70), this method afforded a better overall yield of compound 92 under milder 
conditions.  
 
N
N
OMe
OMeH
TMS 1) TMPMgCl·LiCl
   -10 °C, 3 h
2) CuCl·2LiCl, Et3N 
   - 50 oC, 0.7 h
94
N
N
OMe
OMeCu
TMS
1) LiHMDS (96a), 
   - 60 °C, 1 h
2) -78 °C,12 h
   
3) TBAF, THF,
    25 °C, 2 h
O
O
Cl
ClCl
Cl N
N
OMe
OMeH2N
H
92: 71%95
  
 
Scheme 72: Synthesis of 92, a precursor for the synthesis of rigidin (58). 
 
 
3.2.2 Synthesis of aminated uracil and thymine 
We have examined the reaction scope of this oxidative amination. By using the regioselective 
C6-magnesiation of the 2,4-dimethoxypyrimidine 83a (TMPMgCl·LiCl (1.1 equiv), -40 °C, 
12 h) followed by the transmetalation (CuCl·2LiCl) to the corresponding copper derivative 
(97a),  we could obtained after the successive additions of N-lithiomorpholine 96b and 
chloranil the expected aminated product 98a in 76 % yield (Scheme 73). Similarly, starting 
from the 5-methyl-2,4-dimethoxypyrimidine (83b), the direct magnesiation using 
TMPMgCl·LiCl (1.1 equiv, -5 °C, 3 h) led after transmetalation with CuCl·2LiCl to the 
cuprated protected thymine 97b (Scheme 73). The successive additions of 96b (2 equiv, -
60 °C, 0.7 h) and chloranil (1.2 equiv, -78 °C, 12 h) furnished the corresponding aminated 
pyrimidine 98b in 72% yield. The treatment of the functionalized pyrimidines 98a-b under 
                                                 
123
 1.2 equivalents of Et3N improved the yield of the amination reaction. 
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acidic conditions provided the 6-N-morpholino-uracil (99a) and 6-N-morpholino-thymine 
(99b) in excellent yields (91-96%; Scheme 73).  
 
NO Li
1)  -60 oC, 1 h
2) chloranil, 
    -78oC, 12 h
N
N
OMe
OMe N
N
OMe
OMeCu
N
H
NH
O
ON
O
N
N
OMe
OMeN
O
1) TMPMgCl·LiCl,  THF,  
   T oC,  t h
2) CuCl·2LiCl, Et3N,  
   THF, 
    _50 oC, 0.7 h
HCl/AcOH
reflux, 6 h
83a: R = H
[T  = -40 °C, t= 12 h]
83b: R = Me
[T  = -5 °C, t = 3 h]
R R
97a: R = H
97b: R = Me
98a: R = H, 76% 
98b: R = Me, 72%
99a: R = H, 91% 
99b: R = Me, 96%
R
R
96b
98a: R = H
98b: R = Me
 
 
Scheme 73: Amination of 2,4-dimethoxypyrimidine (83a) and 5-methyl-2,4-
dimethoxypyrimidine (83b). An access to 6-aminated uracil and thymine.  
 
 
3.2.3  Selective aminations of functionalized pyrimidines 
We have applied this method to the amination of several functionalized protected uracils and 
halogenated pyrimidines (Table 6). Thus, the reaction of the copper derivative 97a with 
LiHMDS (96a) furnished after the addition of chloranil and a deprotection using TBAF 6-
amino-2,4-dimethoxypyrimidine 98c (81%, entry 1 of Table 6).  Similarly, starting from 97a, 
the additions of the lithiated N-TBS aniline derivative (96c) and chloranil gave the TBS-
protected 6-aminated pyrimidine 98d (76%, entry 2), a derivative of the antibacterial TMAU, 
developed by Bayer AG.124  The cuprated pyrimidine 97b reacted with the sterically hindered 
TMP-Li (96d, -50 °C, 1 h) providing after the treatment with chloranil the thymine 98e in 
70% yield (entry 3). Starting from 5-bromo-2,4-dimethoxypyrimidine, a Br/Mg exchange 
using i-PrMgCl·LiCl (1.1 equiv, -20 °C, 2 h)31 followed by a transmetalation with CuCl·2LiCl 
gave the C5-cuprated 2,4-dimethoxypyrimidine 97c. The addition of LiHMDS (96a) followed 
by chloranil, furnished the 5-amino-2,4-dimethoxypyrimidine (98f) after N-desilylation (79%, 
entry 4). Similarly, the N-TBS pyrimidine derivative 98g was obtained (68% yield, entry 5). 
                                                 
124
 Kuhl, A.; Svenstrup, N.; Ladel, C.; Otteneder, M.; Binas, A.; Schiffer, G.; Brands, M.; Lampe, T.; 
Ziegelbauer, K.; Ruebsamen-Waigmann, H.; Haebich, D.; Ehlert, K. Antimicrob. Agents Chemother. 2005, 49, 
987. 
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Table 6: Amination of cuprated pyrimidines derivatives of type 97. 
entry copper reagent lithium amide product yield [%][a] 
1 
N
N
OMe
OMeCu
 
97a[b] 
LiHMDS 
96a 
N
N
OMe
OMeH2N
 
98c 81 
2 
 
97a[b] 
N
TBSLi
 
96c 
N
N
OMe
N OMe
TBS
 
98d 76 
3 
N
N
OMe
OMeCu
Me
 
97b[c] 
N Li
 
96d 
N
N
OMe
N
Me
OMe
 
98e 70 
4 
N
N
OMe
OMe
Cu
 
97c[b] 
LiHMDS 
96a 
N
N
OMe
OMe
H2N
 
98f 79 
5 97c[b] 
N
TBS
OMe
OMe
MeO
Li
 
96e 
N
N
OMe
OMe
N
MeO
OMe
OMe
TBS
 
98g 68 
6 
N
N
OMe
OMe
Cu
I
 
97d[c] 
LiHMDS 
96a 
N
N
OMe
OMe
(TMS)2N
I
 
98h 65 
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7 
N
N
OMe
OMe
Cu
Cl
 
97e[c] 
NNMe Li
 
96f 
N
N
OMe
OMeCl
N
N
 
98i 78 
8 97e[c] 
LiHMDS 
96a 
N
N
OMe
OMe
H2N
Cl
 
98j 60 
9 
N
NBr
Cu
 
97f[c] 
O N LI
 
96b 
N
N
Br
N
O
 
98k 70 
10 
N
N
Br
Cu
 
97g[c] 
NNMe Li
 
96f 
N
N
Br
N
NMe
 
98l 66 
[a]
 Isolated yield of analytically pure product. [b]1.2 equiv of (Et2NCH2CH2)2O was added. [c]1.2 equiv of Et3N 
was added. 
 
Commercially available 4-chloro-2,6-dimethoxypyrimidine (70a) and readily prepared 4-
iodo-2,6-dimethoxypyrimidine (87b) could be deprotonated at C5 position using 
TMPMgCl·LiCl (18a, 1.1 equiv, 0-25 °C, 1 h) and transmetalated using CuCl·2LiCl (1.2 
equiv, -50 °C, 0.7 h) affording the corresponding organocoppers  97d-e. Their reaction with 
LiHMDS (96a) or N-lithium amide 96f, in the presence of chloranil, provided 5-amino-2,4-
dimethoxypyrimidine derivatives (98h-i, 65-78%, entries 6-7) and 5-amino-6-chloro-2,4-
dimethoxypyrimidine (98j, 60%, entry 8), after deprotection using TBAF. Similarly, the 
polyfunctionalized cuprated pyrimidines 97f-g were oxidatively aminated by the secondary 
lithium amides 96b and 96f giving the bromo-aminated pyrimidines (98k-l, 66-70%, entries 
9-10). 
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3.3 Selective aminations of purine derivatives 
 
3.3.1 Introduction 
Purines are ubiquitous molecules that exist at relatively high (millimolar) concentrations in 
living organisms. More than 10% of the proteins encoded by the yeast genome evidently 
depend on a purine-containing ligand for their function. Purines libraries might be expected to 
have a high probability of yielding bioactive compounds. It seemed likely that structural 
variation at the 2, 6, 8, or 9 positions might impact specificity towards a variety of target 
proteins.125 Several candidates, containing purine skeleton, include amines as substituents and 
are DNA analogs,120 such as purvalanol A (100),125a, 126 a CDK inhibitor, and cladribine (101), 
127
 a drug commercialized to treat hairy cell leukemia (Scheme 74).  
 
N
N N
N
HN
Cl
N
H
HO
N
N N
N
O
OH
NH2
Cl OH
101: cladribine100: purvalanol A
 
 
Scheme 74: Drugs containing purine skeleton. 
 
The amination of purines in positions 8 and 2 are especially troublesome128  and involve harsh 
reaction conditions for the substitution (Scheme 75)129 or cross-coupling.130 Therefore, we 
have developed a selective cupration of purines (via magnesium intermediates) and 
subsequent oxidative Cu-mediated amination. 
 
                                                 
125
 (a) Chang, Y.-T.; Gray, N. S.; Rosania, G. R.; Sutherlin, D. P.; Kwon, S.; Norman, T. C.; Sarohia, R.; Leost, 
M.; Meijer, L.;  Shultz. P. G. Chem.  Biol. 1999, 6, 361; (b) For a review on the synthesis of C-substituted 
purines using organometallic intermediates, see: M. Hocek. Eur. J. Org. Chem. 2003, 245. 
126
  For a preparation of purvalanol A: Taddei, D.; Slawin, A. M. Z.; Woollins, J. D. Eur. J. Org. Chem. 2005,  5,  
939. 
127
 (a) Cottam, H. B.; Carson, D. A. Drug Discovery Research. 2007, 393; (b) Janeba, Z.; Francom, P.; Robins M. 
J. J. Org. Chem. 2003, 68, 989.  
128
 For a recent method of C8-arylamino substitution on purines see: (a) Bookser, B. C.; Matelich, M. C.; Ollis, 
K., Ugarkar, B. G. J. Med. Chem. 2005, 48, 3389. 
129
 (a) A. Kurimito, T. Ogino, S. Ichii, Y. Isobe, M. Tobe, H. Ogita, H. Takaku, H. Sajiki, K. Hirota, H. 
Kawakami. Bioorg. Med. Chem. 2003, 11, 5501; (b) de Ligt, R. A. F.; van der Klein, P. A. M.; Frijtag Drabbe 
Künzel, J. K.; Lorenzen, A.; El Maate, F. A.; Fujikawa, S.; van Westhoven, R.; van den Hoven, T.; Brussee, J.; 
IJzerman, Ad. P. Bioorg. Med. Chem. 2004, 12, 139. 
130
 Dai, Q.; Ran, C.; Harvey, R. G. Org. Lett. 2005, 7, 999. 
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Scheme 75: Aminations of purines in positions 8 and 2. 
 
 
3.3.2 Selective C8 and C2-aminations of purine derivatives 
We have first concentrated our efforts on the aminations of positions 8 and 2 starting from 
readily available purines. Thus, a selective magnesiation in position 8 could be achieved by 
the reaction of the halogenated purine 102 and 103 (Scheme 76) with TMPMgCl·LiCl (18a) 
under convenient reaction conditions (THF, -10 °C, 2-3 h) giving after Cu-transmetalation the 
8-cuprated purines 104 and 105, which by oxidative amination with lithium N-morpholide 
(96b) or Et2NLi (96g) provided the expected 8-aminated purines (106 and 107) in 63-66% 
yield (Scheme 76).  
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N N
N
Cl
Bn
N
N N
N
I
Me
N
N N
N
I
Me
Cu
N
N N
N
Cl
Bn
Cu
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N N
N
I
Me
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N
N N
N
Cl
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1) TMPMgCl·LiCl
   -10 °C, 3 h
2) CuCl·2LiCl, Et3N 
   -50 oC, 0.7 h
106: 63%
1)  96b, -60 °C, 1 h 
2) chloranil, 
-80 °C to -50 °C,
12 h
102 104
1) TMPMgCl·LiCl
   -10 °C, 2 h
2) CuCl·2LiCl, Et3N 
   -50 oC, 1 h
1)  -60 °C, 1 h
     Et2N-Li (96g)
2) chloranil, 
-80 °C to -50 °C,
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107: 66%103 105
 
 
Scheme 76: Amination at C8 position of protected purines 102 and 103.  
 
 
Using Dvořák´s conditions131  for the selective magnesiation in position 2 of the iodopurine 
108 and a copper transmetalation (CuCl·2LiCl, Et3N, -80 °C, 1.5 h) we obtained after the 
addition of the amide 96b the amidocuprate 109. Its treatment with chloranil (-78 °C, 2 h), 
gave the desired 2-aminated purine 110 in 69% yield (Scheme 77). 
 
 
N
N N
N
I
Cl
N
Li
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N
N N
N
Cu
Cl
N
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O
N
N N
N
Cl
N
O
1) iPrMgCl,
     _80 oC, 0.5 h
2) CuCl·2LiCl, Et3N
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_80 oC, 2 h
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Scheme 77: Amination at C2 position of protected purine 108.  
 
 
                                                 
131
 Tobrman, T.; Dvořák. D. Org. Lett. 2006, 8, 1291. 
B: Results and Discussion  65 
  
  
3.3.3  Selective C6-amination of purines derivatives. An access to adenine, 
adenosine units and to the CDK inhibitor purvalanol A. 
The mild amination conditions tolerated the presence of a protected ribose unit. Thus, the 6-
iodopurine nucleoside 111 was successively magnesiated (iPrMgCl·LiCl (13), -50 °C, 3 h),132 
and finally aminated via the Cu intermediate 112 with the lithiated N-methylpiperazide (96f), 
furnishing the adenosine derivatives 113 (70%, Scheme 78). 
 
N
N N
N
I
O
OO
N
N N
N
Cu
O
OO
N
N N
N
N
O
OO
N
Me
1)  i-PrMgCl·LiCl,
THF, -50 °C, 3 h
2) CuCl·2LiCl, NEt3,
   -50 oC, 0.7 h
1) 96f, -60 oC, 1 h
2) chloranil, 
    -78 oC, 12 h
113: 70%111 112
TrO
TrO TrO
 
 
Scheme 78: Synthesis of an adenosine derivative. 
 
Similarly, adenine analogs were prepared via this oxidative amination. The magnesiation of 
the iodopurine 114, transmetalation to 115 provided after an oxidative amination with 
LiHMDS (96a) and chloranil the adenine 116 in 76% yield (Scheme 79). This encouraging 
result led us to apply the new amination procedure to the synthesis of the CDK inhibitor 
purvalanol A (100).126 Thus, the amination of the 6-cuprated purine 115 with the lithiated N-
TBS-aniline derivative (96h) gave the expected adenine derivative 117 in 71% yield. We have 
completed the synthesis by the reaction of 117 in a sealed tube with D-valinol in the presence 
of Hunig´s base in n-butanol (150 °C, 2 h), and obtained purvalanol A (100) in 65% yield 
(Scheme 79). 
 
 
                                                 
132
 For the magnesiation of 6-purine nucleoside see: Tobrman, T.; Dvořák. D. Org. Lett. 2003, 5, 4289. 
B: Results and Discussion  66 
  
  
 
N
N N
N
I
Cl
N
N N
N
HN
Cl
N
H
HO
N
N N
N
Cu
Cl
N
N N
N
N
Cl
H
Cl
NLi
Cl
TBS
N
N N
N
NH2
Cl
1)  -50 °C, 0.7 h,
  
2) chloranil,
    -80 °C to -50 °C,
    12 h
3) TBAF, 25 °C,
    0.3 h
117: 71%
1) i-PrMgCl·LiCl (13)
   -60 °C, 0.3 h
2) CuCl·2LiCl, 
   (Et2NCH2CH2)2O 
   -60 oC, 1.5 h
1) 96a (2 equiv)
   -50 °C, 0.7 h
2) chloranil,
    -80 °C to -50 °C,
    12 h
3) TBAF, 25 °C, 
    0.3 h 116: 76%
100 (purvalanol A): 65%
D-valinol,
(i-Pr)2NEt
n-butanol,
150°C, 12 h
114 115
115
(96h)
 
 
Scheme 79: Amination at C6 position of the iodopurine 114. Application of to the synthesis 
of adenine derivative (116) and purvalanol A (100).  
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4. Direct Chemo- and Regioselective Zinc Insertions into Polyhalo-
genated Aryl and N-Heteroaryl Compounds.  
 
4.1. Introduction 
The preparation of polyfunctional organozincs is an important synthetic task since they are 
versatile organometallic reagents.2,52 Recently, we have found that the addition of LiCl to zinc 
powder considerably facilitates its insertion into various aryl and heteroaryl iodides and 
bromides.62 It is well known, that metalation-directing groups (DMGs) are essential for the 
regioselective functionalization of aromatics and heterocycles with Li- or Mg-bases.133 DMGs 
have also been used to perform regioselective halogen/metal exchanges19, 134   and 
metalations34b, 35a, 37, 135 but rarely direct metal insertion. By the best of our knowledge, the 
only selective metal insertions described in the literature were made by Rieke (Scheme 80). 136  
These two examples showed a regiocontrol of the zinc and the magnesium insertions using 
bulky alkyl groups as directing groups. Rieke zinc (Zn*) underwent a direct oxidative 
addition to the C-Br bond primarly at the 5-position of 118 at -78 °C (Scheme 80).136a  
 
OCOtBu
Br
Br
S
R
Br Br S
R
BrZn Br
OCOtBu
CH(OH)Ph
Br
S
R
Br ZnBr
1) Mg*/THF
   -78 °C, 15 min
2) PhCHO
Zn*/ THF
-78 °C to rt, 4 h
118: R = n-octyl
+
98             :                    2
119 120: 53 %
 
 
Scheme 80: Regioselective zinc and magnesium insertions. 
 
                                                 
133
 (a) Anctil, E. J.-G.; Snieckus, V. J. Organomet. Chem. 2002, 653, 150. (b) Snieckus, V. Chem. Rev. 1990, 90, 
879. (c) Wagner, F. F.; Comins, D. L. Eur. J. Org. Chem. 2006, 3562. (d) Katritzky, A. R.; Xu, Y.-J.; Jain, R. J. 
Org. Chem. 2002, 67, 8234. 
134
 (a) Rieke, R. D.  Science 1989, 246, 1260. (b) Wu, X.;  Rieke, R. D. J. Org. Chem. 1995, 60, 6658.  
135
 (a) Schlosser, M. Angew. Chem. Int. Ed. 2005, 44, 376.  
136
 (a) For a regioselective Zn/Br-insertion, see: Chen, T.-A.; Wu, X.; Rieke, R. D. J. Am. Chem. Soc. 1995, 117, 
233. (b) For a regioselective Mg/Br insertion, see: Lee, J.-S.; Velarde-Ortiz, R.; Guijarro, A.; Wurst, J. R.; Rieke, 
R. D. J. Org. Chem. 2000, 65, 5428. 
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Rieke demonstrated that highly reactive magnesium displayed unusual selectivity in the 
insertion into bulky ester 119. He postulated that the sterically hindered ester prevented the 
coordination of the ester to the magnesium surface and led to the corresponding para-product 
(120, Scheme 80) after quenching with benzaldehyde.136b 
We decided to focus our attention on the regioselectivity of the zinc insertion in the presence 
of LiCl into poly-iodo and -bromo aryls and N-heteroaryls of type 121 (Scheme 81). We 
studied the control of the insertion by DoMGs (Directing ortho-Metalation Groups) such as 
an ester or a tosylate, or by the presence of an appropriate heteroatom which should lead 
selectively to zincated intermediates of type 122 (Scheme 81). 
 
Zn, LiCl
A
DG
ZnXX
A
DoMG
XX X= I, Br
121: A: aryl or N-heteroaryl 122
 
 
Scheme 81: LiCl-mediated regioselective zinc insertion of aryls and heteroaryl compound of 
type 121. 
 
 
4.2. DoI (Directed ortho-Insertion): a new access to aryl functionalized zinc reagents 
 
4.2.1 Successive zinc insertion into triiodobenzoate and a proposed mechanism 
We first studied the triiodobenzoate 121a137 and showed that it reacted readily with zinc dust7 
(1.15 equiv) and LiCl (1.15 equiv) in THF at 0 °C, furnishing after 0.5 h the ortho-zincated 
intermediate 122a (Scheme 82). After the addition of CuCN·2LiCl (20 mol%), a smooth 
benzoylation with PhCOCl provided the aromatic ketoester 123a in 79% yield (Eq. 1). 
Interestingly, the diiodide 123a further underwent a selective zinc insertion giving the 
polyfunctional zinc reagent 122b which after transmetalation with CuCN·2LiCl reacted with 
3-iodocyclohexenone affording the substitution product 123b in 73% yield (Eq. 2). In the 
absence of LiCl no zinc insertion was observed and higher reaction temperature led to 
unselective reactions. The origin of this unprecedented regioselectivity for a direct metal 
insertion is certainly due to the presence of an ortho-directing group. LiCl may chelate to this 
directing group and to the ortho-iodide, leading after an electron transfer from the zinc 
surface, the intermediate radical anion 124 (Scheme 82). The departure of the radical •ZnI 
                                                 
137
 This example was studied by the co-authors (Sase, S. and  Sinha, P.) of the publication: J. Am. Chem. Soc. 
2007, 129, 12358. 
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(facilitated by the presence of LiCl) provides the radical 125, which gives after the 
recombination with •ZnI the zinc reagent 122a. This directing effect explains also the 
regioselectivity of the second zinc insertion leading to the zinc reagent 122b. 
 
-
+
-  ZnI·LiCl  ZnI·LiCl
CO2Et
COPh
II
CO2Et
I
II
Zn, LiCl
Zn, LiCl
CO2Et
ZnI·LiCl
II
CO2Et
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ZnI·LiClI
O
I
I
II
OEtO LiCl Zn
II
OEtOCO2Et
I
II
Zn, LiCl
CO2Et
COPh
II
CO2Et
COPh
I
O
CO2Et
ZnI·LiCl
II
2. PhCOCl
-20 °C, 9 h
1. CuCN·2LiCl
(20 mol%), -20 °C
121a
(1.15 equiv.)
0 °C, 0.5 h
122a 123a: 79 %
2.
1. CuCN·2LiCl
(1 equiv.), -30 °C
(1.15 equiv.)
0 °C, 0.5 h
123a 122b
-10 °C, 24 h 123b: 73%
124 125 122a121a
(1)
(2)
(3)
 
 
Scheme 82: Regioselective and successive zinc insertions to the triiodobenzoate 121a. 
 
 
4.2.2 Regioselective zinc insertions into diiodo-and dibromo-aryl compounds 
We have found that other chelating groups such as an aryl sulfonate,138 an acetate, or a 
triazene,139 display the similar directing abilities. Thus, the 3,5-diiodobenzonitrile 121c reacts 
regioselectively with zinc dust in the presence of LiCl (1.15 equiv) at 0 °C, furnishing the 
ortho-zincated product 122c (Table 7). After a copper(I)-catalyzed allylation, the aryl iodide 
123c was obtained in 82% yield (entry 1). Similarly, the diiodobenzoate 121d underwent a 
selective zinc insertion providing the arylzinc 122d, which after a reaction with ethyl (2-
bromomethyl)acrylate83 gave the polyfunctional diester 123d in 85 % yield (entry 2). The 
dibromoarene 121e, bearing an acetate as DoI group, is sufficiently reactive toward a zinc 
insertion and afforded the desired zinc reagent 122e (entry 3; 50 °C, 20 h). In the absence of 
LiCl, only starting material decomposition is observed. The zinc reagent 122e underwent a 
                                                 
138
 (a) Sapountzis, I.; Lin, W.; Fischer, M.; Knochel, P. Angew. Chem. Int. Ed. 2004, 43, 4364. (b) Lin, W.; 
Sapountzis, I.; Knochel, P. Angew. Chem. Int. Ed. 2004, 44, 4258. 
139
 (a) Liu, C. J.; Knochel, P. Org. Lett. 2005, 7, 2543. (b) Saeki, T.; Son, E.-C.; Tamao, K. Org. Lett. 2004, 6, 
617. 
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Pd-catalyzed Negishi cross-coupling reaction54 with methyl 4-iodobenzoate furnishing the 
biphenyl 123e in 73 % yield.  
 
Table 7: Preparation and reaction of aryl functionalized zinc reagents of type 122.140 
entry aryl halide zinc reagent
a
 
(conditions) electrophile 
product of type 123, 
yield (%)b 
1 
OTs
R1 I
I
 
121c: R1 = CN 
OTs
R1 ZnI
I
 
(0 ˚C, 12 h) 
122c: R1 = CN 
CH2=CH-
CH2Br 
OTs
R1 R2
I
 
123c: R1 = CN, R2 = C3H5, 
82c 
2 121d: R
1 
= CO2Et 
(0 ˚C, 12 h) 
122d: R1 = CO2Et Br
CO2Et
 
123d: R1 = CO2Et, 
R 2 = CH2C(CO2Et)CH2, 
 85c 
3 
OAc
Br
Br
 
121e 
OAc
ZnBr
Br
 
122e (50 ˚C, 20 h) 
I
CO2Et
 
CO2Et
I
OAc
 
123e: 73e 
4 
Br
BrBr
NN
N
 
121f 
Br
ZnBrBr
NN
N
 
122f (50 ˚C, 20 h) 
CO2Et
I
 
CO2Et
Br
Br
NN
N
 
123f: 76e 
a X = I·LiCl or Br·LiCl b Isolated yield of analytically pure product. c Catalytic amount of CuCN·2LiCl was 
added. d 1 equiv of CuCN·2LiCl was added. e 1 mol % of Pd(Ph3P)4 was added.   
 
Remarkably, the mild conditions of the lithium chloride-mediated zinc insertion tolerate also 
a triazene moiety which is an important synthetic equivalent of a diazonium function.141 Thus, 
the readily available tribromoaryltriazene 121142 was converted with Zn/LiCl (2 equiv) to the 
zinc reagent 122f (50 °C, 20 h) and provided after the Negishi cross-coupling reaction with 
                                                 
140
 These products were prepared by the co-authors (Sase, S.; Sinha, P.; Liu, C;-Y.) of the publication: J. Am. 
Chem. Soc. 2007, 129, 12358. 
141
 Bräse, S. Acc. Chem. Res. 2004, 37, 805. 
142
 For the preparation of tribromoaryltriazene 1h, see: Nicolaou, K. C.; Li, H.; Boddy, C. N. C.; Ramanjulu, J. 
M.; Yue, T. Y.; Natarajan, S.; Chu, X. J.; Bräse, S.; Rübsam, F. Chem. Eur. J. 1999, 5, 2584. 
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methyl 2-iodobenzoate the polyfunctionalized dibromoaryltriazene 123f in 76 % yield (entry 
4). 
 
4.3. DoI (Directed ortho-Insertion): a new access to N-heteroaryl functionalized 
zinc reagents 
We have examinated the scope of this regioselective insertion on various N-heterocycles. 
Interestingly, various di- or tri- iodo- or bromo-pyridines 121g-i bearing a sulfonate 
functionality138 could be chemo- and regioselectively converted to the ortho-zincated pyridyl-
sulfonates 122g-i (Table 8). Their copper(I)-catalyzed allylation or benzoylation afforded the 
polyfunctional pyridines 123g-i in 80-83 % yield (Table 8, entries 1-3). Interestingly, the 
carbamate group 143  smoothly directed the zinc insertion of the diiodopyridine 121j with 
complete regioselectively leading to the zinc derivative 122j (entry 4). After allylation, the 
polyfunctional pyridine 123j was obtained in 83% yield. Various other diiodo- N-heterocyclic 
compounds such as the 4,5-diiodoimidazole 144  121k and the 2,3-diiodoindole 121l were 
converted at 50 °C within 2 h to the zinc reagents 122k and 122l (entries 5 and 6). In the 
presence of CuCN·2LiCl,57 the addition of allyl bromide and benzoyl chloride led to the 
corresponding allylated iodoimidazole (123k) and the indole derivative 123l in 80-83% yield 
(entries 5 and 6). A tosylate is also an excellent DoI group. Thus, the 5,7-diiodoquinoline 
121m inserts selectively zinc in the presence of LiCl at 25 ˚C and led, after transmetalation 
with CuCN·2LiCl and quenching with pivaloyl chloride to the polyfunctional quinoline 123m 
in 78% yield (entry 7). The mild conditions of the Zn/LiCl insertion allow performing 
regioselective zinc insertion on heterocycles, having well differentiated reactivity sites. Thus, 
2,5-dibromothiazole 145  121n underwent a selective zincation at 25 ˚C and gave the 
heteroarylzinc bromide 122n (entry 8). The Pd-catalyzed Negishi cross-coupling with 2-
iodobenzaldehyde furnished the corresponding aldehyde 123n in 85 % yield. A selective zinc 
insertion occured with the tribromopyrimidine 121o at 25 ˚C within 4 h, leading to the 
zincated dibromopyrimidine 122o (entry 9). Addition of ethyl (2-bromomethyl)acrylate83 in 
the presence of catalytic amount of CuCN·2LiCl led to the substituted dibromopyrimidine 
123o in 63% yield. The zinc insertion into the 4,5-diiodo- and 4,5-dibromo-2,6-
dimethoxypyrimidine (89a and 69b) was found to be regioselective. Thus, treatment of 4,5-
diiodo-2,6-dimethoxy-pyrimidine (89a) with Zn/LiCl (1.5 equiv, 50 oC, 3 h, entry 10) resulted 
                                                 
143
 Kauch, M.; Snieckus, V.; Hoppe, D. J. Org. Chem. 2005, 70, 7149. 
144
 (a) For the preparation of 4,5-diiodo-2-methyl-1H-imidazole, see: Bell, A.S.; Campbell, S. F.; Morris, D. S.; 
Roberts, D. A.; Stefaniak, M. H. J. Med. Chem. 1989, 32, 1552. (b) Lipshutz, B. H.; Hagen, W. Tetrahedron Lett. 
1992, 33, 5865. 
145
 Delgado, O.; Heckmann, G.; Mueller, H. M.; Bach, T. J. Org. Chem. 2006, 71, 4599. 
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only in the insertion into the C−I bond at position 5 to give the zinc reagent 122p. Treatment 
of 122p with benzoyl chloride in the presence of CuCN·2LiCl (0.5 equiv) provided the 
product 123p in 83% yield. A regioselective zinc insertion at position C5 into 4,5-dibromo-
2,6-dimethoxypyrimidine (69b) was also achieved under mild reaction conditions (12 h, 25 
oC, entry 11). The corresponding zinc reagent 122q reacted in the Negishi cross-coupling with 
4-iodobenzonitrile to give the polyfunctional 4-bromo-2,6-dimethoxypyrimidine 123q in 86% 
yield. 
 
Table 8: Preparations and reactions of unsaturated organozinc reagents of type 121 leading to 
products of type 122. 
 
entry aryl halide zinc reagent (conditions) electrophile 
product of type 123, 
yield (%)b 
1 f 
N
OSO2Ar
I Cl
I
 
121g 
N
OSO2Ar
I Cl
ZnX
 
122g (0 ˚C, 2.5 h) 
Br
 N
OSO2Ar
I Cl
 
123g: 83c 
2 f 
N
OSO2Ar
I I
I
 
121h 
N
OSO2Ar
I I
ZnX
 
122h (0j ˚C, 2.5 h) 
Br
CO2Et
 
N
OSO2Ar
I I
CO2Et
 
123h: 80c 
3 
N
Br
OTs
Br
 
121i 
N
ZnBr
OTs
Br
 
122i (25 ˚C, 20 h) 
PhCOCl N
COPh
OTs
Br
 
123i: 81d 
4 
N
O
I I
O(Pri)2N
 
121j 
N
O
I ZnI
O(Pri)2N
 
122j (25 ˚C, 5 h) 
CH2=CH- 
CH2Br 
N
O
I
O(Pri)2N
 
123j: 83c 
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5 
N
NI
I
Ts
 
121k 
N
NIZn
I
Ts
 
122k (50 ˚C, 2 h) 
CH2=CH- 
CH2Br N
N
I
Ts
 
123k: 80c 
6 
N
SO2Ph
I
I
 
121l 
N
SO2Ph
I
ZnI
 
122l (50 ˚C, 2 h) 
PhCOCl N
SO2Ph
I
COPh
 
123l: 83d 
7  
N
I
OTs
I
 
121m 
N
I
OTs
IZn
 
122m (25 ˚C, 12 h) 
t-BuCOCl N
I
OTs
O
t-Bu
 
123m: 78d 
8 
N
S
Br
Br
 
121n 
N
S
Br
ZnBr
 
122n (25 ˚C, 0.5 h) CHO
I
 
N
S
Br
OHC
 
123n: 85e 
9 
N N
Br
Br
Br
 
121o 
N N
Br
Br
ZnBr
 
122o (0 ˚C, 12 h) 
Br
CO2Et
 
N N
Br
Br
CO2Et
 
123o: 63c 
10 
N
N
OMe
OMeI
I
 
89a 
N
N
OMe
OMeI
IZn
 
122p (50 ˚C, 3 h) 
PhCOCl 
N
N
OMe
OMeI
O
Ph
 
123p: 83g 
11 
N
N
OMe
OMeBr
Br
 
69b 
N
N
OMe
OMeBr
BrZn
 
122q (25 ˚C, 12 h) 
I
CN
 
NC
N
N
OMe
OMeBr
 
123q: 86h 
a X = I·LiCl or Br·LiCl b Isolated yield of analytically pure product. c Catalytic amount of CuCN·2LiCl was 
added. d 1 equiv of CuCN·2LiCl was added. e 1 mol % of Pd(Ph3P)4 was added.  f Ar = 4-ClC6H4. g 0.5 equiv of 
CuCN·2LiCl was added. h Pd(dba)2 (5 mol%) and P(o-furyl)3 (10 mol%) were added. 
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5. Summary and Outlook 
 
5.1. Functionalizations of Quinoline Moieties via Chemo- and Regioselective 
Magnesiations. 
In summary, we have described various versatile regioselective functionalizations of 
quinolines via chemo- and regioselective magnesiation reactions using appropriate Mg-
reagents such as i-PrMgCl·LiCl, MesMgBr·LiCl, Mes2Mg·2LiBr, TMPMgCl·LiCl, and 
TMP2Mg·2LiCl (Scheme 83). Several sensitive functionalities such as an ester and a ketone 
were tolerated. This approach opened a new route for the direct preparation of drug analogs, 
containing the quinoline skeleton. An application to the total synthesis of the biologically 
active compound talnetant was performed (6 steps, 28%). 
 
N
SMe
CH2Ph
EtO2C
N
Br
 Br
Br
COt-Bu
CO2Et
N
CO2Et
N
CO2Et
Br
COt-Bu
N
FG
FG
FG
FG
N
OH
O NH
EtPh
i-PrMgCl·LiCl (13), MesMgBr·LiCl (39d), 
Mes2Mg·2LiBr (39f), TMPMgCl·LiCl (18a), and 
TMP2Mg·2LiCl (19)
37
44: 
Functionalizations
C3-C4-C2
52:
 Functionalizations
C2-C3-C4
54:
 Functionalizations
C4-C3-C8
talnetant 33f: 
Functionalizations
C4-C3-C2
Electrophiles
2
3
4
8
 
 
Scheme 83: Sequences of selective functionalizations of quinoline cores. 
 
An extension of this study would be the regioselective magnesiation of quinolines at C5, C6 
and C7 positions inducing by DoM groups, and the regioselective functionalizations of 
isoquinoline moiety. 
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5.2. Functionalizations of Protected Uracils via Chemo- and Regioselective 
Magnesiations. 
We have developed a chemo- and regioselective functionalization method of uracils via 
successive Br/Mg-exchanges using i-PrMgCl·LiCl (13). We applied this method to the 
synthesis of biologically active uracils like oxypurinol (60) and emivirine (61) and opened a 
new route to synthesis of their analogs (Scheme 84).  
 
N
N
OCH3
OCH3(Cl)Br
Br
N
N
OCH3
OCH3
O
N
ClO
N
N
H
N
H
NH
O
O
N
OCH3
OCH3
O
N
O
N
OH
N
N
OCH3
OCH3R
E1
N
NH
O
O
O
1) iPrMgCl·LiCl, THF, rt, 15 min
2) E1
3) Br/Mg exchange or 
Nucleophilic substitution of Cl atom
emivirine (61): 47%oxypurinol (60): 58% 79a: 69%72d: 85%
 
 
Scheme 84: Polyfunctionalization of protected uracils via Br/Mg exchange. 
 
By using the mixed Mg/Li amide base TMPMgCl·LiCl (18a), the successive direct 
deprotonations and functionalizations at 6-position (87) and 5-position (89) of 2,4-
dimethoxypyrimidine (83a) has been achieved, opening a novel route for the synthesis of 5,6-
difunctionalized protected uracils (Scheme 85).  
 
N
N
OCH3
OCH3 N
N
OCH3
OCH3E1 N
N
OCH3
OCH3E1
E21) TMPMgCl·LiCl
2) E2+
1) TMPMgCl·LiCl
2) E1+
83a 87 89
N
N
OCH3
OCH3
O
t-Bu
87c: 72%
N
N
OCH3
OCH3I
O
F
89b: 84%
N
N
OCH3
OCH3
EtO2C
87d: 75%
 
 
Scheme 85: Polyfunctionalization of protected uracils via direct magnesiation using 18a. 
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5.3. Amination of DNA and RNA units via cuprated pyrimidines and purines 
Recently, we have found a new amination procedure via the oxidative coupling of aryl and 
heteroaryl amidocuprates using chloranil. We have achieved using this method, the 
preparation of primary, secondary and tertiary amino-pyrimidines and purines (Scheme 86). 
We believe that this method gives an alternative to common amination procedures, usually 
involving harsh reactions conditions. This practical amination protocol led to aminated 
pyrimidine (98l) and uracil derivatives (98f), 6-aminated thymine (99b), adenine and 
adenosine derivatives (100, 111) and to challenging C2 and C8 aminated purines 110 and 107. 
 
Li N
R2
R3
N
N
X = I, Br, H
1) RMgX
2) CuCl·2LiCl
3)
4) chloranil
N
N
R2R1NX
 
N
N N
N
I
Me
NEt2
N
H
NH
O
ON
O
Me
N
N
OMe
OMe
H2N
N
NBr
N
O
N
N N
N
Cl
N
O
N
N
H
HO
N N
N
HN
Cl
110: 69%
 
99b: 69%
107: 66%111: 69% purvalanol A (100): 65%
 
98f: 79%
 
98l: 70%
N
N N
N
N
O
OO
N
Me
TrO
 
 
Scheme 86: Aminated DNA and RNA units via an oxidative coupling method. 
 
As this method tolerates the ribose unit, it may have a real potential for preparing DNA and 
RNA nucleoside analogs. Moreover, one extension of this method could be the use of lithiated 
diprotected amino-alcohols. Amino-alcohols, as amines, are present in several drug 
candidates and are often implemented under harsh conditions (cf the synthesis of purvalanol 
A with D-valinol). 
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5.4. Direct chemo- and regioselective zinc insertions into polyhalogenated N-heteroaryl 
compounds 
We have demonstrated that in the presence of LiCl, a regioselective insertion of zinc powder 
occurred into various poly- iodo- and bromo- aryls and heteroaryls. This exceptional 
regioselectivity was obtained starting from substrates bearing various “ortho-directing group” 
possessing chelating properties such as an ester, a ketone, an aryl sulfonate, an acetate, a 
triazene or a carbamate, or/and the presence of an appropriate heteroatom in the case of 
polyhalogenated heterocycles. By this new concept DoI (Directed ortho-Insertion), we have 
prepared a wide range of polyfunctional N-heterocyclic zinc reagents of type 122 (Scheme 
87).  
 
 
N
N
OMe
OMeI
IZn
Directing group (DG) = -CO2R, -COR, -OAc, -N=N-NR2, -OCON(i-Pr)2, -OSO2Ar
Zn, LiCl A
DG
ZnXX
A
DG
XX X= I, Br
A: aryl or N-heteroaryl
A
DG
EX
N NTs
IClLi·IZn
OSO2Ar
I ClN
ZnI·LiCl
122h: (Ar= 4-ClC6H4)
N N
Br
Br ZnBr·LiCl
O
N
O
I ZnI·LiCl
(i-Pr)2N
122j
122k 122o
Electrophile
122: >90%121 123
122p
 
 
Scheme 87: Regioselective zinc insertion into polyhalogenated N-heteroaryl compounds. 
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1. General Considerations 
All reactions were carried out with magnetic stirring and, if air or moisture sensitive, in 
flame-dried glassware under argon. Syringes were used to transfer reagents, and solvents were 
purged with argon prior to use.  
 
Solvents 
 
Solvents were dried according to standard methods by distillation from drying agents as stated 
below and were stored under argon. 
CH2Cl2 and toluene were predried over CaCl2(s) and distilled from CaH2(s).  
Diethyl ether and THF were continuously refluxed and freshly distilled from sodium 
benzophenone ketyl under nitrogen. 
Dimethylformamide (DMF) was heated to reflux for 14 h over CaH2(s) and distilled from 
CaH2(s). 
Ethanol was treated with phthalic anhydride (25g/L) and sodium, heated to reflux for 6 h and 
distilled. 
Methanol was treated with magnesium turnings (20g/L) and sodium, heated to reflux for 6 h 
and distilled. 
Triethylamine was dried over KOH(s) and distilled from KOH(s).  
 
Reagents: Metal salts solution  
 
CuCN·2LiCl solution (1.0 M/THF) was prepared by drying CuCN (869 mg, 10 mmol) and 
LiCl (848 mg, 20 mmol) in a Schlenk flask under vacuum for 5 h at 140 °C. After cooling to 
25 °C, dry THF (10 mL) was added and stirred continuously until the salts were dissolved.  
 
CuCl·2LiCl solution (1.0 M in THF): A dry and argon-flushed 50 mL Schlenk-flask, 
equipped with a magnetic stirrer and a glass stopper, was charged with LiCl (1.7 g, 40 mmol) 
and heated up to 130 °C under high vacuum for 1 h. After cooling to 25 °C under argon, CuCl 
(1.98 g, 20 mmol, 99.5% Cu) was added under inert atmosphere inside a glove-box. The 
Schlenk-flask was further heated to 130 °C for 5 h under high vacuum, cooled to 25 °C, 
charged with freshly distilled THF (20 mL) under argon flush and wrapped with an 
aluminium foil to protect it from light. The mixture was vigorously stirred until all solid goes 
in solution (ca. 6 h.). The reagent CuCl·2LiCl (1 M in THF) appears as a colourless or slightly 
yellow solution. 
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ZnBr2 solution (1.0 M/THF) was prepared by drying ZnBr2 (33.78 g, 150 mmol) under 
vacuum for 5 h at 150 °C. After cooling to 25 °C, dry THF (150 mmol) was added and stirred 
continuously until the salts were dissolved. 
 
ZnCl2 solution (1.0 M/THF) was prepared by drying ZnCl2 (20.45 g, 150 mmol) under 
vacuum for 5 h at 150 °C. After cooling to 25 °C, dry THF (150 mmol) was added and stirred 
continuously until the salts were dissolved.  
 
LaCl3·2LiCl solution in THF (0.33 M) was prepared following the literature.108 
 
Lithiated reagents 
 
n-Butyllithium was used as a 1.5 M solution in hexane purchased by Chemetall. 
t-Butyllithium was used as a 1.5 M solution in pentane purchased by Chemetall. 
Methyllithium was used as a 1.7 M solution in Et2O purchased by Chemetall. 
 
Magnesiated reagents 
 
i-PrMgCl: A dry three-necked flask equipped with an argon inlet, a dropping funnel and a 
thermometer was charged with magnesium turnings (110 mmol). A small amount of THF was 
added to cover the magnesium, and a solution of isopropyl chloride (100 mmol) in THF (50 
mL) was added dropwise, keeping the temperature of the mixture below 30 °C (water bath). 
After the addition was complete, the reaction mixture was stirred for 12 h at 25 °C. The grey 
solution of i-PrMgCl was cannulated to another flask under argon and removed in this way 
from excess of magnesium. A yield of ca. 95-98 % of i-PrMgCl was obtained and the i-
PrMgCl-solution was titrated prior to use according to reported literature.146  
 
PhMgCl was used as a 2.0 M solution in THF purchased by Chemetall. 
 
i-PrMgCl·LiCl (13): A dry three-necked flask equipped with an argon inlet, a dropping 
funnel and a thermometer was charged with magnesium turnings (110 mmol) and anhydrous 
LiCl (100 mmol). A small amount of THF was added to cover the magnesium, and a solution 
of isopropyl chloride (100 mmol) in THF (50 mL) was added dropwise, keeping the 
                                                 
146
 (a) H. S. Lin, L. Paquette, Synth. Commun. 1994, 24, 2503; (b) A. Krasovskiy, P. Knochel, Synthesis 2006, 5, 
890. 
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temperature of the mixture below 30 °C (water bath). After the addition was complete, the 
reaction mixture was stirred for 12 h at 25 °C. The grey solution of i-PrMgCl·LiCl was 
cannulated to another flask under argon and removed in this way from excess of magnesium. 
A yield of ca. 95-98 % of i-PrMgCl·LiCl was obtained and the i-PrMgCl·LiCl-solution was 
titrated prior to use according to reported literature.146 
 
s-BuMgBr·LiCl (39a), PhMgBr·LiCl (39b), 1-naphtylmagensium chloride (39c), 
MesMgBr·LiCl (39d), and 1,3,5-triisopropylphenylmagnesium bromide (39e), were 
prepared according to the procedure of i-PrMgCl·LiCl (13) from the corresponding 
bromides. 
 
Mes2Mg·2LiBr (39f): A solution of t-BuLi in pentane (190 mmol, 1.70 M) was added 
dropwise at -78 °C to a solution of mesitylbromide (100 mmol) in Et2O (25 mL) for 15 min. 
The resulting mixture was first warmed to -20 °C, and stirred for 1 h, and then warmed to 25 
°C. The solvents were evaporated under vacuum for 1 h. To the obtained lithium salt, a 
solution of MesMgBr147 in THF (105 mmol, 0.65 M) was added at -50 °C and stirred for 1 h. 
Thereafter, the mixture is allowed to warm to 25 °C and stirred for 12 h. A clear solution of 
Mes2Mg·LiBr is obtained and the concentration (0.61 M of [Mg] in THF) was checked by 
titration of iodine (1mmol). 
 
TMPMgCl·LiCl (18a): A dry and nitrogen-flushed 250 mL Schlenk flask, equipped with a 
magnetic stirrer and a septum, was charged with freshly titrated i-PrMgCl·LiCl (100 mL, 1.2 
M in THF, 120 mmol). 2,2,6,6-Tetramethylpiperidine (TMPH) (19.8 g, 126 mmol, 1.05 equiv.) 
was added dropwise at 25 °C. The reaction mixture was stirred at 25 °C until gas evolution 
was completed (ca. 24 h).37 The concentration of the solution of TMPMgCl·LiCl was titrated 
by using benzoic acid in dry THF and 4-(phenylazo)diphenylamine as an indicator. 
 
TMP2Mg·2LiCl (19): was prepared according to the known procedure.40 
 
 
 
 
                                                 
147
 This reagent was directly used from commercial sources such as Aldrich.  
C: Experimental Section  82 
  
  
Other reagents 
 
The following reagents were prepared according to literature procedures:  
Palladium(II)bis(dibenzylidenacetone), 148  tri-(2-furyl)phosphine 149 , ethyl 2-(bromomethyl)-
acrylate,83 S-phenyl benzenesulfonothioate81 and S-phenyl benzenesulfonothioate.82 
 
Chromatography 
 
Thin layer chromatography (TLC) was performed using aluminium plates coated with SiO2 
(Merck 60, F-254). The spots were visualized by UV light and/or by staining of the TLC plate 
with the solution bellow followed, if necessary, by heating with a heat gun: 
• KMnO4 (0.3 g), K2CO3 (20 g), KOH (0.3 g) in water (300 mL) 
• Neat iodine absorbed on silica gel 
• Phosphormolybdic acid (5.0 g), Ce(SO4)2 (2.0 g), conc. H2SO4(12.0 mL) in water 
(230 mL). 
 
Flash column chromatography was performed using SiO2 60 (0.04-0.063 mm, 230-400 mesh 
ASTM) from Merck or aluminium oxide 90 active neutral (0.063-0.200 mm, 70-230 mesh 
ASTM), grade III,150 from Merck. 
 
Preparative TLC were performed using PSC-Plates 20 x 20 cm, Kieselgel 60 F254, 2 mm, from 
Merck. 
 
The diameters of the columns and the amount of silicagel were calculated according to the 
recommendation of W. C. Still.151 
 
Analytical Data 
 
NMR-spectra were recorded on Bruker ARX 200, AC 300, WH 400 or AMX 600 
instruments. Chemical shifts are reported as δ–values in ppm relative to the deuterated solvent 
peak: CDCl3 (δ 3 H = 7.25; δ C (ppm) = 77.0), DMSO-d6 (δ 6 H = 2.49; δ C(ppm) = 39.5).  
                                                 
148
 Y. Takahashi, T. Ito, S. Sakai, Chem. Comm. 1970, 1065. 
149
 D. W. Allen, B. G. Hutley, M. T. J. Mellor, J. Chem. Soc. Perkin Trans. II 1972, 63. 
150
 Brockmann, H.; Schodder, H. Ber. Deut. Chem. Ges. 1941, 74, 73. 
151
 W. C. Still, M. Khan, A. Mitra, J. Org. Chem. 1978, 43, 2923. 
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For the characterization of the observed signal multiplicities, the following abbreviations were 
used: s (singlet), d (doublet), dd (doublet of doublets), t (triplet), td (doublet of triplets), quint 
(quintet), sext (sextet), sept (septet), br (broad). If not otherwise noted, the coupling constants 
given are (CH)- coupling constants. 
 
Melting points are uncorrected and were measured on a Büchi B.540 apparatus. 
 
Infrared spectra were recorded from 4000-400 cm-1 on a Nicolet 510 FT-IR or a Perkin- 
Elmer 281 IR spectrometer. Samples were measured either as film between potassium 
bromide plates (film), as potassium bromide tablets (KBr), or neat (Smiths Detection 
DuraSampl IR II Diamond ATR). 
The absorption bands are reported in wavenumbers (cm-1). For the band characterization, the 
following abbreviations were used: br (broad), vs (very strong), s (strong), m (medium), w 
(weak). 
 
Gas chromatography (GC) was performed with machines of the types Hewlett-Packard 
6890 or 5890 Series II, using a column of the type HP 5 (Hewlett-Packard, 5% 
phenylmethylpolysiloxane; length: 10 m, diameter: 0.25 mm; film thickness: 0.25 µm). The 
detection was accomplished using a flame ionization detector. Depending on the retention 
time of the substrate, decane or tetradecane were used as internal standards. 
Mass Spectra were recorded on a Finnigan MAT 95Q or Finnigan MAT90 instrument for 
electron impact ionization (EI). High resolution mass spectra (HRMS) were recorded on the 
same instrument. 
For the combination of gas chromatography with mass spectroscopic detection, a GC-MS of 
the type Hewlett-Packard 6890 / MSD 5793 networking was used (column: HP 5-MS,  
Hewlett-Packard; 5% phenylmethylpolysiloxane; length: 15 m, diameter 0.25 mm; film 
thickness: 0.25 µm). 
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2. Functionalizations of Quinoline Moieties via Chemo- and 
Regioselective Magnesiations 
 
2.1. General procedure for the Br/Mg exchange reaction using i-PrMgCl·LiCl 
(13) or MesMgBr·LiCl (39d) as magnesiation reagent (GP1). 
A dry and argon flushed flask, equipped with a magnetic stirring bar and a septum, was 
charged with the quinoline derivative (1 equiv) dissolved in dry THF (1.0 M solution). The 
magnesiation reagent i-PrMgCl·LiCl (13) or MesMgBr·LiCl (39d) (1.1 equiv) was added 
slowly, dropwise, at appropriate temperature (as stated in the experiment). The reaction 
mixture was stirred at the same temperature, and the completion of the Br/Mg exchange was 
checked by GC-analysis using decane as internal standard or by TLC. The freshly prepared 
magnesium reagent was cooled to the corresponding temperature or used at 25 °C and the 
corresponding electrophile (1.1-1.5 equiv) or its solution in THF was added. The mixture was 
stirred for a time depending on the reactivity of the electrophile. The consumption of the 
magnesium reagent was checked by GC-analysis, using decane as internal standard. After the 
reaction was completed, sat. NH4Cl solution was added, the mixture was extracted three times 
with Et2O or EtOAc and dried over anhydrous Na2SO4. The solvent was evaporated and the 
product was purified by flash-chromatography (SiO2). 
 
2.2. General procedure for the deprotonation using TMPMg·LiCl (18a) as 
magnesiation reagent (GP2). 
A dry and argon flushed flask, equipped with a magnetic stirring bar and a septum, was 
charged with the quinoline derivative (1 equiv) dissolved in dry THF (1.0 M solution) and 1.1 
equivalents of TMPMg·LiCl (18a) were added dropwise at the given temperature. The 
reaction mixture was stirred at the same temperature, and the completion of the deprotonation 
was checked by GC-analysis of reaction aliquots quenched with iodine using decane as 
internal standard. The freshly prepared magnesium reagent was cooled to the corresponding 
temperature or used at 25 °C and the corresponding electrophile (1.2 equiv) or its solution in 
THF was added. The mixture was stirred for a time depending on the reactivity of the 
electrophile. The consumption of the magnesium reagent was checked by GC-analysis, using 
decane as internal standard. After the reaction was completed, sat. NH4Cl solution was added, 
the mixture was extracted three times with Et2O or EtOAc and dried over anhydrous Na2SO4. 
The solvent was evaporated and the product was purified by flash-chromatography (SiO2). 
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2.3. General procedure for the reaction with acyl chlorides (GP 3) 
According to GP1 or GP2, the freshly prepared magnesium reagent was cooled to −40 °C, 
and CuCN·2LiCl57 (1 equiv, 1.00 M in THF) was added and stirred for 30 min. Thereafter, 
acyl chloride (1.5 equiv) was added at −40 °C, and the reaction mixture was warmed to 25 °C 
and stirred for the appropriate time. The reaction mixture was quenched with sat. aq. NH4Cl 
solution or NH4OH (2M aq.) extracted with Et2O or EtOAc and dried over anhydrous 
Na2SO4. After filtration, the solvent was evaporated in vacuum. Purification by flash-
chromatography furnished the desired product. 
 
 
2.4   Starting material synthesis 
Synthesis of 2,4-dibromoquinoline (37a) 77 
 
N Br
Br
 
 
A mixture of commercially available quinoline-2,4-diol (4.835 g, 30 mmol) and phosphorus 
oxybromide (34 g,120 mmol) was refluxed for 5 h in dry toluene (300 mL). After cooling in 
an ice bath, the reaction mixture was hydrolyzed carefully by addition of ice (200 mL) and 
neutralized using a 6N solution of sodium hydroxide. The insoluble product was collected by 
filtration, washed with water (3 x 100 mL) and dried under vacuum. 2,4-dibromoquinoline 
(37a) was obtained as a pale yellow solid (6.4 g, 75%).  
mp.: 93.8-95.0 °C. 
IR (ATR): ν (cm-1) = 3088 (s), 3060 (vs), 1652 (s), 1562 (s), 1552 (s), 1486 (s), 1452 (m), 
1390 (s), 1262 (m), 1140 (s), 1086 (m), 844 (m), 808 (m), 756 (s), 680 (m). 
1H-NMR (DMSO-d6, 300 MHz): δ (ppm) = 8.17 (s, 1 H), 8.12 (d, 3J = 7.8 Hz, 1 H), 7.99 (d,     
3J = 8.2 Hz, 1 H), 7.89 (m, 1 H), 7.79 (m, 1 H).  
13C-NMR (DMSO-d6, 75 MHz): δ (ppm) = 148.6, 141.2, 135.6, 132.7, 129.7, 129.4, 129.3, 
127.3, 126.8.  
MS (EI, 70 eV): m/z (%) = 288 (41), 287 (10), 286 (100), 284 (46), 207 (67), 205 (76), 126 
(60). 
HRMS (EI) (C9H5Br2N): calculated [M]+: 284.8789  found: 284.8762 
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Synthesis of 2,3-dibromoquinoline (37b)152 
 
N
Br
Br
 
 
Prepared according to GP2 from 3-bromoquinoline (34) (1.24 g, 6 mmol, 1 equiv), 
TMPMgCl·LiCl (18a) [reaction condition: -20 °C for 2 h], and 1,2-dibromo-1,1,2,2-
tetrachloroethane (2.14 g, 6.6 mmol, in 6 mL of THF) [reaction condition: -20 °C to 25 °C for 
12 h]. Purification by flash-chromatography (SiO2, pentane/ether = 19:1) afforded 2,3-
dibromoquinoline (37b, 1.11 g, 65%) as a white solid.  
mp.: 110.2-112.0 °C. 
IR (ATR): ν (cm-1) = 3046 (s), 1614 (m), 1572 (m), 1558 (m), 1546 (s), 1484 (s), 1360 (s), 
1318 (s), 1292 (m), 1200 (m), 1150 (m), 1132 (m), 1110 (vs), 950 (s), 916 (s), 772 (s), 746 
(vs), 662 (m), 626 (m). 
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 8.36 (s, 1 H), 8.01 (d, 3J = 8.8 Hz, 1 H), 7.76 – 7.71 
(m, 2 H), 7.58 (t, 3J = 7.5 Hz, 1 H). 
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 146.7, 142.8, 140.4, 130.8, 130.8, 128.6, 128.0, 
126.7, 119.7. 
MS (EI, 70 eV): m/z (%) = 288 (31) [M+, 81Br], 286 (100) [M+, 81Br, 79Br], 284 (37) [M+, 
79Br], 207 (68), 205 (56), 127 (73), 74 (11). 
HRMS (EI) (C9H579Br2N): calculated [M]+: 284.8789  found: 284.8765 
Synthesis of 3,4-dibromoquinoline (37c) 
 
N
Br
Br
 
 
To a stirred solution of 4-quinolinol (2.08 g, 14.3 mmol, 1.0 equiv) in glacial acetic acid (40 
mL), bromine (0.81 mL, 1.1 equiv) was slowly added. The mixture was refluxed for 24 h, 
cooled to 25 °C and the 3-bromo-4-quinolinol hydrobromide was collected by filtration, 
washed with water and dried in vacuum. 3-bromo-4-quinolinol (3.01 g, 94%) was obtained as 
a colourless solid. 
                                                 
152
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mp.: 81.8-83.6 °C. 
IR (ATR): ν (cm-1) = 3050 (m), 2968 (m), 2894 (s), 2860 (s), 2792 (s), 1626 (m), 1580 (m), 
1552 (vs), 1504 (vs), 1470 (vs), 1440 (s), 1386 (m), 1354 (s), 1298 (m), 1188 (s), 1136 (m), 
836 (m), 754 (m), 744 (m), 688 (m), 600 (m). 
1H-NMR (DMSO-d6, 400 MHz): δ (ppm) = 12.24 (s, 1 H), 8.44 (s, 1 H), 8.11 (d, 3J = 8.0 Hz, 
1 H), 7.68 – 7.63 (m, 1 H), 7.57 (d, 3J = 8.2 Hz, 1 H), 7.36 (t, 3J = 7.4 Hz, 1 H). 
13C-NMR (DMSO-d6, 100 MHz): δ (ppm) = 149.1, 134.4, 127.9, 127.7, 126.5, 126.5, 125.1, 
122.7, 105.0. 
MS (EI, 70 eV): m/z (%) =  224 (98) [M+, 81Br], 222 (100) [M+, 79Br], 144 (11), 116 (27), 115 
(12), 104 (17), 89 (14). 
HRMS (EI) (C9H6BrNO): calculated [M]+: 222.9633  found: 222.9636 
 
A mixture of 3-bromo-4-quinolinol (3.01 g, 13.4 mmol, 1.0 equiv) and phosphorous 
tribromide (12 mL) was refluxed for 5 h. After cooling the reaction mixture was hydrolyzed 
by pouring onto crushed ice (100 mL) and the resulting aq. suspension made strongly alkaline 
with a solution of sodium hydroxide (32 %). The insoluble product was collected by filtration, 
washed with water, and dried in vacuum. 3,4-dibromoquinoline was afforded (37c) (3.11 g, 
76%) as a colourless solid. 
mp.: 236.9-239.9 °C. 
IR (ATR): ν (cm-1) = 3108 (s), 3062 (s), 2924 (s), 1818 (m), 1552 (s), 1484 (vs), 1340 (s), 
1246 (m), 1166 (m), 1106 (m), 964 (m), 848 (m), 808 (m), 750 (s), 662 (m), 628 (w), 594 (w). 
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 8.89 (s, 1 H), 8.21 (d, 3J = 8.4 Hz, 1 H), 8.07 (d, 3J = 
8.4 Hz, 1 H), 7.75 (t, 3J = 7.5 Hz, 1 H), 7.64 (t, 3J = 7.7 Hz, 1 H). 
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 151.3, 146.7, 135.2, 130.3, 129.9, 129.1, 128.9, 
127.4, 121.3. 
MS (EI, 70 eV): m/z (%) = 288 (54) [M+, 81Br], 287 (13), 286 (100) [M+, 81Br, 79Br], 284 (63) 
[M+, 79Br], 207 (26), 205 (23), 180 (12), 127 (29), 100 (14). 
HRMS (EI) (C9H5Br2N): calculated [M]+: 284.8789  found: 284.8769 
 
 
Synthesis of 2,3,4-tribromoquinoline (37d) 
 
N Br
Br
Br
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Prepared according to GP2 from 3,4-dibromoquinoline (37c) (288 mg, 1.0 mmol, 1.0 equiv), 
TMPMgCl·LiCl (18a) [reaction condition: -78 °C for 2 h], and 1,2-dibromo-1,1,2,2-
tetrachloroethane in THF (310 mg, 1.3 mmol, 1.3 equiv) [reaction condition: – 78 °C to 25 °C 
for 12 h]. The crude residue was purified by flash-chromatography (SiO2, pentane/ether = 8:2) 
afforded 2,3,4-tribromoquinoline (37d) (280 mg,  76 %) as a colourless solid. 
mp.: 132.6-134.2 °C. 
IR (ATR): ν (cm-1) = 2358 (m), 2338 (w), 1552 (s), 1484 (m), 1452 (m), 1354 (m), 1338 (s), 
1326 (m), 1290 (m), 1246 (m), 1166 (m), 1140 (w), 1106 (s), 964 (m), 910 (w), 848 (m), 808 
(m), 752 (s), 662 (m). 
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 8.20 (d, 3J = 8.4 Hz, 1 H), 8.03 (d, 3J = 8.4 Hz, 1 H), 
7.78 (t, 3J = 7.6 Hz, 1 H), 7.68 (t, 3J = 7.7 Hz, 1 H). 
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 146.6, 142.8, 137.5, 131.5, 129.5, 129.4, 128.4, 
128.2, 124.2. 
MS (EI, 70 eV): m/z (%) = 368 (29) [M+, 81Br], 366 (97) [M+, 81Br, 81Br, 79Br], 364 (100) 
[M+, 79Br, 79Br, 81Br], 362 (31) [M+, 79Br], 287 (26), 285 (56), 283 (27), 206 (47), 204 (46), 
126 (19), 100 (10), 99 (12).  
HRMS (EI) (C9H4Br3N): calculated: 362.7894 found: 362.7887 
 
 
Synthesis of 2-ethoxy-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (ethyl pinacol borate) 
 
O
B
O
OEt
 
 
Boric acid (1.24 g, 20 mmol, 1 equiv), dry ethanol (4.40 g, 95.4 mmol, 4.77 equiv), and 
pinacol (2.36 g, 20 mmol, 1 equiv) were mixed in 15 mL of dry benzene. After stirring 30 min 
at 25 °C, the ethanol/water/benzene ternary azeotrope was distilled off for 10 h, and most of 
the residual benzene was removed in vacuum at 30 °C. The crude product was distilled (32 
°C, 7 mbar) to give the title compound as a colourless liquid (V= 1.5 mL, 41%) containing no 
traces of benzene. 
1H-NMR (CDCl3, 200MHz): δ (ppm) = 3.84 (q, J = 7.1 Hz, 2H), 1.20 (s, 12H and t 
“overlapped”, 3H). 
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2.5    Preparation of polyfunctionalized quinolines  
 
Synthesis of 2-bromo-4-phenylsulfanyl-quinoline (43a) 
 
N Br
SPh
 
 
Prepared according to GP1 from 2,4-dibromoquinoline (37a) in THF (287 mg, 1.0 mmol, 1.0 
equiv), i-PrMgCl·LiCl (13) [reaction condition: -78 °C for 2 h], and benzenethiosulfonic acid 
S-phenyl ester81 (300 mg, 1.2 mmol, 1.2 equiv) [reaction condition: -50 °C to 25 °C for 12 h]. 
The crude residue was purified by flash-chromatography (SiO2, pentane/ether = 4:1) afforded 
2-bromo-4-phenylsulfanyl-quinoline (43a) (286 mg, 91%) as a yellow solid. 
mp.: 89.0-91.7 °C. 
IR (ATR): ν (cm-1) = 3056 (w), 3044 (w), 1956 (w), 1724 (w), 1544 (m), 1488 (m), 1440 
(m), 1384 (m), 1252 (m), 1140 (s), 1100 (m), 976 (m), 852 (m), 824 (s), 780 (m), 752 (vs), 
688 (s). 
1H-NMR (CDCl3, 300 MHz):  δ (ppm) = 8.17 (d, J = 8.4 Hz, 1H), 8.02 (d, J = 8.4 Hz, 1H), 
7.74 (td, 3J = 8.4 Hz, 4J = 1.5 Hz, 1H), 7.63-7.49 (m, 6H), 6.77 (s, 1H). 
13C-NMR (CDCl3, 75 MHz):  δ (ppm) = 151.8, 147.6, 141.5, 135.5, 135.5, 130.9, 130.3, 
130.3, 129.1, 128.2, 126.9, 124.6, 123.5, 120.8. 
MS (EI, 70 eV): m/z (%) = 316 (81) [M+, 81Br], 314 (81) [M+, 79Br], 236 (100), 208 (11), 
204(13), 190 (10), 166 (20), 159 (10), 127 (18), 117 (14), 108 (30), 104 (14), 101(14), 77 
(17), 75 (21), 68 (15), 65 (26), 51 (28). 
HRMS (EI) (C15H10BrNS): calculated for [M+H]+  315.9791  found: 315.9796  
 
 
Synthesis of 2-bromoquinoline-4-carbonitrile (43b) 
 
N Br
CN
 
 
Prepared according to GP1 from 2,4-dibromoquinoline (37a) in THF (1 mL) (287 mg, 1.0 
mmol, 1.0 equiv), i-PrMgCl·LiCl (13) [reaction condition: -78 °C for 2 h], and tosyl cyanide 
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(220 mg, 1.2 mmol, 1.2 equiv) [reaction condition: -50 °C for 30 min and warmed to 25 °C 
for 6 h]. The crude residue was purified by flash-chromatography (SiO2, pentane/ether = 2:3) 
afforded 2-bromoquinoline-4-carbonitrile (43b) (196 mg, 85%) as a colourless solid. 
mp.: 153.0-155.5 °C. 
IR (ATR): ν (cm-1) = 3055 (w), 2235 (w), 1571 (w), 1539 (m), 1495 (w), 1408 (w), 1279 (m), 
1223 (w), 1146 (m), 1088 (s), 891 (m), 866 (s), 853 (m), 762 (s). 
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 8.15 (t, J = 8.8 Hz, 2H), 7.88 (td, J = 8.4 Hz, J = 1.3 
Hz, 1H), 7.85 (s, 1H), 7.78 (td, J = 8.2 Hz, J = 1.3 Hz, 1H). 
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 148.4, 140.1, 132.3, 129.5, 129.5, 129.4, 125.1, 
124.6, 120.8, 114.2. 
MS (EI, 70 eV): m/z (%) = 233 (71) [M+, 81Br], 231 (74) [M+, 79Br], 152 (100), 125 (14), 99 
(2), 76 (1).  
HRMS (EI) (C10H5BrN2): calculated [M]+: 231.9636  found: 231.9614 
 
 
Synthesis of 2-bromoquinolin-4-ylamine (43c) 
 
N Br
NH2
 
 
Prepared according to GP1 from 2,4-dibromoquinoline (37a) in THF (1 mL) (287 mg, 1.0 
mmol, 1.0 equiv), i-PrMgCl·LiCl (13) [reaction condition: -78 °C for 2 h]. To the freshly 
prepared magnesium reagent, CuCl·2LiCl (1.2 mL, 1.0 M in THF, 1.2 mmol) was added 
dropwise at -50 °C under argon and the mixture was stirred for 1 h. To the formed aryl copper 
reagent, commercially available LiHMDS (1M in THF/ethylbenzene) (2 mL, 2 mmol, 2 
equiv) was added dropwise and the mixture was further stirred for 1 h at -60 oC. The reaction 
mixture was cooled to -78 oC, then a solution of chloranil (22, 298 mg, 1.2 mmol) in dry THF 
(7 mL) was added slowly over a period of 1 h at -78 oC. The reaction mixture was then stirred 
for further 12 h. Et2O (10 mL) was poured into the crude reaction mixture. The resulting 
mixture was then filtered through celite and the residue washed with Et2O (ca. 100 mL). The 
organic phase was washed with 2 x 10 mL portions of aqueous NH4OH (2.0 M) and extracted 
with Et2O. The combined organic layers were dried (MgSO4), filtered, and concentrated under 
reduced pressure. The crude material obtained was redissolved in THF (3 mL) before TBAF 
(1.0 m in THF) (2 mL, 2 mmol) was added in one portion and the mixture was stirred at 25 °C 
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for 15 min, poured over EtOAc (10 mL) and washed with deionised water (3 x 10 mL). The 
combined organic extracts were dried (MgSO4), filtered and concentrated in vacuum. 
Purification by flash-chromatography (SiO2, pentane/ether = 9:1 with 0.5 % NEt3) afforded 2-
bromoquinolin-4-ylamine (43c) (166 mg, 75%) as a pale yellowish solid. 
mp.: 191.9-193.3 °C. 
IR (ATR): ν (cm-1) = 3456 (m), 3310 (m), 3195 (br), 2923 (w), 1685 (s), 1574 (s), 1549 (s), 
1511 (s), 1439 (s), 1351 (m), 1322 (m), 1143 (m), 1106 (m), 907 (s), 816 (m), 808 (m), 752 
(s). 
1H-NMR (DMSO-d6, 400 MHz): δ (ppm) = 8.13 (d, J = 9.1 Hz, 1H), 7.68-7.61 (m, 2H), 
7.45-7.41 (m, 1H), 7.14 (s, 2H), 6.64 (s, 1H). 
13C-NMR (DMSO-d6, 100 MHz): δ (ppm) = 153.7, 148.4, 142.2, 130.2, 127.8, 124.4, 122.6, 
117.8, 104.1. 
MS (EI, 70 eV): m/z (%) = 223 (73) [M+, 81Br], 221 (82) [M+, 79Br], 143 (47), 116 (100), 115 
(12), 89 (22), 76 (5), 63 (5), 50 (5).  
HRMS (EI) (C9H779BrN2): calculated [M]+: 221.9793   found: 221.9786 
 
 
Synthesis of 2-bromo-3-cyanoquinoline (43d)  
 
N
CN
Br
 
 
Prepared according to GP1 from 2,3-dibromoquinoline (37b) (1.23 g, 4.3 mmol, 1.0 equiv),  
i-PrMgCl·LiCl (13) [reaction condition: -50 °C for 2 h],  and tosyl cyanide  (1.02 g, 5.6 mmol, 
1.3 equiv) [reaction condition: -50 °C to 25 °C for 12 h]. The crude residue was purified by 
flash-chromatography (SiO2, pentane/ether = 7:3) afforded 2-bromo-3-cyanoquinoline (43d) 
(837 mg, 84 %) as a colourless solid. 
mp.: 176.6-177.4 °C. 
IR (ATR): ν (cm-1) = 3052 (s), 2230 (m), 1612 (m), 1576 (s), 1556 (s), 1486 (s), 1456 (m), 
1392 (m), 1370 (s), 1358 (m), 1334 (m), 1132 (s), 1020 (vs), 1010 (s), 970 (m), 936 (s), 774 
(m), 760 (vs), 678 (m). 
1H-NMR (CDCl3, 600 MHz): δ (ppm) = 8.50 (s, 1H), 8.10 (d, 3J = 8.60 Hz, 1 H), 7.93-7.88 
(m, 2 H), 7.72-7.70 (m, 1 H). 
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13C-NMR (CDCl3, 150 MHz): δ (ppm) = 149.1, 144.5, 139.7, 134.1, 129.3, 129.0, 128.4, 
125.5, 116.4, 111.1. 
MS (EI, 70 eV): m/z (%) = 233 (47) [M+, 81Br], 231 (50) [M+, 79Br], 153 (10), 152 (100), 125 
(21). 
HRMS (EI) (C10H5BrN2): calculated [M]+: 231.9636  found: 231.9640 
 
 
Synthesis of 1-(2-bromo-quinolin-3-yl)-propan-1-ol (43e) 
 
N Br
OH
 
 
Prepared according to GP1 from 2,3-dibromoquinoline (37b) (287 mg, 1.0 mmol, 1.0 equiv), 
i-PrMgCl·LiCl (13) [reaction condition: -50 °C for 2 h], and propionaldehyde (70 mg, 1.2 
mmol, 1.2 equiv) [reaction condition: -50 °C to 25 °C for 12 h]. The crude residue was 
purified by flash-chromatography (SiO2, pentane/ether = 7:3) afforded 1-(2-bromo-quinolin-
3-yl)-propan-1-ol (43e) (202 mg, 76%) as a colourless solid. 
mp.: 85.5-86.7 °C. 
IR (ATR): ν (cm-1) = 3273 (s), 2964 (w), 2928 (w), 1587 (m), 1489 (m), 1330 (s), 1172 (m), 
1128 (m), 1101 (s), 1019 (m), 1008 (m), 976 (s), 776 (s), 750 (s).  
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 8.21 (s, 1H), 7.95 (d, 7.9 Hz, 1H), 7.72 (d, 7.9 Hz 
,1H), 7.64 (td, 3J = 7.1 Hz, 4J = 1.1 Hz, 1 H), 7.50 (td, 3J = 7.1 Hz, 4J = 1.3 Hz, 1 H), 5.07-
5.03 (dd, J = 3.8 Hz, J = 8.0 Hz, 1H), 2.98 (s, 1H), 1.98-1.97 (m, 1H), 1.77-1.62 (m, 1H), 1.03 
(t, J = 7.5 Hz, 3H). 
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 193.5, 147.4, 141.9, 138.2, 135.3, 130.1, 128.0, 
127.7, 127.4, 73.1, 30.7, 10.0. 
MS (EI, 70 eV): m/z (%) = 267 (8) [M+, 81Br], 265 (8) [M+, 79Br], 238 (97), 236 (100), 156 
(62), 128 (61), 101 (15), 77 (4). 
HRMS (EI) (C12H12BrNO): calculated [M]+: 265.0102  found: 265.0103 
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Synthesis of 4-bromo-3-methylsulfanylquinoline (43f) 
 
N
Br
SMe
 
 
A dry and argon flushed flask, equipped with a magnetic stirring bar and a septum, was 
charged with Mes2Mg·2LiBr (39f) (1.80 mL, 1.1 mmol, 1.1 equiv, 0.62M of [Mg] in THF) 
and TMEDA (0.18 mL, 1.1 mmol, 1.1 equiv) and stirred at -10 °C for 10 min. Thereafter, a 
solution of 3,4-dibromoquinoline (37c) (287 mg, 1.0 mmol, 1.0 equiv) in dry THF (1 mL) was 
added slowly, dropwise, at -10 °C  and stirred for 6 h. The completion of the Br/Mg exchange 
was checked by GC-analysis using decane as internal standard. To the freshly prepared red 
magnesium reagent was added benzenethiosulfonic acid S-methyl ester82 (244 mg, 1.3 mmol, 
1.3 equiv) at -10 °C and the mixture was then stirred and warmed to 25 °C for 6 h. After the 
reaction was completed, sat. NH4Cl solution was added and the mixture was extracted three 
times with CH2Cl2. The combined organic extracts were dried (MgSO4), filtered and 
concentrated in vacuum. Purification by flash-chromatography (SiO2, pentane/ether = 1:1) 
afforded 4-bromo-3-methylsulfanylquinoline (43f) (199 mg, 79%) as a colourless solid. 
mp.: 108.0-109.2 °C. 
IR (ATR): ν (cm-1) = 2921 (w), 1612 (w), 1545 (m), 1483 (s), 1473 (s), 1432 (m), 1331 (s), 
1320 (s), 1253 (m), 1163 (m), 1111 (s), 952 (m), 931 (m), 871 (m), 810 (s), 750 (s), 667 (s). 
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 8.69 (s, 1H), 8.15 (d, J = 8.4 Hz, 1H), 8.05 (d, J = 
8.2 Hz, 1H), 7.71-7.59 (m, 2H), 2.56 (s, 3H). 
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 147.1, 146.2, 133.7, 132.3, 129.7, 129.2, 128.4, 
127.8, 126.1, 16.3. 
MS (EI, 70 eV): m/z (%) = 254 (100) [M+, 81Br], 252 (98) [M+, 79Br], 239 (10), 237 (9), 173 
(10), 159 (34), 132 (8), 87 (7). 
HRMS (EI) (C10H8BrNS): calculated [M]+: 252.9561  found: 252.9540 
 
 
Synthesis of 4-(4-bromoquinolin-3-yl)-benzonitrile (43g) 
 
N
Br
CN
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A dry and argon flushed flask, equipped with a magnetic stirring bar and a septum, was 
charged with Mes2Mg·2LiBr (39f) (1.80 mL, 1.1 mmol, 1.8 mL, 1.1 equiv, 0.62M of [Mg] in 
THF) and TMEDA (0.18 mL, 1.1 mmol, 1.1 equiv) and stirred at -10 °C for 10 min. 
Thereafter, a solution of 3,4-dibromoquinoline (37c) (287 mg, 1.0 mmol, 1.0 equiv) in dry 
THF (1 mL) was added slowly dropwise at -10 °C and stirred for 6 h. The completion of the 
Br/Mg exchange was checked by GC-analysis using decane as internal standard. The 
corresponding freshly prepared red magnesium reagent was transmetalated with ZnCl2 (1.1 
mL, 1.1 equiv, 1 M in dry THF) and the mixture was warmed to 25 °C for 1 h. 4-
Iodobenzonitrile (297 mg, 1.3 mmol, 1.3 equiv) was then added neat to the reaction mixture. 
A flame-dried round bottom flask was charged with Pd(dba)2 (30 mg, 5 mol%), P(o-furyl)3 
(24 mg, 10 mol%) and THF (1 mL). The mixture was stirred at 25 oC for 10 min, and then 
transferred to the reaction flask which was charged with the organozinc solution. The 
resulting mixture was stirred 12 h at 25 °C, quenched with sat. aq. NH4Cl and extracted three 
times with AcOEt. The combined organic extracts were dried (MgSO4), filtered and 
concentrated in vacuum. Purification by flash-chromatography (SiO2, pentane/ether = 1:1) 
afforded 4-(4-bromoquinolin-3-yl)-benzonitrile (43g) (219 mg, 71%) as a colourless solid. 
mp.: 160.0-162.7 °C. 
IR (ATR): ν (cm-1) = 2978 (w), 2230 (w), 1724 (m), 1690 (w), 1603 (w), 1548 (m), 1476 (s), 
1337 (m), 1077 (m), 1022 (w), 958 (w), 871 (w), 839 (s), 759 (s), 671 (s).  
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 8.71 (s, 1H), 8.32 (d, J = 7.9 Hz, 1H), 8.16 (d, 7.9 
Hz, 1H), 7.84-7.60 (m, 6H). 
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 149.9, 148.1, 142.8, 134.3, 133.6, 132.2 (2carbons), 
130.7 (2 carbons), 129.8, 128.7, 127.5 (2carbons), 118.4, 112.4. 
MS (EI, 70 eV): m/z (%) = 309 (100) [M+, 81Br], 307 (94) [M+, 79Br], 230 (17), 229 (86), 228 
(14), 201 (38), 175 (22), 114 (14), 101 (16), 88 (5), 75 (4). 
HRMS (EI) (C16H981BrN2): calculated [M]+: 309.9949  found: 309.9911 
 
 
Synthesis of 2,4-dibromo-quinoline-3-carbonitrile (43h) 
 
N Br
Br
CN
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Prepared according to GP1 from 2,3,4-tribromoquinoline (37d) in THF (1 mL) (365 mg, 1.0 
mmol, 1.0 equiv), MesMgBr·LiCl (39d) [reaction condition: -10 °C for 3 h], and tosyl 
cyanide (220 mg, 1.2 mmol, 1.2 equiv) [reaction condition: -50 °C for 30 min and warmed to 
25 °C for 6 h]. The crude residue was purified by flash-chromatography (SiO2, pentane/ether 
= 9:1) afforded 2,4-dibromoquinoline-3-carbonitrile (43h) (274 mg, 88%) as colourless 
needles (recrystallization ether/AcOEt 1:1). 
mp.: 207.1-208.1 °C. 
IR (ATR): ν (cm-1) = 3059 (w), 3038 (w), 2226 (w), 1544 (m), 1474 (m), 1376 (w), 1354 (w), 
1298 (m), 1203 (w), 1136 (w), 1033 (m), 912 (m), 871 (m), 757 (s), 731 (s). 
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 8.22 (d, J = 8.6 Hz, 1H), 8.07 (d, J = 8.4 Hz, 1H), 
7.93 (t, J = 8.2 Hz, 1H), 7.78 (t, J = 8.2 Hz, 1H). 
13C-NMR (CDCl3, 75MHz): δ (ppm) = 148.3, 141.7, 139.3, 134.3, 129.8, 129.5, 128.1, 
125.8, 115.6, 114.4. 
MS (EI, 70 eV): m/z (%) = 313 (28), 311 (57), 309 (28), 232 (50), 230 (48), 152 (100), 125 
(15), 99 (30), 75 (19), 51 (11). 
HRMS (EI) (C10H4Br2N2): calculated [M+H]+ 310.8820  found: 310.8818 
 
 
Synthesis of 2,4-dibromo-quinoline-3-carboxylic acid ethyl ester (43i) 
 
N Br
Br
CO2Et
 
 
Prepared according to GP1 from 2,3,4-tribromoquinoline (37d) in THF (1 mL) (365 mg, 1.0 
mmol, 1.0 equiv), MesMgBr·LiCl (39d) [reaction condition: -10 °C for 3 h], and ethyl 
cyanoformate (119 mg, 1.2 mmol, 1.2 equiv) [reaction condition: -50 °C for 30 min and 
warmed to 25 °C for 6 h]. The crude residue was purified by flash-chromatography (SiO2, 
pentane/ether = 9:1) afforded 2,4-dibromo-quinoline-3-carboxylic acid ethyl ester (43i) (320 
mg, 90%) as a colourless solid. 
mp.: 109.8-111.8 °C. 
IR (ATR): ν (cm-1) = 2983 (w), 1731 (s), 1692 (w), 1552 (s), 1476 (m), 1377 (m), 1354 (m), 
1319 (m), 1295 (m), 1243 (m), 1230 (s), 1179 (s), 1130 (m), 1018 (m), 919 (m), 857 (w), 808 
(m), 746 (s), 679 (s). 
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1H-NMR  (CDCl3, 300 MHz): δ (ppm) = 8.19 (d, J = 8.4 Hz, 1H), 8.03 (d, J = 8.4 Hz, 1H), 
7.80 (td, J = 7.1 Hz, J = 1.5 Hz, 1H), 7.69 (td, J = 7.2 Hz, J = 1.5 Hz ,1H), 4.53 (q, J = 7.3 Hz, 
2H), 1.46 (t, J = 7.3 Hz, 3H). 
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 165.1, 147.9, 136.2, 132.5, 132.2, 132.1, 129.1, 
129.0, 127.3, 126.1, 62.9, 14.0. 
MS (EI, 70 eV): m/z (%) = 317 (80), 236 (100), 204 (13), 190 (10), 165 (19), 127 (18), 117 
(14), 109 (14), 77 (17), 75 (20), 65 826), 51 (28). 
HRMS (EI) (C12H9Br2NO2): calculated [M+H]+ 357.9079  found: 357.9078 
 
 
Synthesis of 3-benzyl-2,4-dibromoquinoline (43j) 
 
N
Br
Br
Ph
 
 
Prepared according to GP1 from 2,3,4-tribromoquinoline (37d) (1.82  g, 5.0 mmol, 1.0 equiv) 
dissolved in dry THF (5 mL),  MesMgBr·LiCl (39d) [reaction condition: -10 °C for 3 h],  and  
benzyl bromide (1.19 g, 1.4 mmol,  1.4 equiv) [reaction condition: -50 °C for 30 min and 
warmed to 25 °C for 10  h]. The crude residue was purified by flash-chromatography (SiO2, 
pentane/ether = 3:2) afforded 3-benzyl-2,4-dibromoquinoline (43j) (1.67 mg, 89%) as a 
colourless solid. 
mp.: 99.2-100.6 °C. 
IR (ATR): ν (cm-1) = 3028 (w), 2924 (w), 1600 (w), 1552 (s), 1491 (w), 1475 (s), 1451 (m), 
1354 (m), 1299 (m), 1135 (m), 1027 (m), 1016 (m), 908 (m), 879 (m), 762 (s), 722 (s), 693 
(s).  
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 8.22 (d, J = 8.8 Hz, 1H), 8.03 (d, J = 8.3 Hz, 1H), 
7.74 (td, J = 7.1 Hz, J = 1.5 Hz, 1H), 7.66 (td, J = 7.0 Hz, J = 1.5 Hz, 1H), 7.30-7.17 (m, 5H), 
4.65 (s, 2H). 
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 147.2, 144.6, 137.2, 137.0, 134.5, 130.7, 128.9, 
128.5, 128.5, 128.4, 128.3, 128.3, 127.6, 127.5, 126.5, 42.1. 
MS (EI, 70 eV): m/z (%) = 376 (14), 295 (10), 217 (37), 216 (100), 215 (11), 189 (12), 140 
(7), 107 (14), 94 (10), 63 (7), 51 (7). 
HRMS (EI) (C16H11Br2N): calculated [M+H]+: 375.9337  found: 375.9333 
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Synthesis of 2-bromo-quinoline-3-carboxylic acid ethyl ester (43k) 
 
N
CO2Et
Br
 
 
Prepared according to GP1 from 2,3-dibromoquinoline (37b) (1.15 g,  4.0 mmol, 1.0 equiv),  
i-PrMgCl·LiCl (13) [reaction condition: -50 °C for 2 h],  and  ethyl cyanoformate (475 mg,  
4.8 mmol, 1.2 equiv)  [reaction condition: -50 °C to 25 °C for 5 h]. The crude residue was 
purified by flash-chromatography (SiO2, pentane/ether = 7:3) afforded 2-bromoquinoline-3-
carboxylic acid ethyl ester (43k) (1.03 g, 92 %) as a colourless solid. 
mp.: 104.1-107.2 °C. 
IR (ATR): ν (cm-1) = 3056 (w), 2980 (w), 2928 (w), 1724 (s), 1480 (m), 1388 (m), 1368 (m), 
1268 (m), 1264 (m), 1244 (s), 1228 (s), 1196 (s), 1124 (s), 1112 (s), 1028 (s), 996 (s), 936 (s), 
876 (s), 816 (m), 780 (vs), 752 (vs). 
1H-NMR (CDCl3, 300 MHz): δ (ppm) =  8.55 (s, 1H), 8.06 (d, J = 8.6 Hz, 1H), 7.87 (d, J = 
8.2 Hz, 1H), 7.81 (td, J = 7.1 Hz, J = 1.5 Hz ,1H), 7.62 (td, J = 8.1 Hz, J = 1.1 Hz ,1H), 4.47 
(q, J = 7.3 Hz, 2H), 1.45 (t, J = 7.3 Hz, 3H). 
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 165.1, 148.8, 140.4, 138.5, 132.4, 128.6, 128.4, 
127.9, 126.9, 25.9, 62.2, 14.2. 
MS (EI, 70 eV): m/z (%) = 281 (12), 279 (13), 278 (100), 252 (24), 250 (25), 235 (73), 233 
(74), 207 (17), 205 (17), 172 (20), 128 (12). 
HRMS (EI) (C12H10BrNO2): calculated [M]+: 278.9895 found: 278.9956 
 
Synthesis of ethyl 2-bromoquinoline-4-carboxylate (43l) 
 
N
CO2Et
Br
 
 
Prepared according to GP1 from 2,4-dibromoquinoline (37a) (8 mmol, 2.3 g, 1.0 equiv) 
dissolved in THF (10 mL), i-PrMgCl·LiCl (13) [reaction condition: -78 °C for 2 h], and ethyl 
cyanoformate (9.6 mmol, 950 mg, 1.2 equiv) [reaction condition: -78 °C to 25 °C for 12 h]. 
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The crude residue was purified by flash-chromatography (SiO2, pentane/ether = 4:1) afforded 
ethyl 2-bromoquinoline-4-carboxylate (43l) (2.06 g, 92%) as a colourless solid. 
mp.: 74.3-76.9 °C. 
IR (ATR): ν (cm-1) = 3102 (s), 2992 (s), 1724 (s), 1550 (vs), 1480 (s), 1454 (m), 1440 (m),        
1338 (m), 1264 (s), 1238 (s), 1196 (m), 1146 (s), 1100 (s), 1028 (m), 894 (m), 798 (s),        
774 (s), 750 (s), 662 (m), 594 (w). 
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 8.71 (d, 3J = 8.4 Hz, 1 H), 8.07 (d, 3J = 8.4 Hz,        
1 H), 8.00 (s, 1 H), 7.77 (td, 3J = 7.1 Hz, 4J = 1.3 Hz ,1 H), 7.65 (td, 3J = 7.1 Hz, 4J = 1.3 Hz 
,1 H), 4.50 (q, 3J = 7.2 Hz, 2 H), 1.47 (t, 3J = 7.1 Hz, 3 H). 
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 164.7, 149.5, 141.0, 137.5, 130.8, 129.2, 128.4, 
126.9, 125.8, 124.1, 62.3, 14.2. 
MS (EI, 70 eV): m/z (%) = 281 (16), 280 (96) [M+, 79Br], 279 (15), 278 (100) [M+, 81Br],       
251 (11), 236 (29), 234 (29), 207 (23), 205 (22), 200 (40), 172 (29), 128 (35), 126 (42), 116 
(12), 101 (19), 75 (12). 
HRMS (EI) (C12H10BrNO2): calculated [M]+: 278.9895 found: 278.9903 
 
 
Synthesis of 3-benzyl-2-bromo-4-methylsulfanylquinoline (44) 
 
N
SMe
Br
Ph
 
 
Prepared according to GP1 from 3-benzyl-2,4-dibromoquinoline (43j) (1.13 g, 3.0 mmol, 1.0 
equiv) dissolved in THF (3 mL), iPrMgCl·LiCl (13) [reaction condition: -50 °C for 12 h], and 
benzenethiosulfonic acid S-methyl ester (675 mg, 3.6 mmol, 1.2 equiv) [reaction condition: -
50 °C to 25 °C for 12 h]. The crude residue was purified by flash-chromatography (SiO2, 
pentane/ether) afforded 3-benzyl-2-bromo-4-methylsulfanylquinoline (44) (897 mg, 87%) as 
a colourless oil. 
IR (ATR): ν (cm-1) = 3028 (w), 2924 (vw), 1708 (vs), 1476 (m), 1356 (s), 1220 (s), 1136 (m), 
1028 (s), 916 (m), 884 (m), 764 (s), 744 (m), 724 (s), 712 (m). 
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 8.51 (d, J = 8.4 Hz, 1H), 8.10 (d, J = 8.8 Hz, 1H), 
7.78-7.66 (m, 2H), 7.31-7.16 (m, 5H), 4.82 (s, 2H), 2.28 (s, 3H). 
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 147.6, 147.0, 145.6, 138.8, 138.4, 130.1, 130.1, 
129.4, 129.4, 128.8, 128.4, 128.4, 127.9, 126.6, 126.2, 40.3, 20.0. 
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MS (EI, 70 eV): m/z (%) = 345 (100) [M+, 81Br], 343 (94) [M+, 79Br], 329 (5), 327 (6), 264 
(31), 217 (24), 216 (88), 189 (5), 91 (4). 
HRMS (EI) (C17H14BrNS): calculated [M]+: 343.0030  found: 343.0016 
 
 
Synthesis of 2-(3-benzyl-4-methylsulfanylquinolin-2-ylmethyl)-acrylic acid ethyl ester 
(45) 
N
SMe
CH2Ph
EtO2C
 
 
A dry and argon flushed flask, equipped with a magnetic stirring bar and a septum, was 
charged with Mes2Mg·LiBr (39f) (1.1 mmol, 1.1 equiv, 0.62M of [Mg] in THF) and stirred at 
0 °C for 10 min. Therefore, a solution of  3-benzyl-2-bromo-4-methylsulfanyl-quinoline (44) 
(1 mmol, 344 mg, 1.0 equiv) dissolved in THF (1 mL) was added slowly, dropwise, at 0 °C 
and stirred for 12 h. The completion of the Br/Mg exchange was checked by GC-analysis 
using decane as internal standard. Ethyl (2-bromomethyl)acrylate83 was then added to the 
mixture at -20 °C, followed by 2 drops of CuCN·2LiCl (cat., 1M in THF) and the reaction 
mixture was warmed to 25 °C over 12 h. Sat. NH4Cl solution was added and the mixture was 
extracted three times with EtOAc. The combined organic extracts were dried (MgSO4), 
filtered and concentrated in vacuum. Purification by flash-chromatography (SiO2, 
pentane/ether = 7:3) afforded 2-(3-benzyl-4-methylsulfanyl-quinolin-2-ylmethyl)-acrylic acid 
ethyl ester (45) (263 mg, 70%) as a colourless oil. 
IR (ATR): ν (cm-1) = 3060 (w), 2984 (w), 1716 (vs), 1636 (m), 1604 (w), 1556 (m), 1480 
(w), 1380 (m), 1308 (m), 1264 (m), 1176 (m), 1124 (m), 976 (w), 952 (w), 820 (w), 746 (m). 
1H-NMR (CDCl3, 600 MHz):  δ (ppm) = 8.52 (d, J = 8.1 Hz, 1H), 7.99 (d, J = 8.1 Hz, 1H), 
7.70-7.63 (m, 2H), 7.07-7.02 (m, 3H), 6.85-6.83 (m, 2H), 6.25 (d, J = 1.8 Hz, 1H), 5.87 (d, J 
= 1.8 Hz, 1H), 4.19 (q, J = 7.3 Hz, 2H), 4.03 (s, 2H), 2.22 (s, 3H), 1.28 (t, J = 7.3 Hz, 3H). 
13C-NMR (CDCl3, 150 MHz):  δ (ppm) = 166.7, 158.8, 146.6, 145.4, 140.0, 138.0, 137.4, 
130.4, 129.2, 129.1, 129.0, 129.0, 127.8, 127.8, 127.6, 126.2, 125.7, 125.7, 60.6, 54.5, 37.2, 
19.6, 14.2. 
MS (EI, 70 eV): m/z (%) = 324 (1), 308 (5), 254 (28), 240 (100), 193 (15), 68 (11). 
HRMS (EI) (C23H23NO232S): calculated [M]+: 377.1449  found: 377.1444 
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Synthesis of ethyl 2-bromo-4-pivaloylquinoline-3-carboxylate (52) 
 
Br
COt-Bu
CO2Et
N
 
 
Prepared according to GP2 and GP3 from 2-bromoquinoline-3-carboxylic acid ethyl ester 
(43k) (560 mg, 2.0 mmol, 1.0 equiv), TMPMgCl·LiCl (18a) [reaction condition: 0 °C for 3 h], 
CuCN·2LiCl [reaction condition: -40 °C for 10 min], and pivaloyl chloride (240 mg, 2.2 
mmol, 1.2 equiv) [reaction condition: -40 °C to 25 °C for 6 h]. The crude residue was purified 
by flash-chromatography (SiO2, pentane/ether = 7:3) afforded ethyl 2-bromo-4-
pivaloylquinoline-3-carboxylate (52) (612 mg, 84 %) as a colourless solid. 
mp.: 120.2 - 121.9 °C. 
IR (ATR): ν (cm-1) = 2976 (w), 1725 (vs), 1691 (s), 1558 (m), 1267 (m), 1231 (s), 1182 (s), 
1152 (m), 1086 (m), 1012 (m), 977 (m), 771 (s), 756 (m). 
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 8.08 (d, J = 8.4 Hz, 1H), 7.80 (td, J = 6.2 Hz, J = 
1.9 Hz, 1H), 7.64-7.55 (m, 2H), 4.42 (q, J = 7.1 Hz, 2H), 1.41 (t, J = 7.1 Hz, 3H), 1.26 (s, 
9H). 
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 211.4, 165.6, 149.3, 148.2, 137.7, 132.1, 129.3, 
128.2, 126.1, 124.3, 122.4, 62.9, 45.3, 27.7, 27.7, 27.7, 13.9. 
MS (EI, 70 eV): m/z (%) = 320 (4), 318 (4), 309 (40), 308 (29), 307 (41), 280 (98), 278 (100), 
208 (9), 198 (12), 154 (22), 126 (8), 57 (7). 
HRMS (EI) (C17H18BrNO4): calculated [M+H]+ 364.0549  found: 364.0540 
 
 
Synthesis of ethyl 2-bromo-3-pivaloylquinoline-4-carboxylate (53) 
 
N
CO2Et
Br
COt-Bu
 
 
Prepared according to GP2 and GP3 from ethyl 2-bromoquinoline-4-carboxylate (43l) (1.59 
g, 5.7 mmol, 1.0 equiv) dissolved in dry THF (5 mL), TMPMgCl·LiCl (18a) [reaction 
condition: -10 °C for 3 h], CuCN·2LiCl [reaction condition: -40 °C for 30 min], and pivaloyl 
chloride (748 mg, 6.8 mmol, 1.2 equiv)  [reaction condition: -40 °C warmed to 25 °C for 12 
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h]. The crude residue was purified by flash-chromatography (SiO2, pentane/ether = 8:2) 
afforded ethyl 2-bromo-3-pivaloylquinoline-4-carboxylate (53) (1.67 g, 81%) as a colourless 
crystalline solid. 
mp.: 70.8-72.0 °C. 
IR (ATR): ν (cm-1) = 2976 (m), 1724 (vs), 1690 (s), 1552 (s), 1482 (m), 1456 (m), 1270 (m),     
1220 (vs), 1186 (m), 1142 (m), 1078 (s), 1014 (m), 978 (m), 890 (m), 762 (s), 682 (w),       
580 (w). 
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 8.08 (d, 3J = 8.4 Hz, 1 H), 7.98 (d, 3J = 8.4 Hz, 1 H), 
7.80 (t, 3J = 7.1 Hz, 1H), 7.65 (t, 3J = 7.1 Hz, 1H), 4.46 (q, 3J = 7.1 Hz, 2H), 1.41 (t, 3J = 
7.1 Hz, 3 H), 1.33 (s, 9 H). 
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 210.0, 165.4, 147.9, 137.0, 136.2, 134.6, 131.4, 
129.0, 128.7, 125.5, 122.6, 63.0, 45.4, 28.2, 28.2, 28.2, 14.0. 
MS (EI, 70 eV): m/z (%) = 364 [M+] not found, 308 (37), 307 (16), 306 (47), 305 (11), 280 
(13), 279 (98), 278 (14), 277 (100), 153 (18). 
HRMS (EI) (C17H18BrNO3): calculated [M+H]+ 364.0549  found: 364.0573  
 
 
Synthesis of 2-bromo-3-pivaloyl-8-(4-ethoxycarbonyl-phenyl)-quinoline-4-carboxylic 
acid ethyl ester (54) 
CO2Et
N
CO2Et
Br
COt-Bu
 
 
A dry and argon flushed flask, equipped with a magnetic stirring bar and a septum, was 
charged with ethyl 2-bromo-3-pivaloylquinoline-4-carboxylate (53) (365 mg, 1 mmol, 1.0 
equiv) dissolved in dry THF (1 mL). TMP2Mg·2LiCl (19, 2 mL, 1.1 mmol, 0.55 M in THF) 
was added dropwise to the mixture at 0 °C and the resulting mixture was stirred at this 
temperature for 20 h. The freshly prepared magnesium reagent was then transmetalated with 
ZnCl2 (1.1 mL, 1.1 equiv, 1 M in dry THF) at 0 °C and the mixture was warmed to 25 °C for 
1 h. 4-Iodo-benzoic acid ethyl ester (358 mg, 1.3 mmol, 1.3 equiv) was added to the reaction 
mixture at 25 °C. A flame-dried round bottom flask was charged with Pd(dba)2 (30 mg, 5 
mol%), P(o-furyl)3 (24 mg, 10 mol%) and THF (1 mL). The mixture was stirred at 25 oC for 
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10 min then transferred to the reaction flask which was charged with the organozinc solution. 
The resulting mixture was stirred and refluxed for 4 h, quenched with sat. aq. NH4Cl and 
extracted three times with AcOEt. The combined organic extracts were dried (MgSO4), 
filtered and concentrated in vacuum. Purification by flash-chromatography (SiO2, 
pentane/ether = 7:3) afforded 2-bromo-3-(2,2-dimethyl-propionyl)-8-(4-ethoxycarbonyl-
phenyl)-quinoline-4-carboxylic acid ethyl ester (54) (363 mg, 71%) as a colourless solid. 
mp.: 126.0 - 129.1 °C. 
IR (ATR): ν (cm-1) =2968 (w), 2908 (w), 1732 (s), 1718 (vs), 1556 (s), 1478 (m), 1459 (m), 
1364 (m), 1275 (s), 1235 (vs), 1177 (s), 1082 (s), 991 (s), 894 (m), 767 (vs), 699 (m). 
1H-NMR (CDCl3, 600 MHz):  δ (ppm) =  8.16 (d, 3J = 8.3 Hz, 2H), 7.98 (d, 3J = 8.3 Hz, 1H), 
7.85 (d, 3J = 7.3 Hz, 1H), 7.76-7.71 (m, 3H), 4.48 (q, 3J = 7.2 Hz, 2H), 4.42 (q, 3J = 7.2 Hz, 
2H), 1.45-1.41 (m, 6H), 1.33 (s, 9H). 
13C-NMR (CDCl3, 150 MHz): δ (ppm) = 210.1, 166.6, 165.5, 145.2, 142.4, 139.3, 137.4, 
135.8, 134.7, 132.0, 130.7 (2carbons), 129.7, 129.2 (2 carbons), 128.4, 125.5, 123.1, 63.1, 
61.0, 45.3, 28.2 (2 carbons), 14.4, 14.0. 
HRMS (ESI) (C26H26BrNO5): calculated [M+H]+ 512.1070  found: 512.1062 
 
 
Synthesis of 2-bromo-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-quinoline-4-
carboxylic acid ethyl ester  (55). 
 
N
EtO2C
Br
B O
O
 
 
According to GP2 from ethyl 2-bromoquinoline-4-carboxylate (43l) (1.39 g, 5.0 mmol, 1.0 
equiv) dissolved in dry THF (5 mL), TMPMgCl·LiCl (18a) [reaction condition: -10 °C for 3 
h]. To the corresponding obtained 2-bromo-3-magnesiated-4-carboethoxyquinoline was added 
at -10 °C freshly prepared ethyl pinacol borate (1.03 g, 6 mmol, 1.2 equiv) and the resulting 
mixture was stirred and warmed to 25 °C for 12 h. The reaction mixture was cooled to -50 °C 
after which anhydrous HCl (3 mL, 6 mmol, 1.2 equiv, 2M in Et2O) was added. The cooling 
bath was removed and the reaction mixture was allowed to warm to 25 °C. After removal of 
the precipitated MgCl by filtration and removal of the volatiles under reduced pressure, the 
crude residue was purified by flash-chromatography (SiO2, pentane/ether = 9:1) afforded 2-
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bromo-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-quinoline-4-carboxylic acid ethyl 
ester  (55) (1.44 g, 71%) as a colourless solid. 
mp.: 85.9-88.6 °C. 
IR (ATR): ν (cm-1) = 2996 (w), 2976 (w), 1692 (m), 1552 (m), 1368 (m), 1312 (m), 1291 (s), 
1235 (s), 1140 (s), 1119 (s), 1016 (m), 850 (m), 771 (s). 
1H-NMR (CDCl3, 600 MHz): δ (ppm) = 8.30 (d, 3J = 7.3 Hz, 1H), 8.05 (d, 3J = 7.3 Hz, 1H), 
7.74 (t, 3J = 7.0 Hz, 1H), 4.55 (q, 3J = 7.3 Hz, 2H), 1.48 (t, 3J = 7.1 Hz, 3H), 1.45 (s, 12H). 
13C-NMR (CDCl3, 150 MHz): δ (ppm) = 167.9, 149.3, 144.0, 143.7, 131.0, 129.1, 128.0, 
125.6, 122.9, 85.0 (2 carbons), 62.8, 25.1 (4C), 14.3. [C from C-B bond, not visible]. 
MS (EI, 70 eV): m/z (%) = 390 (13), 347 (67), 317 (100), 277 (69), 233 (21), 154 (25), 127 
(21), 43 (32). 
HRMS (EI) (C18H21B79BrNO4): calculated [M]+: 405.0747  found: 405.0746 
 
 
Synthesis of 2-phenyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-quinoline-4-
carboxylic acid ethyl ester (56) 
 
N
EtO2C
B O
O
 
 
To a solution of commercially available phenyl magnesium chloride in THF (1.51 mL, 2.2 
mmol, 1.45 M in THF) at 0 °C was added dropwise ZnCl2 (2.1 mL, 2.2 mmol,  1.1 equiv, 1.0 
M in THF). After 30 min of stirring, a solution of the boronic ester 55 (812 mg, 2 mmol, 1.0 
equiv) in dry THF (1 mL) was added dropwise, followed by the addition of 5 mol% of 
Pd(Ph3)4. The resulting mixture was stirred at 25 °C for 1 h and then quenched with sat. aq. 
NH4Cl and extracted three times with AcOEt. The solvent was evaporated and the product 
was purified by flash-chromatography (SiO2, pentane/ether = 7:3) afforded 2-phenyl-3-
(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-quinoline-4-carboxylic acid ethyl ester (56) 
(612 mg, 76%) as a colourless solid. 
mp.: 237.5-239.9 °C. 
IR (ATR): ν (cm-1) = 2981 (m), 2928 (w), 1694 (vs), 1665 (m), 1560 (m), 1373 (s), 1323 
(vs), 1252 (m), 1220 (m), 1139 (vs), 1096 (vs), 1039 (m), 854 (w), 773 (m), 702 (m). 
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1H-NMR (CDCl3, 300 MHz): δ (ppm) = 8.27 (d, 3J = 7.9 Hz, 1H), 8.20 (d, 3J = 8.1 Hz, 1H), 
7.78-7.69 (m, 3H), 7.59 (t, 3J = 8.1 Hz, 1H), 7.48-7.42 (m, 3H), 4.58 (q, 3J = 7.1 Hz, 2H), 
1.51 (t, 3J = 8.1 Hz, 3H), 1.18 (s, 12H). 
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 168.9, 162.2, 148.4, 143.2, 142.1, 130.2, 130.1, 
129.3 (2 carbons), 128.6, 128.1 (2 carbons), 127.4, 125.0, 122.4, 84.4 (2 carbons), 62.4, 25.0 
(4C), 14.4. [C from C-B bond, not visible]. 
HRMS (ESI)  (C24H26BNO4): calculated [M+H]+: 404.2034   found: 404.2025  
 
 
Synthesis of 3-hydroxy-2-phenyl-quinoline-4-carboxylic acid (57) 
 
N
CO2H
OH
 
 
To a heterogeneous solution of 2-phenyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-
quinoline-4-carboxylic acid ethyl ester (56) (806 mg, 1.2 mmol, 1. equiv) in MeOH (2 mL) at 
25 °C, was added neat LiOH (172 mg, 6 equiv) and aq. solution of H2O2 (0.45 mL, 3 equiv, 
32% in water). The resulting mixture became rapidly yellow and heterogeneous and was 
stirred at 25 °C for 15 h. A precipitate was obtained and was filtrated and dried over vacuum. 
The crude residue was purified by flash-chromatography (SiO2, EtOAc/CH3CN/MeOH/H2O, 
7:1:0.25:0.25 with 0.5% NEt3) giving the corresponding ammonium salt which was dissolved 
in CH3CN/H2O 1:1 and then acidified with HCl conc. to obtain a pH of 2. A precipitate was 
collected by filtration and dried over vacuum. A yellow fluffy solid is obtained (57, 283 mg, 
89%). 
mp.: 183.0-185.9 °C. 
IR (ATR): ν (cm-1) = 3395 (mbroad), 2923 (w), 2596 (mbroad), 1632 (m), 1527 (m), 1500 
(m), 1400 (s), 1322 (s), 1241 (s), 1160 (m), 1027 (m), 877 (m), 755 (s), 696 (s). 
1H-NMR (DMSO-d6, 400 MHz): δ (ppm) = 8.76 (d, J = 7.8 Hz, 1H), 8.04-7.99 (m, 1H), 
7.66-7.58 (m, 3H), 7.56-7.51 (m, 5H). 
13C-NMR (DMSO-d6, 100 MHz): δ (ppm) = 171.0, 153.8, 151.5, 139.7, 135.7, 129.7 (2 
carbons), 129.5, 128.4, 127.9 (2 carbons), 126.5, 125.3, 124.6 (2 carbons), 155.4. 
MS (EI, 70 eV): m/z (%) = 265 [M+] (50), 247 (39), 218 (100), 190 (31), 165 (18), 105 (23), 
76 (15), 44 (22). 
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HRMS (EI) (C16H11NO3): calculated [M]+: 265.0739  found: 265.0729 
 
 
Synthesis of 3-hydroxy-2-phenyl-quinoline-4-carboxylic acid (1-phenyl-propyl)-amide 
(talnetant, 33f). 
 
N
OH
O NH
EtPh
 
 
This compound was prepared following the literature procedure starting from 57.90 A pale 
yellow solid is obtained (33f, 84%). 
mp.: 125.1- 126.2 °C 
IR (ATR): ν (cm-1) = 3266 (wbroad), 3058 (wbroad), 2931 (w), 1646 (s), 1629 (s), 1532 (s), 
1492 (m), 1312 (m), 1236 (m), 1198 (m), 1146 (m), 760 (s), 695 (s). 
1H-NMR (DMSO-d6, 400 MHz): δ (ppm) = 9.78 (s, 1H), 9.12 (d, J = 8.2 Hz, 1H), 7.98-7.94 
(m, 3H), 7.69-7.43 (m, 8H), 7.38-7.34 (m, 2H), 7.28-7.25 (m, 1H), 5.08-5.02 (q, J = 7.0 Hz, 
1H), 1.87-1.74 (m, 2H), 0.95 (t, J = 7.3 Hz, 3H). 
13C-NMR (DMSO-d6, 100MHz): δ (ppm) = 164.6, 152.3, 144.5, 143.4, 142.3, 137.8, 129.4 
(2 carbons), 129.0, 128.7 (2 carbons), 128.1 (2 carbons), 127.9, 126.9, 126.7 (5 carbons), 
125.4, 123.6, 54.8, 29.2, 11.1. 
HRMS (ESI) (C25H22N2O2): calculated [M+H]+ : 383.1760  found: 383.1756 
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3. Functionalizations of Protected Uracils via Chemo- and Regioselective 
Magnesiations. 
 
3.1 General procedure for the Br/Mg exchange reaction on 4-halogeno-2,6-
dimethoxypyrimidines 69a and 69b (GP4): 
A dry and argon flushed 10 mL flask, equipped with a magnetic stirring bar and a septum, 
was charged with the 5-bromo-4-halogeno-2,6-dimethoxypyrimidine 69a or 69b (1mmol, 1 
equiv) dissolved in dry THF (1.0 M). i-PrMgCl·LiCl (13, 1 mL, 1.05 M in THF, 1.05 equiv) 
was added slowly at 25 °C and the resulting mixture was stirred for 15 min to complete the 
bromine-magnesium exchange (checked by GC-MS analysis of reaction aliquots). The freshly 
prepared magnesium reagent was cooled to the corresponding temperature or used at 25 °C 
and the corresponding electrophile (1.1-1.5 equiv.) was added. The mixture was stirred for 
time depending of the reactivity of the electrophile. The consumption of the magnesium 
reagent was checked by GC-analysis, using tetradecane as internal standard. After the reaction 
was completed, sat. NH4Cl solution (10 mL) was added and the mixture was extracted with 
Et2O or AcOEt (3 × 5 mL). The combined organic extracts were dried (MgSO4), filtered and 
concentrated in vacuum. The product was purified by flash chromatography (SiO2). 
 
3.2  General procedure for the Br/Mg exchange reaction on 5-functionalized-2,6-
dimethoxypyrimidines (GP5): 
A dry and argon flushed 10 mL flask, equipped with a magnetic stirring bar and a septum, 
was charged with the halogenated 2,6-dimethoxypyrimidine (1 equiv) dissolved in dry THF 
(1.0 M). i-PrMgCl·LiCl (13, 1.05-1.1 equiv) was added slowly, dropwise, at appropriate 
temperature (as stated in the experiment). The reaction mixture was stirred at the same or plus 
5°C temperature, and the completion of the Br/Mg exchange was checked by GC-analysis 
using tetradecane as internal standard or by TLC. The freshly prepared magnesium reagent 
was cooled to the corresponding temperature or used at 25 °C and the corresponding 
electrophile (1.1-1.5 equiv.) was added. The mixture was stirred for time depending of the 
reactivity of the electrophile. The consumption of the magnesium reagent was checked by 
GC-analysis, using tetradecane as internal standard. After the reaction was completed, sat. 
NH4Cl solution (10 mL) was added and the mixture was extracted with Et2O or AcOEt (3 × 5 
mL). The combined organic extracts were dried (MgSO4), filtered and concentrated in 
vacuum. The product was purified by flash chromatography (SiO2). 
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3.3 General procedure for the direct magnesiation of 2,4-dimethoxypyrimidine 
derivatives using TMPMg·LiCl (18a) (GP6). 
A dry and argon flushed flask, equipped with a magnetic stirring bar and a septum, was 
charged with the 2,6-dimethoxypyrimidine derivative (1 mmol, 1 equiv) dissolved in dry THF 
(1.0 M solution) and TMPMg·LiCl (18a, 1.1 mmol, 1.1 equiv) were added dropwise at the 
given temperature. The reaction mixture was stirred at the same temperature, and the 
completion of the deprotonation was checked by GC-analysis of reaction aliquots quenched 
with iodine using decane as internal standard. The freshly prepared magnesium reagent was 
cooled to the corresponding temperature or used at 25 °C and the corresponding electrophile 
(1.2 equiv) or its solution in THF was added. The mixture was stirred for a time depending on 
the reactivity of the electrophile. The consumption of the magnesium reagent was checked by 
GC-analysis, using decane as internal standard. After the reaction was completed, sat. NH4Cl 
(10 mL) solution was added and the mixture was extracted with Et2O or EtOAc (3 x 5 mL). 
The combined organic extracts were dried (MgSO4), filtered and concentrated in vacuum. The 
product was purified by flash-chromatography (SiO2). 
 
 
3.4 Starting material synthesis 
 
 
Synthesis of 5-bromo-4-chloro-2,6-dimethoxypyrimidine (69a) 
 
N
N
Cl
OMe
OMe
Br
 
 
 
This compound was prepared starting from 4-chloro-2,6-dimethoxypyrimidine (70a) 
according to the literature procedure.103 The analytic data correspond to the analytic data from 
the literature. The product 69a was obtained as a white solid.  
mp.: 98.7-99.7 °C. 
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 4.05 (s, 3H), 3.99 (s, 3H). 
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 168.3, 162.8, 160.4, 97.1, 55.8. 
MS (EI, 70 ev): m/z (%) = 254 (100), 253 (77), 252 (75), 251 (58), 239 (27), 224 (92), 221 
(70), 209 (37), 143 (42). 
C: Experimental Section  108 
  
  
HRMS (EI) C6H6BrClN2O2 : calculated [M+]: 251.9301  found: 251.9284. 
 
 
Synthesis of 4-bromo-2,6-dimethoxypyrimidine (70b) 
 
N
N
Br
OMe
OMe
 
 
4-bromo-2,6-dimethoxypyrimidine (70b) was prepared starting from barbituric acid in two 
steps in 85% yield, according to the literature procedure.104 The analytic data correspond to 
the analytic data from the literature. The product was obtained as a white solid.  
mp.: 90.9-92.0 °C. 
IR (KBr): 1589 (m), 1550 (s), 1463 (s), 1363 (m), 1199 (m), 819 (s). 
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 6.52 (s, 1H), 3.93 (s, 3H), 3.89 (s, 3H). 
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 172.1, 164.9, 152.4, 105.4, 55.8, 54.8. 
MS (EI, 70 ev): m/z (%) = 220 (79), 219 (67), 218 (78), 217 (75), 190 (90), 188 (100), 175 
(37), 109 (51), 82 (65). 
HRMS (EI) C6H7BrN2O2:  calculated [M+]: 217.9691  found: 217.9692. 
 
 
Synthesis of 4,5-dibromo-2,6-dimethoxypyrimidine (69b) 
 
N
N
Br
OCH3
OCH3
Br
 
 
This compound (69b) was prepared with the same procedure for the synthesis of 5-bromo-4-
chloro-2,6-dimethoxypyrimidine (69a), starting from 4-bromo-2,6-dimethoxypyrimidine 
(70b). 5,4-dibromo-2,6-dimethoxypyrimidine (69b) was isolated as a white solid in 96% 
yield. 
mp.: 117.6-118.0 °C 
IR (KBr): 2957 (w), 1526 (s), 1455 (m), 1343 (s), 1311 (m), 1008 (s). 
1H-NMR (CDCl3, 400 MHz): δ (ppm) = 4.05 (s, 3H), 3.99 (s, 3H). 
13C-NMR (CDCl3, 100 MHz): δ (ppm) = 167.7, 162.54, 153.74, 100.8, 55.8 (2 carbons). 
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MS (EI, 70 ev): m/z (%) = 300 (46), 299 (47), 298 (100), 297 (71), 296 (48), 295 (31), 283 
(20), 270 (31), 268 (64), 266 (30), 189 (19), 187 (21). 
HRMS (EI) C6H6Br2N2O2: calculated [M+]: 295.8796  found: 295.8799. 
 
 
3.5 Preparation of polyfunctionalized 2,4-dimethoxypyrimidines 
 
 
Synthesis of 1H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, oxypurinol (60) 
 
N
H
NH
O
O
N
N
H
 
 
A mixture of 4,6-dimethoxy-1H-pyrazolo[3,4-d]pyrimidine (75) (0.54 g, 3 mmol) with 
concentrated hydrochloric acid (30 mL) was heated under reflux for 2 h. After the reaction 
was complete, the solution was treated with activated charcoal and evaporated under reduced 
pressure. The residue was recrystallized from water affording 60 (1.60 g, 81%) as a white 
solid. 
 mp.: > 300 °C. 
IR (KBr): 3268 (m), 3124 (w), 3028 (m), 2804 (w), 1709(s), 1677 (s), 1616 (m), 1419 (m), 
1244 (m), 1169 (s), 1025 (m), 810 (m), 748 (s), 700 (s). 
1H-NMR (DMSO, 300 MHz): δ (ppm) = 13.27 (s, 1H), 11.30 (s, 1H), 10.63 (s, 1H), 8.33 (s, 
1H). 
13C-NMR (DMSO, 75 MHz): δ (ppm) = 159.6, 151.6, 150.8, 128.9, 100.2. 
MS (EI, 70 ev): m/z (%) = 152.0 (100), 109.0 (92), 52.0 (31), 44.0 (14). 
HRMS (EI) C5H4N4O2: calculated [M+]: 152.0334  found: 152.0324. 
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Synthesis of (4-chloro-2,6-dimethoxypyrimidin-5-yl)(phenyl)methanol (72a) 
 
N
N
OCH3
OCH3Cl
OH
 
 
Prepared according to GP4 starting from a solution of 5-bromo-4-chloro-2,6-
dimethoxypyrimidine (69a) (254 mg, 1 mmol, 1.0 equiv) in dry THF (1 mL), i-PrMgCl·LiCl 
(1.0 M/THF, 1.05 mmol, 1.05 equiv), benzaldehyde (117 mg, 1.1 mmol, 1.1 equiv). Reaction 
conditions [5 h, 25 °C]. Purification by flash chromatography (SiO2, n-pentane/diethyl ether = 
3:2) afforded 72a (255 mg, 91%) as a white solid. 
mp.:  90,1- 91,4 °C. 
IR (KBr): 3412 (s), 2955 (w), 1583 (s), 1553 (s), 1464 (m), 1375(s), 1242 (m), 1032 (s). 
1H-NMR (CDCl3, 400 MHz): δ (ppm) = 7.33-7.24 (m, 5H), 6.21 (d, J = 11 Hz, 1H), 4.01 (s, 
3H), 3.96 (s, 3H), 3.41 (d, J = 11 Hz, 1H). 
13C-NMR (CDCl3, 100 MHz): δ (ppm) = 169.7, 163.2, 159.4, 141.7, 128.3 (2 carbons), 
127.4, 125.3 (2 carbons), 114.0, 70.0, 55.4, 55.0. 
MS (EI, 70 ev): m/z (%) = 282 (15), 280 (44), 262 (20), 205 (29), 203 (100), 105 (10), 77 
(12). 
HRMS (EI) C13H13ClN2O3: calculated [M+]: 280.0615   found: 280.0612. 
 
 
Synthesis of (4-chloro-2,6-dimethoxypyrimidin-5-yl)(2-methoxyphenyl)methanol (72b) 
 
N
N
OCH3
OCH3Cl
OHCH3O
 
 
Prepared according to GP4 starting from a solution of 5-bromo-4-chloro-2,6-
dimethoxypyrimidine (69a) (254 mg, 1 mmol, 1.0 equiv) in dry THF (1 mL), i-PrMgCl·LiCl 
(1.0 M/THF, 1.05 mmol, 1.05 equiv), 2-methoxybenzaldehyde (150 mg, 1.1 mmol, 1.1 
equiv). Reaction conditions [10 h, 25 °C]. Purification by flash chromatography (SiO2, n-
pentane/diethyl ether = 3:2) afforded 72b (258 mg, 83%) as a white solid.  
mp.: 106.0-107.3 °C 
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IR (KBr): 3472 (s), 3003 (m), 2963 (w), 1553 (s), 1455 (m), 1375 (s), 1241 (m), 1206 (m), 
1021 (s). 
1H-NMR (CDCl3, 400 MHz): δ (ppm) = 7.34 (d, J = 7.6 Hz, 1H), 7.26 (t, J = 8.8 Hz, 1H), 
6.94 (t, J = 7.5 Hz, 1H), 6.84 (d, J = 8.2 Hz, 1H), 6.38 (d, J = 8.4 Hz, 1H), 3.98 (s, 3H), 3.95 
(s, 3H), 3.79 (s, 3H), 3.33 (d, J = 8.8 Hz, 1H). 
13C-NMR (CDCl3, 100 MHz): δ (ppm) = 170.1, 163.1, 156.8 (2 carbons), 129.4, 128.9, 
127.1, 120.2, 113.5, 110.6, 66.7, 55.5, 55.5, 55.0. 
MS (EI, 70 ev): m/z (%) = 312 (22), 311 (15), 310 (58), 294 (38), 293 (23), 292 (100), 257 
(57), 242 (12), 205 (13), 203 (51), 201 (53), 175 (29), 135 (16), 109 (17), 108 (19), 77 (10). 
HRMS (EI) C14H15ClN2O4: calculated [M+]: 310.0720  found: 310.0733. 
 
 
Synthesis of (4-chloro-2,6-dimethoxypyrimidin-5-yl)(phenyl)methanone (72c) 
 
N
N
OCH3
OCH3Cl
O
 
 
Prepared according to GP4 starting from a solution of 5-bromo-4-chloro-2,6-
dimethoxypyrimidine (69a) (254 mg, 1 mmol, 1 equiv) in dry THF (1 mL), i-PrMgCl·LiCl 
(1.0 M/THF, 1.05 mmol, 1.05 equiv), benzoyl chloride (154 mg, 1.1mmol, 1.1 equiv). 
Reaction conditions [3 h, -20 °C to 25 °C]. Purification by flash chromatography (SiO2, n-
pentane/diethyl ether = 3:2) afforded 72c (231 mg, 86%) as a white solid. 
mp.: 116.0-117.3 °C. 
IR (KBr): 3436 (m), 3000 (w), 2952 (w), 1676 (s), 1589 (s), 1485 (s), 1485 (m), 1389 (s), 
1200 (s), 1027 (m), 921 (m). 
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 7.83 (d, J = 8.5 Hz, 2H), 7.62 (t, J = 7.3 Hz, 1H), 
7.48 (t, J = 7.8 Hz, 2H), 4.07 (s, 3H), 3.94 (s, 3H). 
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 190.7, 169.5, 164.3, 158.1, 136.2, 134.2, 129.4 (2 
carbons), 128.8 (2 carbons), 112.8, 55.7, 55.1. 
MS (EI, 70 ev): m/z (%) = 280 (17), 278 (47), 203 (34), 201 (100), 105 (30), 77 (17), 76 (11). 
HRMS (EI) C13H11ClN2O3: calculated [M+]: 278.0458  found: 278.0441. 
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Synthesis of (4-chloro-2,6-dimethoxypyrimidin-5-yl)(morpholino)methanone (72d) 
 
N
N
OCH3
OCH3
O
N
ClO
 
 
Prepared according to GP4 starting from a solution of 5-bromo-4-chloro-2,6-
dimethoxypyrimidine (69a) (254 mg, 1 mmol, 1 equiv) in dry THF (1 mL), i-PrMgCl·LiCl 
(1.0 M/THF, 1.05 mmol, 1.05 equiv), 4-morpholinecarbonyl chloride (165 mg, 1.1 mmol, 1.1 
equiv). Reaction conditions [15 h, -20 °C to 25 °C]. Purification by flash chromatography 
(SiO2, n-pentane/diethyl ether = 2:3) afforded 72d (244 mg, 85%) as a white solid. 
mp.: 109.9-111.3 °C. 
IR (KBr): 2960 (w), 2862 (w), 1634 (m), 1580 (s), 1534 (s), 1494 (m), 1370 (s), 1357 (m), 
1275 (m), 1235 (s), 1111 (s), 1009 (s). 
1H-NMR (DMSO, 400 MHz): δ (ppm) = 4.01 (2 singulets, 6H), 3.86-3.61 (3 multiplets, 6H), 
3.28 (m, 2H). 
13C-NMR (DMSO, 100 MHz): δ (ppm) = 168.5, 164.1, 162.0, 157.9, 109.4, 66.7, 66.6, 55.6, 
55.2, 46.9, 42.2. 
MS (EI, 70 ev): m/z (%) = 287.0 (9), 252.1 (11), 203.0 (28), 201.0 (100), 75.9 (11). 
HRMS (EI) C11H14ClN3O4: calculated [M+]: 287.0673   found: 287.0664. 
 
 
Synthesis of 4-chloro-2,6-dimethoxypyrimidine-5-carbonitrile (72e) 
 
N
N
OCH3
OCH3Cl
NC
 
 
Prepared according to GP4 starting from a solution of 5-bromo-4-chloro-2,6-
dimethoxypyrimidine (69a) (254 mg, 1 mmol, 1 equiv) in dry THF (1 mL),  i-PrMgCl·LiCl 
(1.0 M/THF, 1.05 mmol, 1.05 equiv), p-toluenesulfonyl cyanide (200 mg, 1.1 mmol, 1.1 
equiv). Reaction conditions [12 h, 25 °C]. Purification by flash chromatography (SiO2, n-
pentane/diethyl ether = 1:4) afforded 72e (178 mg, 89%) as a white solid. 
 mp.: 123.3-124.8 °C. 
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IR (KBr): 3021 (w), 2947 (w), 2233 (m), 1586 (m), 1529 (s), 1474 (m), 1378 (m), 1218 (m), 
1071 (m), 1018 (s). 
1H-NMR (CDCl3, 400 MHz): δ (ppm) = 4.11 (s, 3H), 4.07 (s, 3H). 
13C-NMR (CDCl3, 100 MHz): δ (ppm) = 172.2, 165.1, 164.9, 117.7, 89.7, 56.4, 55.6. 
MS (EI, 70 ev): m/z (%) = 201 (25), 199 (71), 198 (32), 171 (33), 169 (100), 154 (32), 106 
(19), 70 (11). 
HRMS (EI) C7H6ClN3O2: calculated [M+]: 199.0149  found: 199.0131. 
 
 
Synthesis of ethyl 4-chloro-2,6-dimethoxypyrimidine-5-carboxylate (72f) 
 
N
N
OCH3
OCH3Cl
O
EtO
 
 
Prepared according to GP4 starting from a solution of 5-bromo-4-chloro-2,6-
dimethoxypyrimidine (69a) (381 mg, 1.5 mmol, 1 equiv) in dry THF (2 mL), i-PrMgCl·LiCl 
(1.0 M/THF, 1.58 mmol, 1.05 equiv), ethyl cyanoformate (164 mg, 1.1 equiv). Reaction 
conditions [8 h, -20 °C to 25 °C]. Purification by flash chromatography (SiO2, n-
pentane/diethyl ether = 4:1) afforded 72f (322 mg, 87%) as a yellow oil. 
IR (film): 2957 (w), 1731 (s), 1585 (s), 1540 (s), 1488 (m), 1376 (m), 1218 (m), 1071 (m), 
1018 (s). 
1H-NMR (CDCl3, 400 MHz): δ (ppm) = 4.40 (q, J = 7.1 Hz, 2H), 4.02 (s, 6H), 1.38 (t, J = 
7.1 Hz, 3H). 
13C-NMR (CDCl3, 100 MHz): δ (ppm) = 169.2, 163.9, 163.4, 158.9, 108.7, 62.1, 55.7, 55.2, 
14.0. 
MS (EI, 70 ev): m/z (%) = 246 (15), 218 (13), 203 (30), 201 (100), 174 (13), 76 (14). 
HRMS (EI) C9H11ClN2O4: calculated [M+]: 246.0407  found: 246.0388. 
 
 
Synthesis of 5-benzyl-4-chloro-2,6-dimethoxypyrimidine (72g) 
 
N
N
OCH3
OCH3Cl
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Prepared according to GP4 starting from a solution of 5-bromo-4-chloro-2,6-
dimethoxypyrimidine (69a) (381 mg, 1.5 mmol, 1 equiv) in dry THF (2 mL), i-PrMgCl·LiCl 
(1.0 M/THF, 1.58 mmol, 1.05 equiv), benzylbromide (360 mg, 2.1 mmol, 1.4 equiv). 
Reaction conditions [4 h, 25 °C]. Purification by flash chromatography (SiO2, n-
pentane/diethyl ether = 1:4) afforded 72g (300 mg, 75%) as a colourless oil.  
IR (film): 3028 (w), 2950 (w), 1586 (m), 1541 (s), 1453 (m), 1369 (s), 1213 (m), 1078 (m), 
1026 (s). 
1H-NMR (CDCl3, 400 MHz): δ (ppm) = 7.14 (m, 5H), 3.90-3.91 (m, 8H). 
13C-NMR (CDCl3, 100 MHz): δ (ppm) = 170.2, 162.6, 160.2, 138.6, 128.3 (3 carbons), 126.3 
(2 carbons), 112.0, 55.1, 54.8, 31.2. 
MS (EI, 70 ev): m/z (%) = 266 (31), 264 (100), 249 (33), 234 (19), 173 (17), 156 (10), 91 
(18), 77 (8). 
HRMS (EI) C13H13ClN2O2: calculated [M+]: 264.0666  found: 264.0639. 
 
 
Synthesis of 4-chloro-2,6-dimethoxypyrimidine-5-carbaldehyde (72h) 
 
N
N
OCH3
OCH3
Cl
H
O
 
 
Prepared according to GP4 starting from a solution of 5-bromo-4-chloro-2,6-
dimethoxypyrimidine (69a) (1.27 g, 5 mmol, 1 equiv) in dry THF (5 mL), i-PrMgCl·LiCl (1.0 
M/THF, 5.25 mmol, 1.05 equiv), 4-formylmorpholine (0.635 g, 1.1 equiv). Reaction 
conditions [4 h, -35 °C]. The mixture was quenched with a mixture of a solution of acetic acid 
in water (≈ 1M; 3 mL) and saturated aqueous NH4Cl solution (15 mL). The aqueous phase 
was extracted with ether (3 × 20 mL). The organic fractions were dried (Na2SO4) and 
concentrated in vacuum. Purification by flash chromatography (SiO2, n-pentane/diethyl ether 
= 3:2) afforded 72h (840 mg, 83%) as a white solid. 
mp.: 97.8-99.1°C.  
IR (KBr): 3008 (w), 2956 (w), 2882 (w), 2797 (w), 1686 (s), 1528 (s), 1449 (s), 1356 (s), 
1324 (s), 1205 (m), 1014 (m), 789 (s). 
1H-NMR (CDCl3, 600 MHz): δ (ppm) = 10.30 (s, 1H), 4.12 (s, 3H), 4.08 (s, 3H). 
13C-NMR (CDCl3, 150 MHz): δ (ppm) = 169.6, 167.2, 164.3, 160.2, 106.9, 55.8, 55.5. 
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MS (EI, 70 ev): m/z (%) = 203 (40), 202 (76), 201 (100), 185 (22), 174 (17), 172 (43), 155 
(17), 129 (10), 76 (23), 70 (10). 
HRMS (EI) C7H7ClN2O3: calculated [M+]: 202.0145   found: 202.0126. 
 
 
Synthesis of 4,6-dimethoxy-3-phenylisoxazolo[5,4-d]pyrimidine (73) 
 
N
N
OCH3
OCH3
O
N
 
 
To a stirring solution of 4-chloro-2,6-dimethoxypyrimidin-5-yl)(phenyl)methanone (72c) 
(1.39 mg, 5 mmol) in EtOH 50% (100 mL) at 25 °C was added hydroxylamine hydrochloride 
(1.04 g, 15 mmol) and sodium acetate (1.25 g, 15 mmol). The mixture was refluxing during 4 
h. The product was collected by filtration and washed two times with H2O (10 mL). 
Purification by flash chromatography (SiO2, n-pentane/diethyl ether = 3:2) afforded 73 
(1.88 g, 83%) as a white solid. 
mp.: 210.1-211.9 °C. 
IR (KBr): 3017 (w), 2951 (w), 1615 (s), 1539 (s), 1441 (s), 1385 (m), 1318 (s), 1138 (m). 
1H-NMR (DMSO, 400 MHz): δ (ppm) = 8.20 (m, 2H), 7.60 (m, 3H), 4.14 (s, 3H), 4.00 (s, 
3H). 
13C-NMR (DMSO, 100 MHz): δ (ppm) = 166.8, 167.6, 166.8, 132.2, 132.2, 129.2 (2 
carbons), 128.3 (2 carbons), 126.0, 96.3, 55.4, 55.1. 
MS (EI, 70 ev): m/z (%) = 257.1 (100), 227.1 (57), 212.1 (36), 105.0 (65), 91.0 (8), 77.0 (41), 
70.0 (12), 51.0 (11). 
HRMS (EI) C13H11N3O3: calculated [M+]: 257.0800  found: 257.0807. 
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Synthesis of methyl 2,4-dimethoxy-5-phenylthieno[2,3-d]pyrimidine-6-carboxylate (74) 
 
N
N
OCH3
OCH3
SO
MeO
 
 
Triethylamine (0.4 g, 4 mmol) was added dropwise to a mixture of 4-chloro-2,6-
dimethoxypyrimidin-5-yl)(phenyl)methanone (72c) (0.55 g, 2 mmol) and methyl mercapto- 
acetate (0.31 g, 2.6 mmol) in EtOH (10 mL). The reaction mixture was heated at reflux until 
the starting ketone 72c disappeared according to gas chromatography (12 h). After cooling to 
25 °C, the precipitate was filtered off and recrystallized in EtOH 95% affording 74 (456 mg, 
69%) as a white powder. 
mp.: 193.3-194.3 ° C.  
IR (KBr): 3012 (w), 2951 (w), 1716 (s), 1577 (m), 1541 (s), 1473 (m), 1249 (s), 1168 (m), 
1027 (m). 
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 7.40 (m, 3H), 7.38 (m, 2H), 4.08 (s, 3H), 3.79 (s, 
3H), 3.72 (s, 3H). 
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 170.2, 167.2, 163.8, 162.2, 142.1, 134.9, 129.0 (2 
carbons), 127.8, 127.2 (2 carbons), 122.5, 114.9, 55.3, 54.1, 52.2. 
MS (EI, 70 ev): m/z (%) = 331 (16), 330 (100), 329 (15), 300 (11), 299 (26), 284 (11), 251 
(7), 227 (8), 199 (7), 171 (6), 127 (8).  
HRMS (EI) C16H14N2O4S: calculated [M+]: 330.0674  found: 330.0660. 
 
 
Synthesis of 4,6-dimethoxy-1H-pyrazolo[3,4-d]pyrimidine (75) 
 
N
N
OCH3
OCH3
N
N
H
 
 
To a stirring solution of 4-chloro-2,6-dimethoxypyrimidine-5-carbaldehyde (72h) (1.01 mg, 5 
mmol) in EtOH (80 mL) at 25 °C was added hydrazine monohydrate (0.9 g, 15 mmol). The 
mixture was refluxing during 30 min. After cooling to 25 °C, the precipitate was filtered off 
and recrystallized in EtOH 95% affording 75 (823 mg, 91%) as a white powder. 
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mp.: > 300 °C.  
IR (KBr): 3252 (w), 2955 (w), 1608 (s), 1583 (m), 1503 (m), 1386 (m), 1320 (w), 1153 (m), 
1081 (w), 942 (s), 788 (s). 
1H-NMR (DMSO, 300 MHz): δ (ppm) = 8.05 (s, 1H), 4.04 (s, 3H), 3.93 (s, 3H). 
13C-NMR (DMSO, 75 MHz): δ (ppm) = 164.4, 163.9, 157.8, 97.8, 88.2, 54.5, 53.9. 
MS (EI, 70 ev): m/z (%) = 180 (100), 179 (66), 165 (12), 150 (36), 135 (67), 109 (13), 70 
(11). 
HRMS (EI) C7H8N4O4: calculated [M+]: 180.0647  found: 180.0643. 
 
 
Synthesis of 4-bromo-2,6-dimethoxy-5-(trimethylsilyl)pyrimidine (77a) 
 
N
N
OCH3
OCH3Br
Me3Si
 
 
Prepared according to GP4 starting from a solution of 4,5-dibromo-2,6-dimethoxypyrimidine 
(69b) (596 mg, 2 mmol, 1 equiv) in dry THF (3 mL), i-PrMgCl·LiCl (1.0 M/THF, 2.1 mmol, 
1.05 equiv), trimethylsilyl chloride (240 mg, 2.2 mmol, 1.1 equiv).  Reaction conditions [24 h, 
25 °C]. Purification by flash chromatography (SiO2, n-pentane/diethyl ether = 4:1) afforded 
77a (529 mg, 91%) as a white solid. 
mp.: 71.1-72.2 °C.  
IR (KBr): 2955 (w), 2899 (w), 1556 (m), 1524 (s), 1450 (m), 1344 (s), 1278 (m), 1114 (m), 
1015 (m), 839 (s). 
1H-NMR (CDCl3, 400 MHz): δ (ppm) = 3.98 (s, 3H), 3.92 (s, 3H), 0.37 (s, 9H).  
13C-NMR (CDCl3, 100 MHz): δ (ppm) = 175. 5, 164.4, 159.9, 111.8, 55.0, 54.1, 1.2 (3 
carbons). 
MS (EI, 70 ev): m/z (%) = 292 (10), 290 (10), 277 (100), 275 (99), 247 (81), 220 (30), 194 
(13), 137 (33), 72 (38).  
HRMS (EI) C9H15BrN2O2Si: calculated [M+]: 290.0086   found: 290.0062. 
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Synthesis of 5-allyl-4-bromo-2,6-dimethoxypyrimidine (77b) 
 
N
N
OCH3
OCH3Br
 
 
Prepared according to GP4 starting from a solution of 4,5-dibromo-2,6-dimethoxypyrimidine 
(69b) (596 mg, 2 mmol, 1 equiv) in dry THF (3 mL), i-PrMgCl·LiCl (1.0 M/THF, 2.1 mmol, 
1.05 equiv), allyl bromide (266 mg, 2.2 mmol, 1.1 equiv). Reaction conditions [2 h, 25 °C]. 
Purification by flash chromatography (SiO2, n-pentane/diethyl ether = 9:1) afforded 77b (528 
mg, 91%) as a colourless oil.  
IR (film): 3081 (w), 2957 (w), 1639 (w), 1586 (m), 1542 (s), 1459 (m), 1370 (s), 1223 (m), 
1079 (m), 1026 (s). 
1H-NMR (CDCl3, 400 MHz): δ (ppm) = 5.82 (m, 1H), 5.02 (2 dd, 3Jtrans = 13.2 Hz, Jgem and 
3Jci s= 1.7 Hz, 2H), 3.98 (s, 3H), 3.97 (s, 3H), 3.35 (dt, 3J = 6.1 Hz, 4J = 1.5 Hz). 
13C-NMR (CDCl3, 100 MHz): δ (ppm) = 170.1, 162.6, 160.0, 133.4, 115.9, 110.7, 55.1, 54.8, 
29.6. 
MS (EI, 70 ev): m/z (%) = 260 (98), 258 (100), 245 (23), 243 (22), 231 (41), 179 (25), 163 
(14). 
HRMS (EI) C9H11BrN2O2: calculated [M+]: 258.0004   found: 258.0023. 
 
 
Synthesis of ethyl 4-bromo-2,6-dimethoxypyrimidine-5-carboxylate (77c) 
 
N
N
OCH3
OCH3Br
O
EtO
 
 
Prepared according to GP4 starting from a solution of 5-bromo-4-chloro-2,6-
dimethoxypyrimidine (69b) (298 mg, 1.0 mmol, 1 equiv) in dry THF (2 mL), i-PrMgCl·LiCl 
(1.0 M/THF, 1.05 mmol, 1.05 equiv), ethyl cyanoformate (164 mg, 1.1 equiv). Reaction 
conditions [12 h, -20 to 25 °C]. Purification by flash chromatography (SiO2, n-pentane/diethyl 
ether = 4:1) afforded 77c (236 mg, 81%) as a white solid. 
mp.: 42.5-43.8 °C. 
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IR (KBr): 2983 (w), 2960 (w), 1725 (s), 1570 (s), 1529 (s), 1491 (m), 1358 (m), 1265 (s), 
1229 (s), 1048 (m), 1013 (s). 
1H-NMR (CDCl3, 400 MHz): δ (ppm) = 4.38 (q, J = 7.1 Hz, 2H), 4.01 (s, 6H), 1.37 (t, J = 
7.1 Hz, 3H). 
13C-NMR (CDCl3, 100 MHz): δ (ppm) = 166.5, 164.0, 163.6, 149.9, 112.0, 62.2, 55.7, 55.1, 
14.0. 
MS (EI, 70 ev): m/z (%) = 292 (18), 290 (19), 247 (96), 245 (100), 218 (18), 151 (8), 122 
(19), 70 (11). 
HRMS (EI) C9H11BrN2O4: calculated [M+]: 289.9902  found: 289.9902. 
 
 
Synthesis of (4-bromo-2,6-dimethoxypyrimidin-5-yl)(phenyl)methanol (77d) 
 
N
N
OCH3
OCH3Br
OH
 
 
Prepared according to GP4 starting from a solution of 4,5-dibromo-2,6-dimethoxypyrimidine 
(69b) (298 mg, 1.0 mmol, 1 equiv) in dry THF (2 mL), i-PrMgCl·LiCl (1.0 M/THF, 1.05 
mmol, 1.05 equiv), benzaldehyde (117 mg, 1.1 mmol, 1.1 equiv). Reaction conditions [4 h, 
25 °C]. Purification by flash chromatography (SiO2, n-pentane/diethyl ether = 3:2) afforded 
77d (308 mg, 95%) as a white solid. 
mp.: 108.9-111.2°C. 
IR (KBr): 3337 (s), 2953 (w), 2923 (w), 1572 (w), 1543 (s), 1488 (m), 1448 (m), 1368 (s), 
1212 (m), 1016 (s). 
1H-NMR (CDCl3, 400 MHz): δ (ppm) = 7.3 (m, 5H), 6.19 (d, J = 11.1 Hz, 1H), 4.01 (s, 3H), 
3.93 (s, 3H), 3.41 (d, J = 11.1 Hz, 1H). 
13C-NMR (CDCl3, 100 MHz): δ (ppm) = 168.9, 162.9, 152.5, 141.7, 128.3 (2 carbons), 
127.5, 125.3 (2 carbons), 116.6, 72.13, 55.4, 54.9. 
MS (EI, 70 ev): m/z (%) = 326 (41), 324 (33), 308 (18), 306 (18), 249 (67), 247 (100), 227 
(32), 105 (17), 77 (22). 
HRMS (EI) C13H13BrN2O3: calculated [M+]: 324.0110   found: 324.0092. 
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Synthesis of (4-bromo-2,6-dimethoxypyrimidin-5-yl)(morpholino)methanone (77e) 
 
N
N
OCH3
OCH3Br
O
N
O
 
 
Prepared according to GP4 starting from a solution of 5-bromo-4-chloro-2,6-
dimethoxypyrimidine (69b) (298 mg, 1 mmol, 1 equiv) in dry THF (2 mL),  i-PrMgCl·LiCl 
(1.0 M/THF, 1.05 mmol, 1.05 equiv), 4-morpholinecarbonyl chloride (165 mg, 1.1 mmol, 1.1 
equiv). Reaction conditions [12 h, 25 °C]. Purification by flash chromatography (SiO2, n-
pentane/diethyl ether = 2:3) afforded 77e (210 mg, 70%) as a white solid. 
mp: 112.0-113.6 °C. 
IR (KBr): 2960 (w), 2862 (w), 1634 (m), 1580 (s), 1534 (s), 1494 (m), 1370 (s), 1357 (m), 
1275 (m), 1235 (s), 1111 (s), 1009 (s). 
1H-NMR (DMSO, 400 MHz): δ (ppm) = 3.95 (s, 3H), 3.94 (s, 3H), 3.57 (m, 6H), 3.27 (m, 
2H). 
13C-NMR (DMSO, 100 MHz): δ (ppm) = 167.2, 163.1, 161.6, 148.6, 112.5, 66.7, 66.2, 55.3, 
54.9, 46.3, 41.6. 
MS (EI, 70 ev): m/z (%) = 333 (8), 331 (9), 252 (30), 247 (98), 245 (100), 167 (12), 122 (11), 
120 (11), 70 (6). 
HRMS (EI) C11H14BrN3O4: calculated [M+]: 331.0168  found: 331.0177. 
 
 
Synthesis of 2-(4-bromo-2,6-dimethoxypyrimidin-5-yl)propan-2-ol (77f) 
 
N
N
OCH3
OCH3
Br
HO
 
 
In a flame dried, argon-flushed 50 mL Schlenk-flask equipped with a septum and a magnetic 
stirring bar was placed LaCl3·2LiCl in THF (0.33 M; 30 mL, 10.00 mmol, 1.00 equiv). Dried 
acetone (580 mg, 10.0 mmol) was added and the resulting mixture was stirred for 2 h at 
25 °C. A second dry and argon flushed 25 mL flask, equipped with a magnetic stirrer and a 
septum, was charged with a solution of 4,5-dibromo-2,6-dimethoxypyrimidine (69b) (2.98 g, 
10 mmol) in dry THF (10 mL). i-PrMgCl·LiCl (13, 1.0 M/THF, 10.5 mmol, 1.05 equiv) was 
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added very slowly (within 5 min) at 25 °C and the resulting mixture was stirred for 15 min to 
complete the bromine-magnesium exchange (checked by GC-MS analysis of reaction 
aliquots) and obtain the Grignard reagent 76. To the mixture of acetone with LaCl3·2LiCl in 
THF cooled to 0 °C, was added dropwise the solution of the Grignard reagent 76. The 
resulting mixture was allowed to stir at the same temperature for 4 h and was quenched with 
sat. aq. NH4Cl (20 mL) and water (20 mL) was added. The aqueous layer was extracted with 
ethyl acetate (4 × 30 mL), the combined extracts were dried (Na2SO4) and evaporated in 
vacuum. The crude residue was purified by flash column chromatography (SiO2, n-
pentane/diethyl ether = 4:1) afforded 77f (2.40 g, 81%) as a colourless oil. 
IR (film): 3563 (m), 2950 (w), 1562 (m), 1527 (s), 1481 (m), 1383 (m), 1352 (m), 1215 (m), 
1013 (s).  
1H-NMR (CDCl3, 400 MHz): δ (ppm) = 4.03 (s, 3H), 3.97 (s, 3H), 3.95 (s, 3H), 1.70 (s, 6H). 
13C-NMR (CDCl3, 150 MHz): δ (ppm) = 168.9, 161.2, 149.0, 120.7, 72.4, 55.2, 55.0, 30.2 (2 
carbons). 
MS (EI, 70 ev): m/z (%) = 279 (3), 277 (3), 263 (100), 261 (97), 245 (29), 221 (5), 167 (7). 
HRMS (EI) C9H13BrN2O3: calculated [M+H]+: 277.0110  found: 277.0200. 
 
 
Synthesis of 4-allyl-2,6-dimethoxy-5-(trimethylsilyl)pyrimidine (78) 
 
N
N OCH3
OCH3
Me3Si
 
 
Prepared according to GP5 starting from a solution of 4-bromo-2,6-dimethoxy-5-
(trimethylsilyl)pyrimidine (77a) (291 mg, 1.0 mmol) in dry THF (2 mL), i-PrMgCl·LiCl (1.0 
M/THF, 1.05 mmol, 1.05 equiv), reaction conditions [-15 °C, 12 h]. Allyl bromide (145 mg, 
1.2 mmol, 1.2 equiv), reaction conditions [-15 °C, 30 min]. CuCN·2LiCl (cat. (3 drops), 1M 
in THF), reaction conditions [-15 to 25 °C, 6 h]. Purification by flash chromatography (SiO2, 
n-pentane/diethyl ether = 3:2) afforded 78 (204mg, 81%) as a colourless oil. 
IR (film): 3081 (w), 2980 (w), 2960 (w), 2870 (w), 1638 (w), 1571 (s), 1457 (m), 1370 (s), 
1362 (s), 1210 (m), 1084 (w). 
1H-NMR (CDCl3, 600 MHz): δ (ppm) = 6.03 (m, 0.8H), 5.08 (dd, J = 9.5 Hz, 0.8H), 5.02 
(dd, J = 17.1 Hz, 0.8H), 3.96–3.93 (2s, 6H), 3.47 (d, J = 6.2 Hz, 2H), 0.31 (s, 9H). 
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13C-NMR (CDCl3, 150 MHz): δ (ppm) = 176.0, 175.3, 135.8, 116.2, 107.0, 54.3, 53.4, 42.07, 
29.7, 1.41 (3 carbons from TMS group). 
MS (EI, 70 ev): m/z (%) = 253 (11), 252 (56), 251 (100), 237 (19), 207 (23), 89 (25). 
HRMS (EI) C12H20N2O2Si: calculated [M+]: 252.1294  found: 252.1266. 
 
 
Synthesis of (5-(cyclohexyl(hydroxy)methyl)-2,6-dimethoxypyrimidin-4-yl)(morpholino)-
methanone (79a) 
 
N
N
OCH3
OCH3
OH
O
N
O
 
 
A dry and argon flushed 10 mL flask, equipped with a magnetic stirrer and a septum, was 
charged with a solution of 4,5-dibromo-2,6-dimethoxypyrimidine (69b) (596 mg, 2 mmol, 1 
equiv) in dry THF (3 mL). i-PrMgCl·LiCl (13, 1.0 M/THF, 2.1 mmol, 1.05 equiv) was added 
very slowly (within 5 min) at 25 °C and the resulting mixture was stirred for 15 min to 
complete the bromine-magnesium exchange (checked by GC-MS analysis of reaction 
aliquots). Cyclohexanecarboxaldehyde (266 mg, 2.2 mmol, 1.2 equiv) was added at 25 °C and 
the mixture was stirred at 25 °C for12 h. i-PrMgCl·LiCl (13, 1.0 M/THF, 2.0 mmol, 1.5 
equiv) was added at 25 °C to the mixture which was stirred for 24 h to complete the second 
bromine-magnesium exchange (checked by GC-MS analysis of reaction aliquots). 4-
morpholinecarbonyl chloride (597 mg, 2 equiv) was added and the resulting mixture was 
stirred at 25 °C for 12 h. Then, the mixture was quenched with saturated aqueous NH4Cl 
solution. The aqueous phase was extracted with ethyl acetate (3 × 10 mL). The organic 
fractions were dried (Na2SO4) and concentrated in vacuum. Purification by flash 
chromatography (SiO2, diethyl ether) afforded 79a (503 mg, 69) as a colourless oil. 
IR (film): 2924 (m), 2852 (m), 1700 (s), 1599 (m), 1567 (m), 1399 (m), 1218 (s), 1069 (m). 
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 8.09 (s, 1H), 5.64 (d, J = 6.7 Hz), 3.99 (s, 3H), 3.97 
(s, 3H), 1.88-0.88 (m, 11H).  
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 168.3, 164.6, 156.2, 154.6, 114.1, 74.0, 66.6 (3 
carbons), 54.0, 44.1, 42.1, 28.8, 28.4. 
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MS (EI, 70 ev): m/z (%) = 365 (1), 282 (2), 235 (24), 153 (100), 114 (12), 70 (6). 
HRMS (EI) C18H27N3O5: calculated [M+]: 365.1951  found: 365.1935. 
 
 
Synthesis of 5-allyl-2,4-dimethoxy-6-methylpyrimidine (79b) 
 
N
N
OCH3
OCH3Me
 
 
A dry and argon flushed 10 mL flask, equipped with a magnetic stirrer and a septum, was 
charged with a solution of 4,5-dibromo-2,6-dimethoxypyrimidine (69b) (596 mg, 2 mmol, 1 
equiv) in dry THF (3 mL). i-PrMgCl·LiCl (13, 1.0 M/THF, 2.1 mmol, 1.05 equiv) was added 
very slowly (within 5 min) at 25 °C and the resulting mixture was stirred for 15 min to 
complete the bromine-magnesium exchange (checked by GC-MS analysis of reaction 
aliquots). Allyl bromide (266 mg, 2.2 mmol, 1.1 equiv) was added dropwise. The mixture was 
stirred at 25 °C for 2 h. Then, the mixture was cooled down to -5 °C and i-PrMgCl·LiCl (13, 
1.0 M/THF, 3.0 mmol, 1.5 equiv) was added slowly. After 8 h, the Br/Mg-exchange was 
complete (checked by GC-MS analysis of reaction aliquots) and methylene iodide (850 mg, 3 
equiv) was added to the mixture at -5 °C following by the addition of 3 drops of CuCN·2LiCl 
(cat., 1M in THF). The mixture was warmed up to 25 °C for 4 h and quenched with saturated 
aqueous NH4Cl solution. The aqueous phase was extracted with ethyl acetate (3 × 10 mL). 
The organic fractions were dried (Na2SO4) and concentrated in vacuum. Purification by flash 
chromatography (SiO2, n-pentane/diethyl ether = 4:1) afforded 79b (408 mg, 81%) as a 
colourless oil. 
IR (film): 2980 (w), 2955 (w), 2871 (w), 1638 (w), 1571 (s), 1457 (m), 1369 (s), 1358 (s), 
1203 (m), 1090 (w). 
1H-NMR (CDCl3, 400 MHz): δ (ppm) = 5.8 (m, 1H), 4.97 (dq, J  = 10.2 Hz, 1H), 4.90 (dq, J 
= 17.1 Hz, 1H), 3.94 (s, 6H), 3.25 (dt, J = 5.9 Hz, 2H), 2.33 (s, 3H). 
13C-NMR (CDCl3, 100 MHz): δ (ppm) = 169.3, 166.6, 163.0, 134.7, 114.9, 109.7, 54.3, 53.9, 
28.7, 21.2. 
MS (EI, 70 ev): m/z (%) = 196 (45), 194 (100), 193 (49), 179 (28), 164 (29), 138 (11), 122 
(5), 94 (6), 56 (21). 
HRMS (EI) C10H14N2O2: calculated [M+]: 194.1055  found: 194.1036. 
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Synthesis of 4-bromo-5-isopropyl-2,6-dimethoxypyrimidine (80) 
 
N
N
OCH3
OCH3
Br
 
 
To an ice-cooled, rapidly stirred slurry of 77f (1.38 g, 5mmol) dissolved in dry 
dichloromethane (20 mL) and triethylsilane (1.74 g, 3 equiv) was slowly added trifluoroacetic 
acid (1.99 g, 3.5 equiv). When the addition was complete, the mixture was warmed to 25 °C 
and stirred overnight (12 h). At the end of this period, the mixture was poured into 30 mL of 
saturated NaHCO3 and extracted with dichloromethane (3 × 20 mL). Extracts were combined, 
dried over Na2SO4, filtered, and concentrated under reduced pressure at 40 °C (oil bath) to 
give 1.28 g (95 %) of colourless oil. The product was identified as a mixture of 4-bromo-5-
isopropyl-2,6-dimethoxypyrimidine 77f (17%) and the corresponding unsaturated product 
(83%) (4-bromo-2,6-dimethoxy-5-(prop-1-en-2-yl)pyrimidine). The mixture was used for the 
next step without purification. 
 
1H-NMR (CDCl3, 200 MHz): δ (ppm) = 5.34 (s, 1.0H), 4.95 (t, 1.0H), 3.95 (m, 7.1H), 3.40 
(q, 0.37H), 1.96 (m, 3.03H) *, 1.26-1.23 (d, 1.17H)*. 
 
N
N
OCH3
OCH3
Br
unsaturated product from 80
 
 
*These integrations give respectively the yield of 80 (17%) and the corresponding unsaturated 
product (83%) 
 
The mixture (1.27 g) is directly used and solved in dry ethanol (10 mL). Platinium oxide (87 
mg) is added to the solution and the resulting mixture is stirred at atmospheric pressure in a 
hydrogen atmosphere for 30 min. The catalyst was removed by filtration and the filtrate was 
concentrated in vacuum. The crude residue was purified by flash column chromatography 
(SiO2, n-pentane/diethyl ether = 4:1) afforded 80 (1.17 g, 91%) as a colourless oil. 
IR (film): 2986 (w), 2959 (w), 2874 (w), 1575 (m), 1534 (s), 1451 (m), 1362 (s), 1215 (m), 
1017 (s).  
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1H-NMR (CDCl3, 400 MHz): δ (ppm) = 3.98 (s, 3H), 3.95 (s, 3H), 3.39 (sept, 3J = 7.1 Hz), 
1.24 (d, 3J = 7.0 Hz, 6H). 
13C-NMR (CDCl3, 150 MHz): δ (ppm) = 169.5, 161.7, 152.2, 120.2, 55.1, 54.3, 30.5, 19.7 (2 
carbons).  
MS (EI, 70 ev): m/z (%) = 262 (13), 260 (13), 247 (95), 245 (100), 165 (8), 151 (6). 
HRMS (EI) C9H13BrN2O2: calculated [M+]: 260.0160  found: 260.0171. 
 
 
Synthesis of 4-benzyl-5-isopropyl-2,6-dimethoxypyrimidine (81) 
 
N
N
OCH3
OCH3
 
 
Preparing according to GP5 starting from a solution of 4-bromo-5-isopropyl-2,6-
dimethoxypyrimidine (80) (783 mg, 3.0 mmol) in dry THF (2 mL), i-PrMgCl·LiCl (1.0 
M/THF, 3.15 mmol, 1.05 equiv), reaction conditions [5 h, 25 °C]. Benzyl bromide (1.03 g, 
6 mmol, 2 equiv) followed by two drops of CuCN·2LiCl (1 M in THF), reaction conditions 
[20 h, 25 °C].  Purification by flash chromatography (SiO2, n-pentane/diethyl ether = 1:1) 
afforded 81 (709 mg, 87%) as a pale yellow oil. 
1H-NMR (CDCl3, 400 MHz): δ (ppm) = 7.22 (m, 5H), 4.06 (s, 2H), 3.95 (2 singulets, 6H), 
3.16 (sept, 3J = 7.0 Hz, 1H), 1.11 (d, 3J = 7.0 Hz, 6H).  
13C-NMR (CDCl3, 150 MHz): δ (ppm) = 170.2, 166.3, 162.5, 138.8, 128.5 (2 carbons), 128.3 
(2 carbons), 126.2, 117.8, 54.3, 53.4, 41.4, 26.7, 20.1 (2 carbons). 
MS (EI, 70 ev): m/z (%) = 272 (80), 271 (100), 257 (93), 244 (29), 243 (23), 241 (16), 227 
(10), 167 (14), 91 (14). 
IR (film): 2956 (w), 2872 (w), 1562 (s), 1475 (w), 1451 (m), 1366 (s), 1217 (m), 1035 (w). 
HRMS (EI) C16H20N2O2: calculated [M+]: 272.1525   found: 272.1534. 
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Synthesis of 6-benzyl-5-isopropylpyrimidine-2,4(1H,3H)-dione (82) 
 
N
H
NH
O
O
 
 
A solution of 4-benzyl-5-isopropyl-2,6-dimethoxypyrimidine (81) (0.544 g, 2mmol) in MeOH 
(10 mL) with concentrated hydrochloric acid (30 mL) was heated under reflux for 4 h. After 
the reaction was complete, the solution was treated with activated charcoal and evaporated 
under reduced pressure. The residue was recrystallized from MeOH/ H2O (4:1) to afford 82 
(450 mg, 92%) as a white solid. 
mp.: 103.1.-104.2. 
IR (KBr): 2957 (w), 2869 (w), 1724 (s), 1640 (S), 1461 (m), 1411 (w), 1358 (w), 1193 (w). 
1H-NMR (CDCl3, 400 MHz): δ (ppm) = 8.18 (s, 1H), 7.94 (s, 1H), 7.38-7.29 (m, 3H), 7.19 
(dd, 2H), 3.82 (s, 2H), 3.03 (septuplet, 3J = 7.0 Hz, 1H), 1.30 (d, 3J = 7.0 Hz, 6H). 
13C-NMR (CDCl3, 150 MHz): δ (ppm) = 163.7, 150.8, 148.3, 137.0, 128.5 (2 carbons), 127.9 
(2 carbons), 126.5, 113.8, 35.1, 26.3, 20.0 (2 carbons). 
MS (EI, 70 ev): m/z (%) = 244 (72), 230 (17), 215 (5), 229 (100), 186 (14), 153 (7), 91 (17), 
69 (7). 
HRMS (EI) C14H16N2O2: calculated [M+]: 244.1212  found: 244.1225. 
 
 
Synthesis of 6-benzyl-1-(ethoxymethyl)-5-isopropylpyrimidine-2,4(1H,3H)-dione, 
emivirine (61) 
N
NH
O
O
O
 
 
6-Benzyl-5-isopropylpyrimidine-2,4(1H,3H)-dione (82) (366 mg, 1.5 mmol) was suspended 
in dry acetonitrile (10 mL) under nitrogen and BSA (1.33 ml, 5.2 mmol) was added. The 
reaction mixture was stirred for 10 min at 25 °C and then cooled to -45 °C. Diethoxymethane 
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(218 mg, 3 mmol) in dry acetonitrile (1 mL) and TMS-triflate (350 mg, 1.6 mmol) in dry 
acetonitrile (1 mL) were added to the reaction mixture, which was slowly warmed to 25 °C 
for 3.5 h. The reaction mixture was quenched with saturated aqueous NaHCO3 (10 mL) 
followed by evaporation under reduced pressure. Water (20 mL) was added followed by the 
extraction with diethyl acetate (3 × 20 mL). The combined organic phases were dried and 
evaporated under reduce pressure. Purification by recristallization from EtOH/ H2O (4:1) to 
afford 61 (407 mg, 90%) as a white solid. 
 mp.: 109.1-110.7 °C. 
IR (KBr): 3188 (w), 2968 (w), 1710 (s), 1673 (s), 1445 (m), 1100 (m), 1025 (m), 719 (m). 
1H-NMR (CDCl3, 400 MHz): δ (ppm) = 9.2 (s, 1H), 7.34-7.27 (m, 3H), 7.11-7.12 (m, 2H), 
5.12 (s, 2H), 4.18 (s, 2H), 3.62 (q, 3J = 6.9 Hz, 2H), 2.86 (septuplet, 3J = 6.9 Hz, 1H), 1.28 (d, 
3J = 6.9 Hz, 6H), 1.18 (t, J = 6.9 Hz, 3H). 
13C-NMR (CDCl3, 150 MHz): δ (ppm) = 162.3, 151.9, 148.6, 135.3, 129.2, 127.2 (3 
carbons), 127.2, 119.7, 72.9, 65.0, 33.4, 28.3, 20.4 (2 carbons), 15.0. 
MS (EI, 70 ev): m/z (%) = 303 (19), 302 (60), 287 (16), 273 (39), 257 (100), 241 (80), 229 
(64), 135 (34), 91 (21), 59 (29). 
HRMS (EI) C17H22N2O3: calculated [M+]: 302.1630   found:[M+]: 302.1641. 
 
 
Synthesis of 4-iodo-2,6-dimethoxypyrimidine (87b) 
 
N
N
OCH3
OCH3I
 
 
Prepared according to GP6 starting from a solution of 2,4-dimethoxypyrimidine (83a) (10.0 
mmol, 1.40 g, 1.0 equiv) dissolved in dry THF (5 mL), TMPMgCl·LiCl (11.0 mmol, 1.12 M, 
9.8 mL, 1.1 equiv), reaction conditions [–40 °C, 12 h]. Iodine (11.0 mmol, 2.80 g, 1.1 equiv), 
reaction conditions [–30 °C, 1 h]. The reaction mixture was quenched with sat. aq. Na2S2O3 
solution at 0 °C, extracted with EtOAc (3 x 50 ml). Purification by flash chromatography 
(SiO2, CH2Cl2) afforded 87b (3.78 g, 87 %) as a colourless solid. 
mp.: 100.5-101.9 °C.  
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IR (film): ν (cm-1) =  3108 (m), 3020 (m), 2956 (m), 1542 (vs), 1458 (vs), 1392 (m), 1360 
(vs), 1336 (s), 1232 (s), 1198 (s), 1116 (m), 1088 (s), 1006 (m), 972 (s), 926 (m),  830 (m), 
808 (m), 776 (m). 
1H NMR (300 MHz, CDCl3): δ (ppm): δ = 6.85 (s, 1 H), 3.96 (s, 3 H), 3.92 (s, 3 H). 
13C NMR (75 MHz, CDCl3): δ (ppm): δ = 170.6, 163.6, 127.8, 112.5, 55.3, 54.1. 
MS (EI, 70 eV): m/z (%) =  265 (100) [M+], 264 (26), 235 (23), 139 (19), 124 (10), 82 (9). 
HRMS C6H7IN2O2: calculated [M+]: 265.9552   found.265.9560 
 
 
Synthesis of 1-(2,6-dimethoxypyrimidin-4-yl)-2,2-dimethylpropan-1-one (87c) 
 
 
N
N
OCH3
OCH3
O
t-Bu
 
 
Prepared according to GP6 starting from a solution of 2,4-dimethoxypyrimidine (83a) (5.0 
mmol, 700 mg, 1.0 equiv) dissolved in dry THF (2.5 mL), TMPMgCl·LiCl (5.5 mmol, 1.12 
M, 4.9 mL, 1.1 equiv), reaction conditions [–40 °C, 12 h]. Transmetalation with CuCN·2LiCl 
(5 mL, 1 equiv, 1.00 M in THF), reaction conditions [–40 °C, 15 min]. Pivaloyl chloride (900 
mg, 1.5 equiv), reaction conditions [–40 °C, 5 h]. Purification by flash chromatography (SiO2, 
n-pentane/ethyl acetate = 9:1) afforded 87c (806 mg, 72%) as a colourless solid. 
mp.: 67.8-69.0 °C.  
IR (film): ν (cm-1) = 2962 (w), 1689 (m), 1578 (s), 1560 (s), 1476 (s), 1459 (s), 1372 (s), 
1344 (s), 1253 (w), 1196 (m), 1096 (m), 1030 (m), 978 (s), 939 (s), 857 (m), 772 (m), 679 
(w). 
1H NMR (300 MHz, CDCl3) δ (ppm): 6.76 (s, 1H), 4.01 (s, 3H), 3.97 (s, 3H), 1.39 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ (ppm): 205.1, 172.7, 164.7, 163.4, 101.1, 55.1, 54.2, 44.0, 
26.9 (3 carbons). 
MS (EI, 70 eV): m/z (%) = 224.1 [M+] (7), 209.0 (7), 140.0 (100), 82.0 (9), 57.0 (23), 41.1 
(18).  
HRMS C11H16N2O3: calculated [M+]: 224.1161  found. 224.1142 
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Synthesis of ethyl 4-(2,6-dimethoxypyrimidin-4-yl)benzoate (87d) 
 
N
N
OCH3
OCH3
EtO2C
 
 
Prepared according to GP6 starting from a solution of 2,4-dimethoxypyrimidine (83a) (5.0 
mmol, 700 mg, 1.0 equiv) dissolved in dry THF (2.5 mL), TMPMgCl·LiCl (5.5 mmol, 1.12 
M, 4.9 mL, 1.1 equiv), reaction conditions [–40 °C, 12 h]. Transmetalation with ZnCl2 (5 mL, 
1 equiv, 1.00 M in THF), reaction conditions [–40 to 25 °C, 30 min]. Ethyl iodobenzoate 
(1.93 mg, 7 mmol, 1.4 equiv). In another flame-dried round bottom flask, Pd(dba)2 (135 mg, 5 
mol%) and P(o-furyl)3 (110 mg, 10 mol%) were dissolved in dry THF (2 mL) and stirred for 5 
min. The resulting solution was then transferred to the zinc reagent flask, reaction conditions 
[reflux, 4 h]. Purification by flash chromatography (SiO2, n-pentane/ethyl acetate = 3:2) 
afforded 87d (1.080 g, 75%) as a colourless solid. 
mp. = 116.0-118.2 oC 
IR (neat): ν (cm-1) =   1714 (m), 1597 (m), 1578 (m), 1559 (s), 1467 (m), 1350 (s), 1274 (s), 
1217 (m), 1104 (s), 1013 (m), 825 (s), 771 (s), 703 (s) . 
1H NMR (CDCl3, 300 MHz): δ (ppm) = 8.11 (m, 4H), 6.82 (s, 1H), 4.41 (q, J = 7.50 Hz, 
2H), 4.09 (s, 3H), 4.02 (s, 3H), 1.41 (t, J = 7.05, 3H) . 
13C NMR (CDCl3, 75 MHz): δ (ppm) = 172.7, 166.1, 165.6, 164.8, 140.7, 132.2, 129.9 (2 
carbons), 126.9 (2 carbons), 98.0, 61.2, 54.9, 54.1, 14.3 ppm. 
MS (EI, 70 eV): m/z (%) = 288 (M+, 100), 258 (49), 243 (30), 143 (10), 99 (10). 
HRMS (EI) C15H16N2O4 calculated [M+]: 288.1110    found: 288.1097. 
 
 
Synthesis of ethyl 2,6-dimethoxypyrimidine-4-carboxylate (87e) 
 
N
N
OCH3
OCH3EtO2C
 
 
Prepared according to GP6 starting from a solution of 2,4-dimethoxypyrimidine (83a) (5.0 
mmol, 700 mg, 1.0 equiv) dissolved in dry THF (2.5 mL), TMPMgCl·LiCl (5.5 mmol, 1.12 
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M, 4.9 mL, 1.1 equiv), reaction conditions [–40 °C, 12 h]. Ethyl cyanoformate (10 mmol, 990 
mg, 2.0 equiv), reaction conditions [–60 °C, 10 h]. Purification by flash chromatography 
(SiO2, n-pentane/ethyl acetate = 4:1) afforded 87e (752 mg, 71%) as a colourless solid. 
mp.: 67.2-68.9 °C 
IR (ATR): 3104 (w), 2988 (w), 2956 (w), 2940 (w), 2868 (w), 1720 (m), 1600 (s), 1564 (s), 
1484 (s), 1404 (s), 1352 (vs), 1264 (s), 1200 (s), 1100 (s), 1028 (vs), 880 (s), 776 (vs). 
1H NMR (300 MHz, CDCl3): δ (ppm): 7.03 (s, 1H), 4.44-4.37 (q, 2H, J = 7.0 Hz), 4.04 (s, 
3H), 4.00 (s, 3 H), 1.41-1.37 (t, 3H, J = 7.0 Hz). 
13C NMR (75 MHz, CDCl3): δ (ppm): 172.8, 165.9, 163.9, 157.2, 103.1, 62.2, 55.1, 54.1, 
14.1. 
MS (EI, 70 eV): m/z (%) = 212 (21) [M+], 211 (10), 182 (15), 167 (11), 140 (100), 139 (13), 
125 (31), 82 (9). 
HRMS  (EI) C9H12N2O4: calculated [M+]: 212.0797  found: 212.0794 
 
 
Synthesis of 4,5-diiodo-2,6-dimethoxypyrimidine (89a) 
 
N
N
OCH3
OCH3I
I
 
 
A dry and argon flushed flask, equipped with a magnetic stirring bar and a septum, was 
charged with TMPMgCl·LiCl (18a, 11.0 mmol, 1.12 M, 9.8 mL, 1.1 equiv) and 2,4-
dimethoxypyrimidine (83a) (10.0 mmol, 1.40 g, 1.0 equiv) dissolved in dry THF (10 mL) was 
added dropwise at –40 °C. The reaction mixture was stirred for 12 h at this temperature and 
the completion of the deprotonation was checked by GC-analysis of reaction aliquots 
quenched with iodine using decane as internal standard. Iodine (11.0 mmol, 2.80 g, 1.2 equiv) 
was added and the reaction mixture was stirred for 2 h at –30 °C. The mixture was warmed to 
–30 °C and TMPMgCl·LiCl (18a, 15.0 mmol, 1.12 M, 13.4 mL, 1.5 equiv) was added 
dropwise. The mixture was warmed to 0 °C and stirred for 2 h. Iodine (20 mmol, 5.14 g, 2 
equiv) was added at 25 °C and the mixture was stirred for 3 h. The reaction mixture was 
quenched with sat. aq. Na2S2O3 (60 mL) solution at 0 °C, extracted with EtOAc (3 x 50 ml), 
the organic layer was washed with brine, dried over Na2SO4 and concentrated in vacuum. 
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Purification by flash chromatography (SiO2, CH2Cl2) afforded 89a (3.74 g, 87%) as a 
colourless solid. 
mp.: 144.1-145.4 °C. 
IR (ATR): ν (cm-1) =   2996 (m), 2948 (m), 2864 (m), 1516 (vs), 1476 (s), 1450 (s), 1376 (s), 
1336 (s), 1292 (s), 1222 (m), 1196 (s), 1102 (m), 1020 (m), 996 (s), 930 (m), 806 (m),         
772 (m). 
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 3.98 (s, 3 H), 3.96 (s, 3 H). 
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 168.9, 163.6, 141.8, 84.1, 55.8, 55.6 
MS (EI, 70 eV): m/z (%) =  391 (100) [M+], 390 (23), 361 (16), 249 (20), 192 (10). 
HRMS (EI) (C6H6I2N2O2): calculated  [M+]: 391.8519    found: 391.8498 
 
 
Synthesis of (4-fluorophenyl)(4-iodo-2,6-dimethoxypyrimidin-5-yl)methanone (89b) 
 
N
N
OCH3
OCH3I
O
F
 
 
A dry and argon flushed flask, equipped with a magnetic stirring bar and a septum, was 
charged with TMPMgCl·LiCl (18a, 1.1 mmol, 1.16 M, 0.96 mL, 1.1 equiv) and 4-iodo-2,6-
dimethoxypyrimidine (87b) (1.0 mmol, 266 mg, 1.0 equiv) dissolved in dry THF (1.0 mL) 
was added dropwise at 0 °C. The reaction mixture was stirred for 1 h at this temperature and 
the completion of the deprotonation was checked by GC-analysis of reaction aliquots 
quenched with iodine using decane as internal standard. CuCN·2LiCl (1 mL, 1 equiv, 1.00 M 
in THF) was added at –20 °C and stirred for 15 min. Thereafter, 4-fluorobenzoyl chloride 
(190 mg, 1.2 mmol, 1.2 equiv) was added at –20 °C, and the reaction mixture was warmed to 
25 °C for 5 h. The resulting mixture was quenched with sat. aq. NH4Cl solution, extracted 
with EtOAc (3 x 10 ml), the organic layer was washed with brine, dried over Na2SO4 and 
concentrated in vacuum. Purification by flash chromatography (SiO2, n-pentane/diethyl ether, 
1:1) afforded 89b (325 mg, 84%) as a colourless solid. 
mp. = 151.9-157.1 oC 
IR (neat): ν (cm-1) =  1669 (m), 1595 (m), 1566 (s), 1525 (s), 1506 (m), 1475 (m), 1455 (m), 
1381 (s), 1364 (s), 1312 (s), 1255 (s), 1245 (s), 1225 (s), 1158 (s), 1076 (s), 1015 (s), 920 (s). 
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1H NMR (CDCl3, 300 MHz): δ (ppm) = 7.83-7.77 (m, 2H), 7.12-7.05 (m, 2H), 3.98 (s, 3H), 
3.83 (s, 3H) ppm. 
13C NMR (CDCl3, 75 MHz): δ (ppm) = 191.4, 168.1, 167.2, 164.7, 163.5, 132.5, 132.1, 
126.6, 120.1, 116.3, 116.1, 55.7, 54.8 ppm. 
MS (EI, 70 eV), m/z (%): 388 (M+, 66), 358 (5), 293 (31), 261 (10), 136 (25), 123 (100), 95 
(80), 75 (24). 
HRMS (EI) C13H10FIN2O3 : calculated [M+]:387.9720     found: 387.9722. 
 
 
Synthesis of ethyl 5-benzoyl-2,6-dimethoxypyrimidine-4-carboxylate (89c) 
 
N
N
OCH3
OCH3EtO2C
O
Ph
 
 
A dry and argon flushed flask, equipped with a magnetic stirring bar and a septum, was 
charged with TMPMgCl·LiCl (18a, 1.1 mmol, 1.16 M, 0.96 mL, 1.1 equiv) and ethyl 2,6-
dimethoxypyrimidine-4-carboxylate (87e) (1.0 mmol, 212 mg, 1.0 equiv) dissolved in dry 
THF (1.0 mL) was added dropwise at -40 °C. The reaction mixture was stirred for 2 h at this 
temperature and the completion of the deprotonation was checked by GC-analysis of reaction 
aliquots quenched with iodine using decane as internal standard. CuCN·2LiCl (1 mL, 1 equiv, 
1.00 M in THF) was added at –40 °C and stirred for 1 h. Thereafter, benzoyl chloride (210 
mg, 1.5 mmol, 1.5 equiv) was added at –40 °C, and the reaction mixture was warmed to 25 °C 
for 12 h.  The resulting mixture was quenched with sat. aq. NH4Cl solution, extracted with 
EtOAc (3 x 10 ml), the organic layer was washed with brine, dried over Na2SO4 and 
concentrated in vacuum. Purification by flash chromatography (SiO2, n-pentane/diethyl ether, 
1:1) afforded 89c (246 mg, 78%) as a colourless solid. 
mp. = 98.4-100.4 oC 
IR (neat): ν (cm-1) = 3067 (w), 2962 (w), 2925 (w), 1727 (s), 1668 (s), 1571 (s), 1556 (s), 
1463 (m), 1447 (m), 1380 (s),1254 (s), 1229 (s), 1176 (m), 1082 (s), 1035 (s), 929 (m), 903 
(s), 776 (s), 691 (s). 
1H NMR (CDCl3, 300 MHz): δ (ppm) = 7.80-7.77 (m, 2H), 7.60-7.54 (m, 1H), 7.47-7.41 (m, 
2H), 4.21-4.13 (q, 2H, J = 7.3 Hz), 4.11 (s, 3H),3.95 (s, 3H), 1.11-1.06 (t, 3H, J = 7.1 Hz).  
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13C NMR (CDCl3, 75 MHz): δ (ppm) = 192.0, 169.9, 165.2, 163.3, 155.3, 137.0, 133.6, 
128.9, 128.9, 128.7, 128.7, 116.1, 62.6, 55.5, 55.0, 13.5. 
MS (EI, 70 eV): m/z (%): 316 (M+, 45), 272 (67), 243 (55), 239 (54), 215 (19), 211 (27), 186 
(12), 167 (62), 139 (24), 118 (12), 109 (12), 105 (100), 82 (17), 77 (83), 51 (14).   
HRMS (EI): C16H16N2O5 calculated [M+]: 316.1059    found: 316.1036. 
 
 
Synthesis of 2,4-dimethoxy-7H-pyrrolo[2,3-d]pyrimidine (90) 
 
N
N
OMe
OMeN
H
 
 
To a stirred solution of KH (126 mg, 3 mmol, 3 equiv) in NMP (6 mL), was added at 25 °C, a 
solution of 92 (179 mg, 1 mmol, 1 equiv) in NMP (2 mL). The resulting mixture was 
vigorously stirred at 60 °C for 8 h and quenched with water (2 mL). The aqueous layer was 
extracted CH2Cl2 (3 x 80 mL) and Et2O (2 x 50 mL) and the combined organic layer were 
washed with brine (2 x 80 mL) and dried (MgSO4), filtered, and concentrated under reduced 
pressure. The residue was purified by flash chromatography (SiO2, n-pentane/Et2O = 9:1) 
afforded 90 (144 mg, 81%) as a colorless solid. 
mp.: 202.4-204.8 oC. 
IR (Diamond ATR): ν (cm-1) =  3212 (m), 3156 (m), 3004 (m), 2944 (m), 1604 (s), 1584 (s), 
1472 (s), 1404 (s), 1316 (s), 1216 (s), 1192 (s), 1152 (s), 1088 (vs), 1076 (vs), 1052 (s), 944 
(s), 896 (s), 744 (vs), 724 (s). 
1H NMR (400 MHz, DMSO-d6): δ (ppm) = 11.71 (s, 1H), 7.08 (dd, Jcis = 3.0 Hz, 1H), 6.34 
(dd, Jcis = 3.0 Hz, 1H), 3.97 (s, 3H), 3.87 (s, 3H). 
13C NMR (100 MHz, DMSO-d6): δ (ppm) = 163.4, 161.1, 153.7, 121.8, 99.6, 98.1, 54.0, 
53.2. 
MS (70 eV, EI): m/z (%) = 179 (100) [M]+, 150 (15), 134 (21), 108 (5), 78 (5). 
HRMS (EI) C8H9N3O2: calculated [M]+: 179.0695    found: 179.0690. 
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Synthesis of 4-chloro-2,6-dimethoxy-5-trimethylsilanylethynyl-pyrimidine (91) 
 
N
N
OMe
OMeCl
TMS
 
 
A dry and argon flushed 50 mL flask, equipped with a magnetic stirring bar and a septum, 
was charged with a solution of commercially available 4-chloro-2,6-dimethoxypyrimidine 
(70a) (6.16 g, 28 mmol, 1.4 equiv) in dry THF (15 mL). TMPMgCl·LiCl (18a, 27.5 mL, 
1.09 M in THF, 30 mmol, 1.5 equiv) was added dropwise at 25 °C. The reaction mixture was 
stirred at this same temperature for 1 h. The completion of the metalation was checked by 
GC-analysis. At -20 °C, ZnCl2 (30 mL, 1 m in THF, 1.5 equiv) was then added to the freshly 
prepared magnesium reagent and allowed to warm to 25 °C for 1 h. Iodoethynyl-trimethyl-
silane4 (3.1 mL, 20 mmol, 1 equiv) was added to the reaction mixture at 25 °C. A round 
bottom flask was charged with Pd(dba)2 (230 mg, 2 mol%), P(o-furyl)3 (185 mg, 4 mol%) and 
THF (5 mL). The mixture was stirred at 25 oC for 10 min then transferred to the reaction flask 
which was charged with the organozinc solution. The resulting mixture was stirred 2 h at 
40 °C, cooled to 25 oC, and quenched with sat. NH4Cl solution (40 mL). The aqueous layer 
was extracted with AcOEt (3 x 40 mL). The combined organic extracts were dried with 
Na2SO4 and concentrated in vacuum. The solvent was evaporated and the product was 
purified by flash chromatography (SiO2, n-pentane/Et2O =7:3). 4-Chloro-2,6-dimethoxy-5-
trimethylsilanyl-ethynyl-pyrimidine (91) was afforded (3.31 g, 64 %) as a pale yellowish 
solid. 
mp.: 62.4-64.2 oC. 
IR (Diamond ATR): ν (cm-1) = 3024 (vw), 2957 (w), 2156 (m), 1584 (m), 1528 (s), 1473 (s), 
1456 (s), 1379 (s), 1328 (s), 1247 (s), 1215 (m), 1184 (m), 1084 (s), 1028 (s), 944 (m), 840 
(vs), 788 (s), 758 (s), 639 (m). 
1H NMR (300 MHz, CDCl3): δ (ppm) = 4.03 (s, 3H), 3.99 (s, 3H), 0.26 (s, 9H).  
13C NMR (75 MHz, CDCl3): δ (ppm) = 171.7, 163.1, 162.3, 106.0, 99.1, 94.1, 55.6, 55.3, -
0.2 (3 CH3 of TMS group). 
MS (70 eV, EI): m/z (%) = 245 (21), 236 (34) [M]+, 221 (100), 191 (28), 71 (10), 57 (13). 
HRMS (EI) C11H16N2O2Si: calculated [M]+: 236.0981   found: 236.0977. 
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Synthesis of 5-ethynyl-2,6-dimethoxy-pyrimidin-4-ylamine (92) starting from 91  
 
 
N
N
OMe
OMeH2N
H
 
 
A solution of 91 (135 mg, 0.5 mmol) dissolved in NH3 sat. in MeOH (3 mL, 3 M in MeOH, 6 
equiv) was introduced in a 25cm3 autoclave and was heated 2 days at 90 °C. The consumption 
of the starting material was checked by TLC. The solvent was evaporated under vacuum. The 
crude oily residue was purified by flash chromatography (SiO2) using pentane/Et2O (95:5, 
with NEt3 0.5 %). A colourless solid was obtained (56 mg, 31%) afforded to 5-ethynyl-2,6-
dimethoxy-pyrimidin-4-ylamine (92). Analytic data matched data from the preparation of 9a 
starting from 6a. 
mp.: 166.5-168.4 oC. 
IR (Diamond ATR): ν (cm-1) = 2956 (w), 2900 (w), 2153 (w), 1568 (m), 1535 (s), 1364 (vs), 
1247 (s), 1109 (s), 1086 (s), 837 (broad vs), 680 (m). 
1H NMR (400 MHz, DMSO-d6): δ (ppm) = 6.86 (broad s, NH2), 4.33 (s, 1H), 3.83 (s, 3H), 
3.79 (s, 3H). 
13C NMR (100 MHz, DMSO-d6): δ (ppm) = 171.1, 166.7, 163.2, 89.0, 76.2, 75.1, 54.0, 53.6. 
MS (70 eV, EI): m/z (%) = 179 (79) [M]+, 149 (26), 121 (23), 111 (35), 97 (51), 83 (50), 71 
(74), 57 (100), 43 (75). 
HRMS (EI) C8H9N3O2: calculated [M]+: 179.0695   found: 179.0699. 
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4. Amination of DNA and RNA units via cuprated pyrimidines and 
purines intermediates. 
 
4.1 General procedure for the amination via magnesiation using Br/Mg exchange 
reaction (GP7): 
A dry and argon-flushed 50 mL flask, equipped with a magnetic stirrer and a septum, was 
charged with the aromatic or heteroaromatic halide (1.0 mmol) in THF (1 mL). i-
PrMgCl·LiCl (13) or i-PrMgCl (Solution in THF, 1.1 equiv) was added dropwise and stirred 
at the indicated temperature for the indicated time [reaction conditions: temperature, time] to 
afford the corresponding Grignard reagent. The completion of the halogen/Mg-exchange was 
checked by GC analysis of reaction aliquots quenched with sat. aqueous NH4Cl solution using 
decane as internal standard. This reagent was added dropwise to a solution of CuCl·2LiCl (1.0 
m in THF; 1.2 mL, 1.2 mmol, 1.2 equiv) and the indicated ligand (bis[2-(N,N-
dimethylamino)ethyl] ether (192 mg, 1.2 mmol, 1.2 equiv), or NEt3 (121 mg, 1.2 mmol, 1.2 
equiv) at -50 °C and the mixture was stirred for 0.7 h leading to the cuprated reagent. To the 
so formed aryl copper reagent, the indicated lithium amide (2.0 mmol, 2 equiv) was added 
dropwise and the mixture was further stirred for 1 h at -60 °C. The reaction mixture was 
cooled to -78 oC, then chloranil (22, 298 mg, 1.2 mmol), in dry THF (7 mL), was added 
slowly over a period of 1 h. The reaction mixture was stirred for 12 h. Diethyl ether (10 mL) 
was added to the crude reaction mixture and it was filtered through Celite, washed with Et2O 
thoroughly, and the liquors washed with 2 x 10 mL portions of NH4OH (aq., 2.0 m) and 
extracted with Et2O. The combined organic extracts were dried over Na2SO4 and concentrated 
in vacuum. The crude residue was purified by column chromatography (SiO2 or Al2O3 neutral 
deactivated) or by preparative TLC (SiO2). 
 
4.2 General procedure for the amination via magnesiation using TMPMg·LiCl (GP8): 
A dry and argon-flushed 50 mL flask, equipped with a magnetic stirrer and a septum, was 
charged with the aromatic or heteroaromatic halide (1.0 mmol) in THF (1 mL). 
TMPMgCl·LiCl (18a, solution in THF, 1.1 equiv) was added dropwise and stirred at the 
indicated temperature for the indicated time [reaction conditions: temperature, time] to afford 
the corresponding Grignard reagent. The completion of the metalation was checked by GC 
analysis of reaction aliquots quenched iodine using decane as internal standard. This reagent 
was added dropwise to a solution of CuCl·2LiCl (1.0 m in THF; 1.2 mL, 1.2 mmol, 1.2 equiv) 
and the indicated ligand (bis[2-(N,N-dimethylamino)ethyl] ether (192 mg, 1.2 mmol, 1.2 
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equiv), or NEt3 (121 mg, 1.2 mmol, 1.2 equiv) at -50 °C and the mixture was stirred for 0.7 h 
leading to the cuprated reagent. To the so formed aryl copper reagent, the indicated lithium 
amide (2.0 mmol, 2 equiv) was added dropwise and the mixture was further stirred for 1 h at -
60 °C. The reaction mixture was cooled to -78 oC, then chloranil (22, 298 mg, 1.2 mmol), in 
dry THF (7 mL), was added slowly over a period of 1 h. The reaction mixture was stirred for 
12 h. Diethyl ether (10 mL) was added to the crude reaction mixture and it was filtered 
through Celite, washed with Et2O thoroughly, and the liquors washed with 2 x 10 mL portions 
of NH4OH (aq., 2.0 m) and extracted with Et2O. The combined organic extracts were dried 
over Na2SO4 and concentrated in vacuum. The crude residue was purified by column 
chromatography (SiO2 or Al2O3 neutral deactivated) or by preparative TLC (SiO2). 
 
 
4.3 Typical procedure (TP1): Preparation of the N-lithium morpholide (96b). 
 
O
N
Li
 
 
In a dry and argon flushed Schlenk-flask equipped with a magnetic stirrer and a septum, 
morpholine (174 mg, 2 mmol) was dissolved in 4 mL of dry THF. n-BuLi (2 mmol, solution 
in hexane) was added dropwise at -40 oC and stirred for 30 min and then 5 min at 20 °C. 
 
4.4 Typical procedure (TP2): Preparation of the lithium silinamide 96c. 
 
N
Li
TBS
 
 
In a dry and argon flushed Schlenk-flask equipped with a magnetic stirrer and a septum, 5-
aminoindane (266 mg, 2 mmol) was dissolved in dry THF (1 mL) and cooled to -50 °C. MeLi 
(1.70 M in Et2O; 1.21 mL, 2.05 mmol) was added dropwise and the mixture was stirred for 10 
min. Then, TBDMSCl (315 mg, 2.1 mmol), dissolved in dry THF (1 mL), was added 
dropwise. The reaction mixture was allowed to reach 25 °C and was further stirred for 30 min. 
The solvent and volatiles were removed under high vacuum for 1 h. The residue was 
redissolved in dry THF (1 mL) and was again cooled to -50 °C. MeLi (1.70 M in Et2O; 1.21 
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mL, 2.05 mmol) was added dropwise and the mixture was stirred for 10 min, affording the 
lithium silanamide 8c. 
 
 
4.5  Starting material synthesis 
 
 
Synthesis of 2,4-dimethoxy-5-bromo-pyrimidine (starting material of compounds 83b 
and 94)  
 
 
 
 
 
Commercially available 2,4-dimethoxpyrimidine (83a) (4.20 g, 30 mmol, 1.0 equiv) was 
slurried with NaHCO3 (4.0 g) in 90 mL of 50% aq. MeOH. Bromine (8.63 g, 2.70 mL, 1.8 
equiv) was added dropwise with an efficient stirring over a period of 1 h. After 30 min of 
bromine addition, an additional 7.0 g of sodium bicarbonate was added and the mixture was 
stirred at 25 °C for a total of 2 h. The white precipitated obtained was collected by filtration, 
washed with MeOH (1 x 20 mL) and water (2 x 30 mL). The obtained solid was dried under 
reduced pressure. 2,4-Dimethoxy-5-bromopyrimidine was afforded as colourless crystalline 
plates (5.51 g, 84%). 
mp.: 68.0-69.2 °C. 
IR (ATR): ν (cm-1) =  3024 (m), 2958 (m), 1556 (vs), 1486 (m), 1442 (m), 1394 (s), 1366 (s), 
14 (m), 1272 (m), 1232 (m), 1192 (m), 1094 (s), 1032 (m), 1000 (s), 974 (m), 932 (m), 0 (m), 
762 (m), 662 (w). 
1H-NMR (CDCl3, 600 MHz): δ (ppm) = 8.29 (s, 1 H), 4.04 (s, 3 H), 3.97 (s, 3 H). 
13C-NMR (CDCl3, 150 MHz): δ (ppm) = 166.8, 164.3, 159.2, 96.1, 55.3, 54.9. 
MS (EI, 70 eV): m/z (%) = 219 (100) [M+, 81Br], 219 (65), 218 (79), 217 (78) [M+], 204 (34), 
202 (27), 190 (20), 189 (76), 188 (24), 187 (81), 174 (28), 172 (25), 109 (16), 82 (11), 69 
(12). 
HRMS (EI) C6H779BrN2O2: calculated [M+, 81Br]: 217.9691   found: 219.9650  
 
 
N
N
OMe
OMe
Br
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Synthesis of 2,6-dimethoxy-5-trimethylsilanylethynyl-pyrimi-dine (94) 
 
N
N
OMe
OMeH
TMS
 
 
A dry and argon flushed 50 mL flask, equipped with a magnetic stirring bar and a septum, 
was charged with a solution of 5-bromo-4-chloro-2,6-dimethoxypyrimidine (6.57 g, 37 mmol, 
1.4 equiv) in dry THF (25 mL). i-PrMgCl·LiCl (13, 38 mL, 1.05 M in THF, 40 mmol, 1.5 
equiv) was added dropwise at -20 °C. The reaction mixture was stirred at this temperature for 
2 h. The completion of the Br/Mg exchange was checked by GC-analysis of quenching 
reaction aliquots. At 25 °C, ZnCl2 (30 mL, 1 m in THF, 1.5 equiv) was then added to the 
freshly prepared magnesium reagent and stirred for 1 h. Iodoethynyl-trimethylsilane118 (4.2 
mL, 27 mmol, 1 equiv) was added to the reaction mixture at 25 °C. A round bottom flask was 
charged with Pd(dba)2 (342 mg, 2 mol%), P(o-furyl)3 (280 mg, 4 mol%) and THF (6 mL). 
The mixture was stirred at 25 oC for 10 min then transferred to the reaction flask which was 
charged with the organozinc solution. The resulting mixture was stirred 12 h at 25 oC, and 
quenched with sat. NH4Cl solution (60 mL). The aqueous layer was extracted with AcOEt (3 
x 60 mL). The combined organic extracts were dried with Na2SO4 and concentrated in 
vacuum. Purification by flash chromatography (SiO2, n-pentane/AcOEt = 95:5) afforded 2,6-
dimethoxy-5-trimethylsilanylethynyl-pyrimidine (94) (5.54 g, 76 %) as a colourless solid. 
mp.: 51.5-53.0 oC. 
IR (Diamond ATR): ν (cm-1) = 2956 (m), 2160 (m), 1600 (m), 1544 (s), 1472 (s), 1380 (s), 
1248 (s), 1215 (m), 1183 (m), 1083 (m), 1030 (s), 943 (w), 829 (vs), 787 (s), 759 (s). 
1H NMR (300 MHz, CDCl3): δ (ppm) = 8.31 (s, 1H), 4.02 (s, 3H), 3.98 (s, 3H), 0.24 (s, 9H). 
13C NMR (75 MHz, CDCl3): δ (ppm) = 170.7, 164.0, 162.0, 101.2, 100.0, 96.1, 55.1, 54.5, -
0.1(3 CH3 of TMS group). 
MS (70 eV, EI): m/z (%) = 270 (27) [M]+, 255 (100), 240 (59), 225 (15), 168 (6), 43 (9). 
HRMS (EI) C11H15ClN2O2Si: calculated [M]+: 270.0591   found: 270.0581. 
 
 
Synthesis of 2,4-dimethoxy-5-methyl-pyrimidine (83b) 
 
 
 
N
N
OMe
OMe
Me
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A dry and argon flushed flask, equipped with a magnetic stirring bar and a septum, was 
charged with 5-bromo-2,6-dimethoxypyrimidine (2.74 g, 12.5 mmol, 1 equiv.) dissolved in 
dry THF (10 mL). i-PrMgCl·LiCl (13, 11 mL, 1.25 M in THF, 1.1 equiv) was added dropwise 
at -20°C. CuCN·2LiCl57 (12.5 mL, 1.0 m in THF, 1.0 equiv) was added dropwise to the 
corresponding  Grignard reagent at -30 °C and the mixture was stirred for 30 min. Methyl 
iodide (2.3 g, 1.3 equiv) was added dropwise and the reaction mixture allowed to warm to 25 
°C and stirred for 12 h. The reaction was quenched with sat aq. NH4Cl (20 mL) and extracted 
with EtOAc (5x 20 ml). The combined organic layers were dried (MgSO4), filtered, and 
concentrated under reduced pressure. Purification by flash chromatography (SiO2, n-
pentane/Et2O = 9:1) afforded 83b (1.69 g, 88%) as a colourless crystalline solid.  
mp.: 61.9-63.2 oC. 
IR (Diamond ATR): ν (cm-1) = 3020 (w), 2952 (w), 1604 (s), 1572 (s), 1464 (s), 1444 (vs), 
1388 (vs), 1348 (s), 1288 (s), 1200 (vs), 1068 (s), 1016 (vs), 1004 (vs), 784 (vs). 
1H NMR (300 MHz, CDCl3): δ (ppm) = 7.90 (s, 1H), 3.91 (s, 3H), 3.88 (s, 3H), 1.97 (s, 3H). 
13C NMR (75 MHz, CDCl3): δ (ppm) = 169.5, 163.9, 156.7, 110.9, 54.4, 53.6, 11.7. 
MS (70 eV, EI): m/z (%) = 154 (100)[M+], 139 (32), 124 (59), 109 (24), 96 (6), 82 (5). 
HRMS (EI) C7H10N2O2:  calculated [M]+: 154.0742   found: 154.0747. 
 
 
Synthesis of 5-bromo-2-iodo-pyrimidine 
 
N N
Br
I
 
This compound was prepared following the literature procedure.153 
 
 
Synthesis of 9-benzyl-6-chloro-9H-purine (102)  
 
N
N
N
N
Cl
Ph
 
                                                 
153
 F. Lutz, T. Kawasaki, K., Soai. Tetrahedron Asymmetry 2006, 17, 486.  
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This compound was prepared from commercially available 6-chloropurine using the literature 
procedure.154 The analytic data were found to match literature data. 
1H NMR (300 MHz, CDCl3): δ (ppm) = 8.76 (s, 1H), 8.10 (s, 1H), 7.39-7.27 (m, 5H), 5.44 
(s, 2H). 
 
 
Synthesis of 6-iodo-9-methyl-9H-purine (103) 
 
N
N
N
N
I
 
 
This compound was prepared from 6-iodopurine155 by the method used for the preparation of 
6-chloro-9-methyl-9H-purine.156  
6-Iodo-9-methyl-9H-purine 103 was afforded as a pale yellowish solid in 55% yield. 
mp.: 210.0-212.2 oC. 
IR (Diamond ATR): ν (cm-1) = 3064 (w), 2952 (w), 1668 (w), 1552 (s), 1436 (s), 1388 (m), 
1324 (s), 1228 (s), 1132 (s), 904 (s), 836 (s), 732 (s), 636 (vs). 
1H NMR (300 MHz, CDCl3): δ (ppm) = 8.59 (s, 1H), 8.59 (s, 1H), 3.81 (s, 3H). 
13C NMR (75 MHz, CDCl3): δ (ppm) = 151.6, 148.3, 147.0, 137.8, 122.2, 30.0. 
MS (70 eV, EI): m/z (%) = 260 (100), 133 (44), 16 (17), 79 (24), 52 (9). 
HRMS (EI) C6H5IN4: calculated [M]+:  259.9559   found: 259.9563. 
 
 
Synthesis of 6-chloro-2-iodo-9-isopropyl-9H-purine (108)  
 
N
N N
N
I
Cl
 
This compound was prepared following the literature procedure.157 
                                                 
154
 Kanie, K.; Mizuno, K.; Kuroboshi, M.;  Hiyama, T. Bull. Chem. Soc. Jpn. 1998, 71, 1973. 
155
 6-Iodopurine was prepared according to literature procedure: Elion, G. B.; Hitchings, G. H. J. Am. Chem. 
Soc. 1956,78,3508. 
156
 K. Bok Young, A. Joong Bok, L. Hong Woo, K. Sung Kwon, L. Jung Hwa,; S. Jae Soo, A. Soon Kil, H. 
Chung Il, Y. Seung Soo. Eur. J. Med. Chem. 2004, 39, 433.  
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Synthesis of 9-(2,2-dimethyl-6-trityloxymethyl-tetrahydro-furo[3,4 d][1,3]dioxol-4-yl)-6-
iodo-9H-purine (111)  
 
N
N N
N
I
O
OO
TrO
 
This compound was prepared following the literature procedure.158 
 
 
Synthesis of 2-chloro-6-iodo-9-isopropyl-9H-purine (114)  
 
N
N N
N
I
Cl
 
 
This compound was prepared from 2-chloro-6-iodo-9H-purine155by the Mitsonobu reaction 
procedure described in the literature. 159 Purification by flash chromatography (SiO2, n-
pentane/acetonitrile = 1:1) afforded 114 (8.55 g, 83%) as a colorless solid.  
mp.: 148.8-151.5 oC. 
IR (Diamond ATR): ν (cm-1) = 3112 (w), 2980 (w), 2936 (w), 1572 (m), 1560 (w), 1540 (s), 
1352 (s), 1208 (s), 1148 (s), 1136 (s), 936 (s), 836 (vs), 764 (s), 636 (s).  
1H NMR (400 MHz, DMSO-d6): δ (ppm) = 8.79 (s, 1H), 4.77 (sept, J = 6.9 Hz), 1.53 (d, J = 
6.9 Hz, 6H). 
13C NMR (100 MHz, DMSO-d6): δ (ppm) = 150.4, 148.8, 145.7, 138.0, 123.4, 47.8, 21.7, 
21.7. 
MS (70 eV, EI): m/z (%) = 324 (25) [37Cl], 322 (100) [35Cl], 279 (32), 195 (10), 159 (13), 
153 (17), 134 (7). 
HRMS (EI) C8H835Cl127IN4: calculated [M]+: 321.9482   found: 321.9486.   
 
                                                 
157
 M. Legraverend, O. Ludwig, E. Bisagni, S. Leclerc, L. Meijer, N. Giocanti, R. Sadri, V. Favaudon. Bioorg. 
Med. Chem. 1999, 7, 1281.  
158
 M. Hocek, A. Holy. Collect.Czech. Chem. Commun. 1999, 64, 229.  
159
 A. Toyota, N. Katagari, C. Kanebo. Synth. Commun. 1993, 23, 1295. 
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4.6 Preparation of aminated pyrimidines 
 
 
Synthesis of 5-ethynyl-2,6-dimethoxy-pyrimidin-4-ylamine (92) starting from 94  
 
N
N
OMe
OMeH2N
H
 
 
According to GP8, starting from 94 (236 mg, 1 mmol, 1 equiv) dissolved in 1 mL dry THF; 
TMPMg·LiCl (0.91 mL, 1.1 equiv, 1.20 M in THF)[reaction conditions: -10 °C, 3 h];  
CuCl·2LiCl (1.2 mL, 1.2 equiv) and NEt3 (121 mg, 1.2 equiv) to afford the corresponding 
cuprated reagent 95; LiHMDS (2 mL, 2 mmol, 1 M in THF/Ethylbenzene); chloranil (298 
mg, 1.2 equiv) in 7 mL of THF. The crude material obtained was redissolved in THF (3 mL) 
before TBAF (1.0 m in THF) (2 mL, 2 mmol) was added in one portion and the mixture was 
stirred at 25 °C for 2 h, poured over EtOAc (10 mL) and washed with deionised water (3 x 10 
mL). The combined organic extracts were dried (MgSO4), filtered and concentrated in 
vacuum. Purification by flash chromatography (SiO2, n-pentane/Et2O = 9:1) afforded 92 
(127 mg, 71 %) as a colourless solid. The analytical data matched the data for the preparation 
of 92 starting from 91. 
 
 
Synthesis of 4-(2,6-dimethoxy-pyrimidin-4-yl)-morpholine (98a)  
 
N
N
OMe
OMeN
O
 
 
Prepared according to GP8 from 2,4-dimethoxypyrimidine (83a) (280 mg, 2 mmol, 1 equiv), 
and TMPMgCl·LiCl (1.8 mL, 1.23 M in THF, 1.1 equiv) [reaction conditions: -40 °C, 12 h]; 
CuCl·2LiCl (2.4 mL, 1.2 equiv) and bis[2-(N,N-dimethylamino)ethyl] ether (284 mg, 2.4 
mmol, 1.2 equiv) to afford the corresponding cuprated reagent 97a; N-lithium morpholide 
(96b, 4 mmol, 2 equiv); chloranil (595 mg, 1.2 equiv) in 14 mL of THF. Purification by flash 
chromatography (SiO2, pentane/ Et2O = 4:1) afforded 98a (341 mg, 76%) as a grey solid.  
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mp.: 93.9-95.7 oC. 
IR (Diamond ATR): ν (cm-1) = 2984 (w), 2972 (w), 2940 (w), 2876 (w), 1596 (vs), 1568 
(vs), 1460 (s), 1368 (vs), 1264 (s), 1220 (s), 1200 (vs), 1100 (vs), 1036 (vs), 1000 (s), 868 (s), 
788 (vs). 
1H NMR (300 MHz, CDCl3): δ (ppm) = 5.46 (s, 1H), 3.89 (s, 3H), 3.88 (s, 3H), 3.73 (t, J = 
4.5 Hz, 4H), 3.53 (t, J = 5.0 Hz, 4H). 
13C NMR (75 MHz, CDCl3): δ (ppm) = 172.5, 165.3, 164.8, 79.2, 66.4, 66.4, 54.2, 53.6, 
44.6, 44.6. 
MS (70 eV, EI): m/z (%) = 225 (66) [M]+, 194 (84), 180 (51), 168 (100), 140 (49), 125 (23), 
86 (7), 82 (8). 
HRMS (EI): C10H15N3O: calculated [M]+: 225.1113, found: 225.1101. 
 
 
Synthesis of 4-(2,6-dimethoxy-5-methyl-pyrimidin-4-yl)-morpholine (98b) 
 
N
N
OMe
OMeN
O
Me
 
 
Prepared according to GP8 from 2,4-dimethoxy-5-methyl-pyrimidine 83b (175 mg, 1.0 
mmol) in dry THF (0.5 mL), and TMPMgCl·LiCl (1.20 m in THF; 0.92 mL, 1.1 mmol) 
[reaction conditions: -5 °C, 3 h]; CuCl·2LiCl (1.2 mL, 1.2 equiv) and NEt3 (121 mg, 
1.2 equiv) to afford the corresponding cuprated reagent 97b; N-lithium morpholide (96b) (2 
mmol, preparation described in TP1); chloranil (298 mg, 1.2 equiv) in 7 mL of THF. 
Purification by flash chromatography (SiO2, pentane/Et2O = 9:1) afforded 98b (171 mg, 72 
%) as a colourless oil.  
IR (Diamond ATR): ν (cm-1) =  2956 (w), 2924 (w), 2852 (w), 1584 (s), 1564 (vs), 1456 (s), 
1372 (vs), 1360 (vs), 1260 (m), 1212 (s), 1188 (m), 1148 (s), 1112 (s), 1084 (m), 1044 (s), 
988 (m), 860 (w), 792 (m). 
1H NMR (300 MHz, CDCl3): δ (ppm) = 3.92 (s, 3H), 3.89 (s, 3H), 3.77 (t, J = 4.7 Hz, 4H), 
3.31 (t, J = 4.8 Hz, 4H), 1.95 (s, 3H). 
13C NMR (75 MHz, CDCl3): δ (ppm) = 170.3, 167.3, 162.2, 95.3, 66.8, 66.8, 54.1, 53.9, 
49.0, 49.0, 11.1. 
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HRMS (ESI) C11H17N3O3: calculated [M]+:  239.1270,    found: 239.1235. 
 
 
Synthesis of 6-morpholin-4-yl-1H-pyrimidine-2,4-dione (99a) 
 
N
H
NH
O
ON
O
 
 
A solution of 4-(2,6-dimethoxy-pyrimidin-4-yl)-morpholine (98a, 113 mg, 0.5 mmol) in 
acetyl chloride (1 mL) was stirred at reflux overnight in the presence of a few drops of water. 
The reagent was removed under vacuum. Methanol (3 x 15 mL) was added and distilled off. 
The residue was dissolved in 2-propanol/methanol (3:2) at reflux, and the solution was then 
cooled and the precipitate collected by filtration. The solid was dissolved in deionised water, 
and the clear solution was lyophilized to result in a white solid, which was dried under 
vacuum to afford 99a (88 mg, 91%). 
mp.: 290-300 oC (decomposed). 
IR (Diamond ATR): ν (cm-1) =  3160 (m), 3080 (w), 3020 (w), 2920 (w), 2872 (w), 1708 
(m), 1628 (s), 1596 (s), 1444 (s), 1376 (s), 1240 (s), 1112 (s), 1012 (s), 884 (s), 820 (s), 732 
(m), 700 (vs), 600 (vs). 
1H NMR (400 MHz, DMSO-d6): δ (ppm) = 9.76 (broads, 2H), 4.56 (s, 1H), 3.59 (t, J = 4.7 
Hz, 4H), 3.21 (t, J = 4.7 Hz, 4H) 
13C NMR (100 MHz, DMSO-d6): δ (ppm) = 165.1, 159.8, 154.4, 76.5, 65.8, 65.8, 45.7, 45.7. 
MS (70 eV, EI): m/z (%) = 197 (100) [M]+, 182 (31), 167 (21), 153 (17), 140 (41), 97 (18), 
68 (78), 56 (12). 
HRMS (ESI) C8H11N3O3 calculated [M]+:197.0800    found: 197.0796.  
 
 
Synthesis of 5-methyl-6-morpholin-4-yl-1H-pyrimidine-2,4-dione (99b) 
 
N
H
NH
O
ON
O
Me
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A solution of 4-(2,6-dimethoxy-5-methyl-pyrimidin-4-yl)-morpholine (98b, 119 mg, 0.5 
mmol) in acetyl chloride (1 mL) was stirred at reflux overnight in the presence of a few drops 
of water. The reagent was removed under vacuum. Methanol (3 x 15 mL) was added and 
distilled off. The residue was dissolved in 2-propanol/methanol (3:2) at reflux. The solution 
was then cooled and the precipitate collected by filtration. The solid was dissolved in 
deionised water, and the clear solution was lyophilized to result in a white solid, which was 
dried under vacuum to afford 99b (106 mg, 96%). 
mp.: 230-240 oC (decomposed). 
IR (Diamond ATR): ν (cm-1) =  3140 (broad w), 3040 (broad m), 2964 (m), 2860 (m), 2804 
(m), 1700 (s), 1628 (s), 1588 (vs), 1500 (s), 1408 (s), 1360 (s), 1196 (s), 1108 (s), 1024 (s), 
864 (s), 780 (s), 756 (s). 
1H NMR (400 MHz, DMSO-d6): δ (ppm) = 10.71 (broad s, 2H), 3.62 (t, J = 4.1 Hz, 4H), 
3.09 (t, J = 4.1 Hz, 4H), 1.71 (s, 3H).  
13C NMR (100 MHz, DMSO-d6): δ (ppm) = 165.5, 153.5, 150.7, 92.2, 66.2, 66.2, 48.2, 10.3. 
MS (70 eV, EI): m/z (%) = 211 (29) [M]+, 166 (16), 142 (79), 126 (15), 99 (25), 86 (21), 56 
(100), 44 (65). 
HRMS (ESI) C9H13N3O2: calculated [M]+: 211.0957   found: 211.0954. 
 
 
Synthesis of 2,6-dimethoxypyrimidin-4-ylamine (98c) 
 
N
N
OMe
OMeH2N
 
 
Prepared according to GP8 from 2,4-dimethoxypyrimidine (83a)(140 mg, 1 mmol, 1 equiv); 
TMPMgCl·LiCl (0.9 mL, 1.23 M in THF, 1.1 equiv)[reaction conditions: -40 °C, 12 h];  
CuCl·2LiCl (1.2 mL, 1.2 equiv) and (bis[2-(N,N-dimethylamino)ethyl] ether (192 mg, 1.2 
mmol, 1.2 equiv) to afford the corresponding cuprated reagent 97a; LiHMDS (96a, 2 mL, 2.0 
mmol, 1 M in THF/Ethylbenzene); chloranil (298 mg, 1.2 equiv) in 7 mL of THF. For the 
workup of this reaction, the organic layer was only washed one time with brine (50 mL). The 
crude material obtained was redissolved in THF (3 mL) before TBAF (1.0 M in THF) (2 mL, 
2 mmol) was added in one portion and the mixture was stirred at 25 °C for 10 min, poured 
over EtOAc (10 mL) and washed with deionised water (3 x 10 mL). The combined organic 
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extracts were dried (MgSO4), filtered and concentrated in vacuum. Purification by flash 
chromatography (Al2O3, CH2Cl2/MeOH 4%) afforded 98c (125 mg, 81%) as a colourless 
solid.  
mp.: 150.9-153.7 oC. 
IR (Diamond ATR): ν (cm-1) = 3452 (m), 3140 8m), 2952 (w), 1640 (s), 1572 (vs), 1452 (s), 
1352 (s), 1204 (vs), 1048 (s), 956 (s). 
1H NMR (400 MHz, DMSO-d6): δ (ppm) = 6.58 (broad s, NH2), 5.36 (s, 1H), 3.74 (s, 3H), 
3.73 (s, 3H). 
13C NMR (100 MHz, DMSO-d6): δ (ppm) = 171.0, 166.0, 164.9, 79.1, 53.5, 53.0.  
MS (70 eV, EI): m/z (%) = 155 (100) [M]+, 152 (68), 125 (18), 110 (11), 67 (6). 
HRMS (EI) C6H9N3O2: calculated [M]+: 155.0695   found: 155.0667. 
 
 
Synthesis of (tert-butyl-dimethyl-silanyl)-(2,6-dimethoxy-pyrimidin-4-yl)-indan-5-yl-
amine (98d)  
 
N
N
OCH3
N OCH3
TBS
 
 
Prepared according to GP8 from 2,4-dimethoxypyrimidine (83a)(140 mg, 1 mmol, 1 equiv), 
and TMPMgClLiCl (0.89 mL, 1.23 M in THF, 1.1 equiv)[reaction conditions: -40 °C, 12 h]; 
CuCl·2LiCl (2.4 mL, 1.2 equiv) and (bis[2-(N,N-dimethylamino)ethyl] ether (121 mg, 
1.2 equiv) to afford the corresponding cuprated reagent 97a; lithium-(t-butyl-dimethyl-
silanyl)-indan-5-yl-amine 96c (2.0 mmol, preparation described in TP2); chloranil (298 mg, 
1.2 equiv) in 7 mL of THF. Purification by flash chromatography (SiO2, n-pentane/Et2O = 
95:5) afforded 98d (296 mg, 76%) as a pale yellowish solid.  
mp.: 90.0-92.4 oC (brown). 
IR (Diamond ATR): ν (cm-1) = 2956 (w), 2928 (w), 2892 (w), 2856 (w), 1584 (s), 1552 (vs), 
1440 (s), 1352 (vs), 1256 (s), 1196 (vs), 1172 (s), 1064 (s), 976 (m), 836 (s), 800 (vs), 780 (s), 
680 (s), 672 (s). 
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1H NMR (600 MHz, CDCl3): δ (ppm) = 7.18 (d, J = 7.7 Hz, 1H), 6.88 (s, 1H), 6.80 (d, J = 
7.7 Hz, 1H), 4.86 (s, 1H), 3.97 (s, 3H), 3.78 (s, 3H), 2.89 (q, J = 7.9 Hz, 4H), 2.09 (q, J = 7.5 
Hz, 2H), 1.03 (s, 9H), 0.15 (s, 6H). 
13C NMR (150 MHz, CDCl3): δ (ppm) = 171.5, 170.6, 164.3, 145.8, 124.6, 141.4, 127.5, 
125.6, 125.1, 83.6, 54.6, 53.3, 32.8, 32.4, 23.4 (2 carbons from Si-(t-Bu) group), 25.8, 20.0, -
1.6 (2 carbons from SiMe2 group). 
MS (70 eV, EI): m/z (%) = 385 (7) [M]+, 370 (5), 328 (100), 189 (3), 164 (4), 115 (2), 89 (3), 
73 (2), 59 (2). 
HRMS (EI) C21H31N3O2Si: calculated [M]+: 385.2186    found: 385.2161. 
 
 
Synthesis of 2,4-dimethoxy-5-methyl-6-(2,2,6,6-tetramethyl-piperidin-1-yl)-pyrimidine 
(98e) 
 
N
N
OMe
N
Me
OMe
 
 
Prepared according to GP8 from 2,4-dimethoxy-5-methyl-pyrimidine (83b) (175 mg, 1.0 
mmol, 1 equiv) in dry THF (0.5 mL), and TMPMgCl·LiCl (1.20 m in THF; 0.92 mL, 1.1 
mmol) [reaction conditions: -5 °C, 3 h]; CuCl·2LiCl (1.2 mL, 1.2 equiv) and NEt3 (121 mg, 
1.2 equiv) to afford the corresponding cuprated reagent 97b;  TMPLi (96d) (2 mmol in Et2O, 
prepared according to the literature 160 ); chloranil (298 mg, 1.2 equiv) in 7 mL of THF. 
Purification by flash chromatography (SiO2, n-pentane/Et2O = 9:1) afforded 98e (205 mg, 
70%) as a colourless solid.  
mp.: 77.5-78.7 oC 
IR (Diamond ATR) 2980 (m), 2920 (s), 2872 (m), 2840 (m), 1560 (s), 1476 (m), 1448 (s), 
1372 (vs), 1356 (vs), 1200 (s), 1132 (s), 1076 (s), 1044 (s), 776 (s), 696 (m). 
1H NMR (300 MHz, CDCl3): δ (ppm) = 3.94 (s, 3H), 3.92 (s, 3H), 2.05 (s, 3H), 1.98-1.57 
(m, 6H), 1.40 (s, 6H), 0.74 (s, 6H). 
13C NMR (75 MHz, CDCl3): δ (ppm) = 171.2, 166.7, 161.9, 111.9, 55.0, 55.0, 54.2, 53.9, 
41.2, 41.2, 31.5, 31.5, 24.9, 24.9, 18.3, 11.9. 
                                                 
160
  Salman, H.; .Abraham, Y.; Tal, S.; Meltzman, S.; Kapon, M.; Tessler, N., Speiser, S.; Eichen, Y.  Eur. J. 
Org. Chem. 2005, 2207. 
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HRMS (ESI) C16H27N3O2: calculated [M+H]+ : 294.2182    found:  294.2176. 
 
 
Synthesis of 2,4-dimethoxypyrimidin-5-ylamine (98f)  
 
N
N
OMe
OMe
H2N
 
 
Prepared according to GP7 from 5-bromo-2,4-dimethoxypyrimidine (214 mg, 1 mmol, 1 
equiv), and i-PrMgCl·LiCl (1.17M in THF, 0.94 mL, 1.1 equiv)[reaction conditions: - 20°C, 
2 h]; CuCl·2LiCl (2.4 mL, 1.2 equiv) and (bis[2-(N,N-dimethylamino)ethyl] ether (121 mg, 
1.2 equiv) to afford the corresponding cuprated reagent 97c; LiHMDS (96a, 2 mL, 2.0 mmol 
1 M in THF/Ethylbenzene); chloranil (298 mg, 1.2 equiv) in 7 mL of THF. For the workup of 
this reaction, the organic layer was only washed one time with water (50 mL). The crude 
material obtained was redissolved in THF (3 mL) before TBAF (1.0 m in THF) (2 mL, 2 
mmol) was added in one portion and the mixture was stirred at 25 °C for 10 min, poured over 
EtOAc (10 mL) and washed with deionised water (3 x 10 mL). The combined organic extracts 
were dried (MgSO4), filtered and concentrated in vacuum. Purification by flash 
chromatography (Al2O3, CH2Cl2/MeOH 3%) afforded 98f (122 mg, 79%) as a colourless 
solid.  
mp.: 76.9-77.9 oC. 
IR (Diamond ATR): ν (cm-1) = 3404 (m), 3320 (m), 2960 (w), 1580 (s), 1484 (s), 1456 (s), 
1416 (s), 1376 (vs), 1284 (s), 1240 (s), 1200 (s), 1072 (s), 1016 (s), 936 (m), 904 (m), 776 
(m), 648 (s). 
1H NMR (300 MHz, CDCl3): δ (ppm) = 7.72 (s, 1H), 4.02 (s, 3H), 3.91 (s, 3H), 3.21 (broad 
s, NH2). 
13C NMR (75 MHz, CDCl3): δ (ppm) = 161.0, 158.2, 140.0, 123.6, 54.6, 54.1. 
MS (70 eV, EI): m/z (%) = 155 (100) [M]+, 140 (14), 126 (25), 110 (7), 83 (7), 70 (6), 58 (5), 
55 (6), 42 (7).  
HRMS (EI): m/z calc. for [C6H9N3O2] 155.0695, found: 155.0694. 
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Synthesis of (tert-Butyl-dimethyl-silanyl)-(2,4-dimethoxy-pyrimidin-5-yl)-(3,4,5-
trimethoxy-phenyl)-amine (98g) 
 
N
N
OMe
OMe
N
MeO
OMe
OMe
TBS
 
 
Prepared according to GP7 from 5-bromo-2,4-dimethoxypyrimidine (214 mg, 1 mmol, 1 
equiv), and i-PrMgCl·LiCl (1.17M in THF, 0.94 mL, 1.1 equiv)[reaction conditions: - 20°C, 
2 h]; CuCl·2LiCl (2.4 mL, 1.2 equiv) and bis[2-(N,N-dimethylamino)ethyl] ether (121 mg, 
1.2 equiv) to afford the corresponding cuprated reagent 97c; N-lithium-(tert-butyl-dimethyl-
silanyl)-(3,4,5-trimethoxy-phenyl)-amide (96e, 2 mmol, 2 equiv; prepared according to TP2 
from 3,4,5-trimethoxyphenylamine); chloranil (298 mg, 1.2 equiv) in 7 mL of THF. 
Purification by flash chromatography (SiO2, n-pentane/Et2O = 9:1) afforded 98g (mg, 68%) as 
a yellow oil.  
IR (Diamond ATR): ν (cm-1) = 2956 (w), 2932 (w), 2856 (w), 1588 (m), 1556 (m), 1504 
(m), 1460 (s), 1396 (s), 1376 (vs), 1280 (m), 1232 (s), 1184 (m), 1124 (s), 1076 (s), 1012 (s), 
932 (m), 804 (s). 
1H NMR (300 MHz, CDCl3): δ (ppm) = 8.07 (s, 1H), 6.13 (s, 2H), 3.97 (s, 3H), 3.91 (s, 3H), 
3.75 (s, 3H), 3.73 (s, 6H), 0.92 (s, 9H), 0.14 (s, 6H).  
13C NMR (75 MHz, CDCl3): δ (ppm) = 168.8, 162.5, 158.6, 152.9, 152.9, 145.2, 133.2, 
124.0, 100.5, 100.5, 60.9, 55.9, 55.9, 54.9, 53.9, 27.4 (2 carbons from Si-(t-Bu) group), 20.1, -
2.6 (2 carbons from SiMe2 group). 
MS (70 eV, EI): m/z (%) = 435 (54) [M]+, 378 (58), 363 (100), 348 (47), 332 (7), 318 (8), 
233 (3), 181 (4), 167 (3), 89 (17), 73 (29).  
HRMS (EI) C21H33N3O5Si: calculated [M]+: 435.2189   found: 435.2170. 
 
 
Synthesis of 5-(1,1,1,3,3,3-hexamethyl-disilazan-2-yl)-4-iodo-2,6-dimethoxy-pyrimidine 
(98h)  
N
N
OMe
OMeI
(TMS)2N
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Prepared according to GP8 from 4-iodo-2,6-dimethoxypyrimidine (87b) (1.33 g, 5 mmol, 1 
equiv), and TMPMgCl·LiCl (1.16 M in THF, 4.75 mL, 1.1 equiv)[reaction conditions: -0 °C, 
1 h]; CuCl·2LiCl (6.0 mL, 1.2 equiv) and NEt3 (605 mg, 1.2 equiv) to afford the 
corresponding cuprated reagent 97d; and LiHMDS (96a, 10 mL, 10.0 mmol, 1 M in 
THF/Ethylbenzene); chloranil (1.47 g, 1.2 equiv) in 35 mL of THF. Purification by flash 
chromatography (Al2O3, n-pentane/ Et2O = 9:1) afforded 98h (276 mg, 65%) as a pale 
yellowish solid.  
mp.: 85.1-87.2 oC. 
IR (Diamond ATR): ν (cm-1) = 2956 (w), 2900 (w), 1560 (m), 1520 (s), 1456 (s), 1364 (s), 
1304 (s), 1252 (s), 1180 (s), 1080 (s), 1020 8s), 896 (vs), 836 (vs), 816 (vs), 804 (vs), 780 
(vs). 
1H NMR (300 MHz, CDCl3): δ (ppm) = 3.94 (s, 3H), 3.90 (s, 3H), 0.12 (s, 9H). 
13C NMR (75 MHz, CDCl3): δ (ppm) = 166.6, 159.3, 137.8, 128.8, 55.2, 54.1, 2.3 (6C from 
two TMS group). 
HRMS (ESI) C12H24IN3O2Si2: calculated [M-H]+: 426.0531   found: 426.0521. 
 
 
Synthesis of 4-chloro-2,6-dimethoxy-5-(4-methyl-piperazin-1-yl)-pyrimidine (98i)  
 
N
N
OMe
OMeCl
N
N
 
 
Prepared according to GP8 from commercially available 4-chloro-2,6-dimethoxy pyrimidine 
(70a) (175 mg, 1.0 mmol) in dry THF (0.5 mL), and TMPMgCl·LiCl (1.20 m in THF; 0.92 
mL, 1.1 mmol) [reaction conditions: 25 °C, 1 h]; CuCl·2LiCl (1.2 mL, 1.2 equiv) and NEt3 
(121 mg, 1.2 equiv) to afford the corresponding cuprated reagent 97e; N-lithium piperazide 
(96f, prepared according to TP2 starting from N-methyl piperazine); chloranil (298 mg, 1.2 
equiv) in 7 mL of THF. Purification by flash chromatography (SiO2, CH2Cl2/MeOH; 95:5) 
afforded 98i (213 mg, 78%) as a white crystalline solid.  
mp.: 72.2-74.3 oC. 
IR (Diamond ATR): ν (cm-1) =  2931, 2840, 2792, 1586, 1533, 1459, 1452, 1385, 1334, 
1283, 1240, 1218, 1187, 1180, 1089, 1023, 1009, 943, 859, 786, 739, 635. 
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1H NMR (300 MHz, CDCl3): δ (ppm) = 3.93 (s, 3H, OMe), 3.91 (s, 3H, OMe), 2.99 (br.s, 
4H), 2.47 (br.s, 4H), 2.29 (s, 3H). 
13C NMR (75 MHz, CDCl3): δ (ppm) = 169.3, 160.3, 159.1, 123.5, 55.7, 55.2, 54.2, 49.5, 
46.3. 
MS (70 eV, EI): m/z (%) = 272 [M]+ (100), 237 (20), 209 (12), 200 (17), 202 (14), 201 (15), 
194 (9), 187 (20), 71 (34), 70 (11), 43 (20). 
HRMS (EI) C11H17O2N435Cl: calculated [M]+: 272.1040,   found: 272.1039.    
 
 
Synthesis of 4-chloro-2,6-dimethoxypyrimidin-5-amine (98j)  
 
N
N
OMe
OMe
Cl
H2N
 
 
Prepared according to GP8 from commercially available 4-chloro-2,6-dimethoxy pyrimidine 
(70a) (175 mg, 1.0 mmol) in dry THF (0.5 mL), and TMPMgCl·LiCl (1.20 m in THF; 0.92 
mL, 1.1 mmol) [reaction conditions: 25 °C, 1 h]; CuCl·2LiCl (1.2 mL, 1.2 equiv) and NEt3 
(121 mg, 1.2 equiv) to afford the corresponding cuprated reagent 97e; LiHMDS (96a, 2.0 
mmol); chloranil (298 mg, 1.2 equiv) in 7 mL of THF. The crude residue was dissolved in 
Et2O (3 mL) before TBAF (1.0 m in THF) (2 mL, 2 mmol) was added in one portion and the 
mixture was stirred at 25 °C for 10 min, poured over EtOAc (10 mL) washed with water (3 x 
10 mL). The combined organic extracts were dried (MgSO4), filtered and concentrated in 
vacuum. Purification by flash chromatography (SiO2, n-pentane/EtOAc; 8:2; 0.5 mol% NEt3) 
afforded 98j (114 mg, 60%) as a light brown solid. 
mp.: 76.0–77.5 oC. 
IR (Diamond ATR): ν (cm-1) = 3452, 3360, 2955, 1560, 1470, 1405, 1382, 1247, 1192, 
1123, 1083, 1028, 941, 769. 
1H NMR (300 MHz, CDCl3): δ (ppm) = 4.03 (s, 3H, OMe), 3.91 (s, 3H, OMe), 3.62 (br.s, 
2H, NH2). 
13C NMR (150 MHz, CDCl3): δ (ppm) = 160.0, 156.1, 145.5, 120.3, 55.0, 54.8. 
MS (70 eV, EI): m/z (%) = 189 [M]+ (100), 174 (13), 160 (20), 159 (22), 124 (7), 104 (10), 
70 (10), 58 (7), 53 (9), 42 (10). 
HRMS (EI) C6H8O2N335Cl: calculated [M]+ :189.0305    found: 189.0314.    
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Synthesis of 4-(5-bromo-pyrimidin-2-yl)-morpholine (98k)  
 
N N
Br
N
O
 
 
Prepared according to GP7 from 5-bromo-2-iodo-pyrimidine (284 mg, 1.0 mmol, 1 equiv) in 
dry THF (3.0 mL), and i-PrMgCl (0.92 mL, 1.20 m in THF, 1.1 mmol) [reaction conditions: -
80 °C, 0.5 h]; CuCl·2LiCl (1.2 mL, 1.2 equiv) and NEt3 (121 mg, 1.2 equiv), [reaction 
conditions: -80 °C, 1.5 h], to afford the corresponding cuprated reagent 97f; N-lithium 
morpholine (96b, 2.0 mmol, preparation described in TP1), [reaction conditions: -80 °C, 1.5 
h]; chloranil (298 mg, 1.2 equiv) in 7 mL of THF. Purification by flash chromatography 
(SiO2, n-pentane/CH2Cl2 = 6:1) afforded 98k (170 mg, 70%) as colourless needles.  
mp.: 125.0-127.7 oC. 
IR (Diamond ATR): ν (cm-1) = 2960 (m), 2924 (m), 2868 (m), 1576 (s), 1496 (vs), 1452 
(vs), 1356 (s), 1304 (s), 1248 (vs), 1112 (vs), 952 (vs), 848 (s), 788 (s). 
1H NMR (300 MHz, CDCl3): δ (ppm) = 8.29 (s, 2H), 3.78-3.71 (m, 8H). 
13C NMR (75 MHz, CDCl3): δ (ppm) = 159.9, 157.9, 157.9, 106.2, 66.7, 66.7, 44.4, 44.4. 
MS (70 eV, EI): m/z (%) = 245 (81)[M]+, 243 (79), 228 (23), 214 (89), 212 (73), 200 (24), 
188 (49), 186 (51), 160 (100), 158 (90), 107 (6), 79 (11), 53 (7). 
HRMS (EI) C8H1081BrN3O: calculated [M]+: 245.0001,   found: 244.9971. 
 
 
Synthesis of 5-bromo-4-(4-methyl-piperazin-1-yl)-pyrimidine (98l)  
 
N N
Br
N
N
 
 
Prepared according to GP8 from commercially available 5-bromopyrimidine (160 mg, 1.0 
mmol) in dry THF (1.0 mL), and TMPMgCl·LiCl (1.31 m in THF; 0.92 mL, 1.2 mmol) 
[reaction conditions: -55 to -40 °C, 2 h]; CuCl·2LiCl (1.2 mL, 1.2 equiv) and NEt3 (121 mg, 
1.2 equiv) to afford the corresponding cuprated reagent 97g; N-lithium 4-methylpiperazide 
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(96f, prepared according TP1 starting from N-methylpiperazine); chloranil (298 mg, 1.2 
equiv) in 7 mL of THF. Purification by flash chromatography (SiO2, CH2Cl2/MeOH = 98:2) 
afforded 98l (169 mg, 66%) as pale yellowish oil. 
IR (Diamond ATR): ν (cm-1) = 2936 (w), 2848 (w), 2796 (m), 1564 (vs), 1516 (m), 1444 (s), 
1360 (m), 1252 (m), 1140 (s), 1008 (s), 956 (m), 764 (w). 
1H NMR (300 MHz, CDCl3): δ (ppm) = 8.56 (s, 1H), 8.41 (s, 1H), 3.76 (t, J = 4.7 Hz, 4H), 
2.58 (t, J = 4.9 Hz, 4H), 2.37 (s, 3H). 
13C NMR (75 MHz, CDCl3): δ (ppm) = 161.0, 159.6, 156.0, 104.7, 54.6, 54.6, 47.2, 47.2, 
45.8. 
MS (70 eV, EI): m/z (%) = 258 (12), 256 (14), 201 (10), 199 (15), 199 (10), 188 (35), 186 
(37), 160 (18), 158 (20), 83 (72), 70 (100).  
HRMS (EI) C9H1379BrN4: calculated [M]+:256.0324    found: 256.0303. 
 
 
4.7 Preparation of aminated purine 
 
Synthesis of 9-benzyl-6-chloro-8-morpholin-4-yl-9H-purine (106)  
 
N
N
N
N
Ph
Cl
N O
 
 
Prepared according to GP8 from 9-benzyl-6-chloro-9H-purine (102) (248 mg, 1 mmol, 1 
equiv), and TMPMgCl·LiCl (0.89 ml,1.23 M in THF, 1.1 equiv)[reaction conditions: -10 °C, 
3 h]; CuCl·2LiCl (1.2 mL, 1.2 equiv) and NEt3 (121 mg, 1.2 equiv) to afford the 
corresponding cuprated reagent 104; N-lithium morpholine (96b, 2.0 mmol); chloranil (298 
mg, 1.2 equiv) in 7 mL of THF, [reaction conditions: -78 to 50 °C, 12 h]. For the workup of 
this reaction, the organic layer was only washed one time with brine (50 mL). Purification by 
flash chromatography (SiO2, n-pentane/AcOEt = 1:1 with 0.5% NEt3) afforded 106 (207 mg, 
63%) as colourless oil. 
IR (Diamond ATR): ν (cm-1) = 2964 (w), 2920 (w), 2856 (w), 1596 (vs), 1572 (m), 1532 (s), 
1452 (m), 1380 (m), 1344 (m), 1264 (m), 1152 (m), 1116 (m), 920 (m), 732 (m). 
1H NMR (300 MHz, CDCl3): δ (ppm) = 8.55 (s, 1H), 7.37-7.30 (m, 3H), 7.16-7.14 (m, 2H), 
5.35 (s, 2H), 3.72 (t, J = 4.5 Hz, 4H), 3.37 (t, J = 4.9 Hz, 4H). 
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13C NMR (75 MHz, CDCl3): δ (ppm) = 158.1, 154.4, 150.2, 145.8, 134.9, 130.5, 129.1, 
129.1, 128.2, 126.4, 126.4, 66.1, 66.1, 49.7, 49.7, 47.5. 
MS (70 eV, EI): m/z (%) = 329 (15) [M+], 301 (11), 272 (29), 238 (10), 111 (12), 97 (20), 91 
(100), 83 (20), 69 826), 57 (32), 38 (21). 
HRMS (EI) C16H16 ClN5O: calculated [M]+: 329.1043    found: 329.1024. 
 
 
Synthesis of diethyl-(6-iodo-9-methyl-9H-purin-8-yl)-amine (107)  
 
N
N N
N
I
NEt2
 
 
Prepared according to GP8 from 6-Iodo-9-methyl-9H-purine (103) (370 mg, 1.4 mmol, 1 
equiv), and TMPMgClLiCl (1.25 ml,1.23 M in THF, 1.1  equiv)[reaction conditions: -10 °C, 
2 h]; CuCl·2LiCl (1.7 mL, 1.2 equiv) and NEt3 (170 mg, 1.2 equiv) to afford the 
corresponding cuprated reagent 105; N-lithium diethylamide (96g, 2.8 mmol, 2 equiv, 
prepared according to TP1 starting from dried diethyl amine); chloranil (417 mg, 1.2 equiv) 
in 10 mL of THF, [reaction conditions: -78 to 50 °C, 12 h]. Purification by preparative TLC 
(SiO2, dichloromethane/Et2O = 5:5 with 0.5% NEt3) afforded 107 (219 mg, 66%) as colourless 
oil. 
IR (Diamond ATR): ν (cm-1) = 2936 (m), 2868 (w), 1592 (vs), 1536 (vs), 1476 (s), 1372 (s), 
1324 (vs), 1252 (s), 1132 (s), 1068 (s), 1016 (s), 896 (s), 844 (vs), 784 (s), 704 (vs). 
1H NMR (300 MHz, CDCl3): δ (ppm) = 8.35 (s, 1H), 3.67 (s, 3H), 3.52 (q, J = 7.1 Hz, 4H), 
1.26 (t, J = 7.1 Hz, 6H). 
13C NMR (75 MHz, CDCl3): δ (ppm) = 157.7, 150.7, 149.1, 138.2, 113.5, 44.9, 44.9, 30.8, 
13.4, 13.4. 
MS (70 eV, EI): m/z (%) = 331 (60), 303 (33), 288 (100), 42 (7).  
HRMS (EI) C10H4IN4: calculated [M]+: 331.0294    found: 331.0286. 
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Synthesis of 6-chloro-9-isopropyl-2-morpholin-4-yl-9H-purine (110) 
 
N
N N
N
Cl
N
O
 
 
Prepared according to GP7 from 6-chloro-2-iodo-9-isopropyl-9H-purine (108) (322 mg, 1.0 
mmol) in dry THF (5.0 mL), and i-PrMgCl (0.92 mL, 1.20 m in THF, 1.1 mmol) [reaction 
conditions: -80 °C, 30 min]; The reaction mixture is added to CuCl·2LiCl (1.2 mL, 1.2 equiv) 
and NEt3 (121 mg, 1.2 equiv) added at -80 °C and stirred for 1.5 h N-lithium morpholine 
(96b, 2.0 mmol, preparation described in TP1) is added at -80 °C and stirred for 2 h to afford 
the corresponding amidocuprated reagent 109; chloranil (298 mg, 1.2 equiv) in 7 mL of THF, 
[reaction conditions: -78 °C, 2 h]. Purification by flash chromatography (SiO2, n-pentane/Et2O 
= 3:2) afforded 110 (170 mg, 69%) as colourless solid.  
mp.: 155.4-157.3 oC (red). 
IR (Diamond ATR): ν (cm-1) = 3096 (w), 2968 (w), 2924 (w), 2872 (w), 2852 (w), 1612 (m), 
1552 (s), 1528 (vs), 1440 (s), 1352 (s), 1224 (s), 1104 (vs), 932 (vs), 848 (s), 780 (s), 652 (s). 
1H NMR (300 MHz, CDCl3): δ (ppm) = 7.78 (s, 1H), 4.68 (sept, J = 6.8 Hz, 1H), 3.85-3.74 
(m, 8H), 1.56 (d, J = 6.9 Hz, 6H).   
13C NMR (75 MHz, CDCl3): δ (ppm) = 158.1, 153.3, 150.8, 139.8, 124.8, 66.7, 66.7, 47.2, 
45.0, 45.0, 22.3, 22.3. 
MS (70 eV, EI): m/z (%) =    281 (81), 252 (31), 250 (100), 236 (21), 224 (50), 196 (44), 181 
(32), 154 (25), 119 (16).  
HRMS (EI) C12H16ClN5O: calculated [M]+: 281.1043    found: 281.1036. 
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Synthesis of 9-(2,2-dimethyl-6-trityloxymethyl-tetrahydro-furo[3,4-d] [1,3]dioxol-4-yl)-6-
(4-methyl-piperazin-1-yl)-9H-purine (113)  
 
N
N N
N
N
O
OO
N
Me
TrO
 
 
Prepared according to GP7 from 6-chloro-2-iodo-9-isopropyl-9H-purine (111) (330 mg, 0.5 
mmol) in dry THF (1.0 mL), and i-PrMgCl (0.46 mL, 1.20 m in THF, 0.55 mmol) [reaction 
conditions: -50 °C, 3 h]; CuCl·2LiCl (0.6 mL, 1.2 equiv) and NEt3 (61 mg, 1.2 equiv), to 
afford the corresponding cuprated reagent 112; N-lithium 4-methylpiperazide (96f, 1.0 mmol, 
prepared according to TP1 starting from N-methyl piperazine); chloranil (148 mg, 1.2 equiv) 
in 4 mL of THF. Purification by flash chromatography (SiO2, chloroform/acetonitrile = 9:1) 
afforded 113 (221 mg, 70%) as pale yellowish crystalline oil.  
mp.: 95.1-100.5 oC (black, decomposed). 
IR (Diamond ATR): ν (cm-1) = 2936 (m), 2868 (m), 2792 (m), 1584 (vs), 1476 (s), 1448 (s), 
1380 (s), 1288 (s), 1248 (s), 1208 (s), 1072 (vs), 1004 (s), 872 (s), 764 (s), 748 (s), 700 (vs), 
632 (vs). 
1H NMR (400 MHz, DMSO-d6): δ (ppm) = 8.51 (s, 1H), 8.30 (s, 1H), 7.49-7.38 (m, 15H), 
6.45 (d, J = 1.5 Hz, 1H), 6.64 (dd, J = 6.3 Hz, J = 1.5 Hz, 1H), 5.18-5.16 (m, 1H), 4.55-4.52 
(m, 1H), 4.44 (broad s, 3H), 3.43-3.28 (m, 2H), 2.73-2.70 (m, 8H), 1.73 (s, 3H), 1.50 (s, 3H). 
13C NMR (100 MHz, DMSO-d6): δ (ppm) = 153.1, 151.7, 149.7, 143.4, 139.1, 128.0, 128.0, 
128.0, 128.0, 128.0, 128.0, 127.7, 127.7, 127.7, 127.7, 127.7, 127.7, 127.7, 126.9, 126.9, 
126.9, 119.6, 113.2, 89.3, 86.0, 85.7, 83.2, 81.4, 64.0, 64.0, 54.3, 54.3, 54.3, 45.3, 26.9, 25.2. 
HRMS (ESI) C37H40N6O4: calculated [M]+: 633.3190    found: 633.3186  
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Synthesis of 2-chloro-9-isopropyl-9H-purin-6-ylamine (116) 
 
 
N
N N
N
NH2
Cl
 
 
Prepared according to GP7 from 2-Chloro-6-iodo-9-isopropyl-9H-purine (114) (322 mg, 1.0 
mmol, 1 equiv) in dry THF (1.0 mL), and i-PrMgCl·LiCl ( 0.89 mL, 1.23 M in THF, 1.1 
mmol) [reaction conditions: -60 °C, 0.3 h]; CuCl·2LiCl (1.2 mL, 1.2 equiv) and (bis[2-(N,N-
dimethylamino)ethyl] ether (192 mg, 1.2 mmol, 1.2 equiv), [reaction conditions: -60 °C, 1 h], 
to afford the corresponding cuprated reagent 115; LiHMDS (96a, 1 M in THF/Ethylbenzene, 
2 mL, 2.0 mmol) ; chloranil (298 mg, 1.2 equiv) in 7 mL of THF. Purification by flash 
chromatography (SiO2, dichloromethane/methanol = 95:5) afforded 116 (160 mg, 76%) as a 
pale yellowish solid.  
mp.: 253.5-254.9 oC (black). 
IR (Diamond ATR): ν (cm-1) = 3312 (m), 3140 (m), 2976 (w), 2936 (w), 1652 (s), 1596 (s), 
1568 (s), 1464 (m), 1348 (s), 1304 (s), 1248 (s), 1216 (s), 1196 (s), 1020 (s), 928 (s), 788 (s), 
680 (vs).  
1H NMR (400 MHz, DMSO-d6): δ (ppm) = 8.24 (s, 1H), 7.69 (broad s, NH2), 4.64 (sept, J = 
6.8 Hz, 6H). 
13C NMR (100 MHz, DMSO-d6): δ (ppm) = 156.7, 152.6, 150.0, 139.3, 118.0, 46.6, 22.0, 
22.0. 
MS (70 eV, EI): m/z (%) = 211 (68) [M]+, 196 (17), 171 (100), 134 (24), 108 (44), 80 (8), 53 
(10), 41 (14). 
HRMS (EI)C8H1035ClN5: calculated [M]+ : 211.0625    found: 211.0648.   
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Synthesis of (2-Chloro-9-isopropyl-9H-purin-6-yl)-(3-chloro-phenyl)-amine (117)  
 
N
N N
N
NH
Cl
Cl
 
 
Prepared according to GP7 from 2-chloro-6-iodo-9-isopropyl-9H-purine (114) (322 mg, 1.0 
mmol, 1 equiv) in dry THF (1.0 mL), and i-PrMgCl·LiCl (0.92 mL, 1.20 M in THF, 1.1 
mmol) [reaction conditions: -60 °C, 0.3 h]; CuCl·2LiCl (1.2 mL, 1.2 equiv) and (bis[2-(N,N-
dimethylamino)ethyl] ether (192 mg, 1.2 mmol, 1.2 equiv), [reaction conditions: -60 °C, 1 h], 
to afford the corresponding cuprated reagent 115; N-lithium (tert-butyl-dimethyl-silanyl)-(3-
chloro-phenyl)-amide (96h, 2.0 mmol, prepared according to TP2 starting from freshly 
distilled 3-chloro-phenylamine); chloranil (298 mg, 1.2 equiv) in 7 mL of THF. The crude 
residue was dissolved in Et2O (3 mL) before TBAF (1.0 m in THF) (2 mL, 2 mmol) was 
added in one portion and the mixture was stirred at 25 °C for 10 min, poured over EtOAc (10 
mL) washed with water (3 x 10 mL). The combined organic extracts were dried (MgSO4), 
filtered and concentrated in vacuum. Purification by flash chromatography (SiO2, 
dichloromethane/methanol = 95:5) afforded 117 (228 mg, 71%) as yellow solid. 
mp.: 131.3-132.3 oC  
IR (Diamond ATR): ν (cm-1) = 3240 (w), 2980 (w), 2920 (w), 2870 (w), 1624 (vs), 1570 
(vs), 1446 (s), 1423 (m), 1319 (m), 1218 (m), 1194 (m), 1076 (w), 1024 (s), 939 (m), 895 (m), 
880 (s), 772 (s). 
1H NMR (400 MHz, CDCl3): δ (ppm) = 8.55 (s, 1H), 8.12 (s, 1H), 7.93 (t, J = 2.0 Hz, 1H), 
7.70 (d, J = 8.1 Hz, 1H), 7.30 (t, J = 8.1 Hz, 1H), 7.11 (d, J = 8.0 Hz, 1H), 4.90 (sept, J = 6.8 
Hz, 1H), 1.64 (d, J = 6.7 Hz, 6H).  
13C NMR (150 MHz, CDCl3): δ (ppm) = 153.7, 152.0, 150.5, 139.3, 138.7, 134.7, 130.1, 
123.8, 120.0, 119.5, 118.1, 47.3, 22.8, 22.8. 
MS (70 eV, EI): m/z (%) = 321 (100) [M]+, 278 (67), 244 (87), 209 (9), 111 (10). 
HRMS (EI) C14H1335Cl2N5: calculated [M]+: 321.0548      found: 321.0537.   
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Synthesis of 2-[6-(3-chloro-phenylamino)-9-isopropyl-9H-purin-2-ylamino]-3-methyl-
butan-1-ol, purvalanol A (100) 
 
N
N N
N
HN
Cl
N
H
HO
 
 
To a solution of (2-chloro-9-isopropyl-9H-purin-6-yl)-(3-chloro-phenyl)-amine (117) (140 
mg, 0.43 mmol, 1 equiv) in n-butanol (1 mL) was added Hunig´s base (75 µL, 1 equiv) and 
D-valinol (220 mg, 5 equiv). The resulting solution was heated in a sealed tube at 150 °C for 
12 h. Following cooling down and evaporation to dryness, the resulting oil was purified by 
flash chromatography (SiO2, dichloromethane/methanol = 97:3) afforded 100 (108 mg, 65 %) 
as a colourless solid. 
mp.: 158.0-159.5 oC  
IR (Diamond ATR): ν (cm-1) = 3320 (w), 3240 (w), 2938 (m), 2924 (w), 2868 (w), 1636 (s), 
1576 (vs), 1472 (vs), 1452 (s), 1408 (s), 1360 (s), 1308 (s), 1244 (s), 1152 (m), 1096 (s), 1068 
(s), 1008 (vs), 876 (m), 848 (s), 768 (s), 700 (s), 636 (vs).  
1H NMR (300 MHz, CDCl3): δ (ppm) = 7.99 (broad s, 1H), 7.96 (broad s, 1H), 7.58 (s, 1H), 
7.42 (d, J = 8.0 Hz, 1H), 7.13 (t, J = 8.1 Hz, 1H), 6.99 (d, J = 7.5 Hz, 1H), 5.16 (d, J = 5.8 Hz, 
1H), 4.55 (sept, J = 6.8 Hz, 1H), 4.00-3.88 (m, 2H), 3.77-3.71 (m, 1H), 2.01 (m, 1H), 1.47 
(dd, J = 6.1 Hz, J = 4.7 Hz, 6H), 1.03 (d, J = 6.2 Hz, 6H). 
13C NMR (100 MHz, CDCl3): δ (ppm) = 159.5, 151.8, 151.8, 140.3, 135.1, 134.3, 129.7, 
122.7, 119.7, 117.7, 114.8, 65.2, 59.7, 46.8, 30.1, 22.5, 22.4, 19.5, 19.0. 
HRMS (ESI) C19H26O35ClN6: calculated [M+H]+: 389.1857    found: 389.1852.   
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5. Direct chemo- and regioselective zinc insertions into polyhalogenated 
N-heteroaryl compounds 
 
5.1 General procedure for the zinc insertion into polyiodo- and polybromo-heteroaryls 
compounds (GP9): 
Anhydrous LiCl was placed in an Ar-flushed flask and dried additionally 10-20 min at 150-
170 °C on high vacuum (1 mbar) or 2-3 min at 450 °C. Zinc powder was added under Ar, and 
heterogeneous mixture of Zn and LiCl was dried again 10-20 min at 150-170 °C on high 
vacuum (1 mbar). Afterwards flask was evacuated and refilled with argon three times. After 
the addition of THF, Zn was activated by treatment first with 1,2-dibromoethane (5 mol%) 
and then with chlorotrimethylsilane (2 mol%).53d,62 The substrate was added neat or dissolved 
in THF at the temperature T1. The completion of the insertion reaction was checked by GC 
analysis of reaction aliquots quenched with a solution of NH4Cl in water (the conversion was 
more than 90 %). The organozinc solution in THF was carefully removed from the rest of 
zinc powder using syringe and was transferred to the new dry and Ar-flushed flask. The 
electrophile or its solution in THF was added at the temperature T2. After the completion of 
the reaction (checked by GC analysis of reaction aliquots quenched with sat. aqueous NH4Cl 
solution) the reaction mixture was quenched with sat. aqueous NH4Cl (10 mL) solution. The 
aqueous layer was extracted with ethyl acetate or diethyl ether (3 x 10 mL). The combined 
organic extracts were dried with Na2SO4 and concentrated in vacuum. The crude residue was 
purified by flash column chromatography on silica gel. 
 
 
5.2 Starting material synthesis 
 
Synthesis of 4-chlorobenzenesulfonic acid 2-chloro-4,6-diiodo(pyridin-3-yl) ester (121g) 
 
N
OSO2Ar
I Cl
I
 
This material was prepared over two steps from commercially available 2-chloro-3-
hydroxypyridine according to the procedure reported by Knochel et al.161 
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Synthesis of 4-chlorobenzenesulfonic acid 2,4,6-triiodo(pyridin-3-yl) ester (121h) 
 
N
OSO2Ar
I I
I
 
 
 To a solution of 3-hydroxypyridine (9.5 g, 100 mmol) and Na2CO3 (45.6 g, 430 mmol) in 
water was added iodine (76.2 g, 300 mmol) with stirring at 25 °C. After 24 h, the solid is 
filtered off and dried to give 2,4,6-triiodo-pyridin-3-ol as a yellow solid. A dry 250 mL round-
bottomed flask, equipped with a magnetic stirrer and a septum, was charge with a solution of 
2,4,6-triiodo-pyridin-3-ol in dry CH2Cl2 (100 mL). After cooling to 0 °C, Et3N (18.8 mL, 135 
mmol) was added, and then 4-chloro-benzenesulfonyl chloride (23.5 g, 108 mmol) was added 
portionwise. After the addition was completed, the reaction mixture was stirred at 25 °C 
overnight. This mixture was diluted with CH2Cl2 (100 mL). Saturated aqueous NH4Cl 
solution (100 mL) was then added, and the resulting mixture was extracted with CH2Cl2 (2 × 
100 mL). The organic extracts were dried over anhydrous Na2SO4, and concentrated. 
Purification by flash chromatography (SiO2, n-pentane/ether = 40:1) afforded 121h (37.5 g, 
58 %; overall yield of two steps) as a yellow solid. 
mp.: 154.4-154.8 °C.  
IR (KBr): ν (cm-1) = 3078 (m), 1584 (m), 1511 (m), 1497 (s), 1474 (m), 1374 (vs), 1287 (s), 
1182 (s), 1166 (m), 1083 (m), 1011 (w).  
1H-NMR (CDCl3, 300 MHz): δ (ppm) =  8.09 (s, 1H), 7.95 (d, J = 8.8 Hz, 2H), 7.58 (d, J = 
8.8 Hz, 2H).  
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 150.8, 144.6, 142.1, 135.9, 134.4, 129.9, 113.1, 
113.0, 103.0;  
MS (70 eV, EI): m/z (%): 646 (100, M+), 518 (12), 471 (25), 344 (28), 253 (21), 189 (15), 
175 (79), 127 (11), 111 (26).  
HRMS (EI) C11H5ClI3NO3S: calculated [M]+: 646.6813  found: 646.6824. 
 
 
Synthesis of p-toluenesulfonic acid 3,5-dibromo(pyridin-2-yl) ester (121i) 
 
N
Br
OTs
Br
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This material was prepared from commercially available 3,5-dibromo-2-hydroxypyridine 
according to the procedure reported by Knochel et al.162 
 
 
Synthesis of diisopropylcarbamic acid 2,6-diiodo(pyridin-3-yl) ester (121j) 
 
N
O
I I
O(Pri)2N
 
This material was prepared from commercially available 3-hydroxy-2,6-diiodopyridine 
according to the procedure from the literature.163 
 
 
Synthesis of 4,5-diiodo-2-methyl-1-(p-toluenesulfonyl)-1H-imidazole (121k) 
 
N
NI
I
Ts
 
To a mixture of 4,5-diiodo-2-methyl-1H-imidazol144 (10.0 g, 30 mmol) and p-toluenesulfonyl 
chloride (5.9 g, 31 mmol) in acetone (50 mL) at 25 °C was added Et3N (90 mmol), and the 
resulting mixture was stirred at 25 °C for 12 h. The solvent was removed under vacuum, and 
the residue was purified by flash chromatography (SiO2, n-pentane/diethyl ether = 2/1) 
afforded 121k (13.7 g, 94 %) as a light yellow solid 
mp.:119.3-121.4 °C 
IR (film): ν (cm-1) = 2950 (w), 1593 (w), 1520 (m), 1385 (s), 1371 (s), 1280 (m), 1158 (s), 
1093 (s), 995 (w), 814 (w), 665 (m), 578 (m). 
1H NMR (CDCl3, 300 MHz): δ (ppm) = 7.86 (d, 3J(H,H) = 8.3 Hz, 2H), 7.37 (d, 3J(H,H) = 
8.5 Hz, 2H), 2.78 (s, 3H), 2.45 (s, 3H). 
13C NMR (CDCl3, 75 MHz): δ (ppm) = 152.1, 146.7, 134.4, 130.2, 130.2, 128.0, 128.0, 
127.9, 76.8, 21.8, 18.2. 
MS (EI, 70 eV): m/z (%) = 487 (100), 154 (75), 90 (71), 65 (11). 
HRMS (EI) C11H10N2O2I2: calculated [M]+: 487.8552     found: 487.8551. 
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Synthesis of 2,3-diiodo-1-(p-toluenesulfonyl)-1H-indole (121l) 
 
N
SO2Ph
I
I
 
This material was prepared from commercially available 1H-indole according to the 
procedure from the literature.164 
 
 
Synthesis of p-toluenesulfonic acid 5,7-diiodoquinolin-8-yl ester (121m) 
 
N
I
OTs
I
 
This material was prepared from commercially available 5,7-diiodo-8-quinolinol according to 
the procedure from the literature.165 
 
 
Synthesis of 2,4-dibromothiazole (121n) 
 
N
S
Br
Br
 
This material was prepared from commercially available 2,4-thiazolidinedione according to 
the procedure from the literature.166 
 
 
Synthesis of 2,4,6-tribromopyrimidine (121o) 
 
N N
Br
Br
Br
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This material was prepared from commercially available barbituric acid according to the 
procedure from the literature.104 
 
 
5.3 Preparation of halogenated functionalized N-heterocycles via direct zinc insertion 
 
Synthesis of 4-chlorobenzenesulfonic acid 2-chloro-4-(2-cyclohexen-1-yl)- 6-
iodo(pyridin-3-yl) ester (123g)  
N
OSO2Ar
I Cl
 
Prepared according to GP9 from 4-chlorobenzenesulfonic acid 2-chloro-4,6-diiodo(pyridin-3-
yl) ester[2] (121g) (1.112 g, 2 mmol), LiCl (172 mg, 4 mmol), zinc dust (260 mg, 4 mmol, 2.0 
equiv, <10 micron, 98+%, Aldrich), BrCH2CH2Br (5 mol%), Me3SiCl (2 mol%). Insertion 
conditions: 0 °C, 2.5 h; reaction with electrophile: transmetalation with CuCN·2LiCl (5 mol 
%) at –20 °C, followed by addition of 3-bromocyclohex-1-ene (2.3 mmol) at T2 = –20 oC. The 
reaction mixture was allowed to warm gradually to 25 °C and stirred for 4 h. Purification by 
flash chromatography (SiO2, n-pentane/ethyl acetate = 98:2) afforded 123g (846 mg, 83%) as 
white solid. 
mp.: 183.2-184.3 ˚C. 
IR (): ν (cm-1) = 2934 (w), 2910 (w), 1565 (m), 1403 (w), 1371 (s), 1335 (m), 1313 (w), 1187 
(s), 1147 (s), 1084 (m), 865 (w), 773 (s), 708 (m). 
1H-NMR (CDCl3, 300 MHz) δ (ppm) = 7.97 (d, 3J(H,H) = 7.9 Hz, 2H), 7.60 (d, 3J(H,H) = 
7.3 Hz, 3H), 6.02 (m, 1H), 5.54 (dd, 3J(H,H) = 10.1 Hz, 4J(H,H) = 2.0 Hz, 1H), 3.89 (m, 1H), 
2.14 (m, 3H), 1.75-1.39 (m, 3H).    
13C-NMR (CDCl3, 75 MHz) δ (ppm) = 154.6, 144.7, 141.8, 141.7, 134.9, 134.8, 130.9, 
129.9, 129.8, 129.8, 129.7, 126.5, 111.9, 36.0, 30.5, 24.6, 20.8. 
MS (70 eV, EI) m/z (%) = 511 (16), 509 (22), 336 (34), 335 (40), 334 (100), 333 (48), 292 
(34), 207 (36), 175 (17), 115 (13), 111 (23), 77 (10).   
HRMS (EI) C17H14Cl2INO3S: calculated [M+]: 508.9116    found: 508.9130. 
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Synthesis of 2-{3-[(4-chlorobenzenesulfonyl)oxy]-2,6-diiodo(pyridin-4-yl)}methylacrylic 
acid ethyl ester (123h) 
 
N
OSO2Ar
I I
CO2Et
 
 
Prepared according to GP9 from 4-chlorobenzenesulfonic acid 2,4,6-triiodopyridin-3-yl ester 
121h (647 mg, 1 mmol), LiCl (86 mg, 2 mmol), zinc dust (130 mg, 2 mmol, 2.0 equiv, <10 
micron, 98+%, Aldrich), BrCH2CH2Br (5 mol%), Me3SiCl (2 mol%). Insertion conditions: 0 
°C, 3 h; reaction with electrophile: 2-bromomethyl acrylate (232 mg, 1.2 mmol) was added 
followed by the addition of CuCN·2LiCl(one drop of 1.0 M solution in THF, ca. 0.02 mmol, 
ca. 0.4 mol%) at -30 oC. The reaction mixture was afterwards warmed to 25 °C for 1h. 
Purification by flash chromatography (SiO2, n-pentane/ether = 4:1) afforded 123h (482 mg, 
80%) as colourless liquid. 
IR (Diamond ATR): ν (cm-1) = 3092 (w), 2979 (w), 1709 (vs), 1632 (w), 1554 (m), 1516 
(m), 1388 (vs), 1316 (s), 1237 (m), 1189 (s), 1134 (s), 1083 (s), 1014 (m), 955 (w). 
1H-NMR (CDCl3, 300 MHz): δ (ppm) = 7.96 (d, 3J(H,H) = 8.8 Hz, 2H), 7.58 (d, 3J(H,H) = 
8.8 Hz, 2H), 7.47 (s, 1H), 6.40 (s, 1H), 5.74 (s, 1H), 4.14 (q, 3J(H,H) = 7.1 Hz, 2H), 3.77 (s, 
2H), 1.22 (t, 3J(H,H) = 7.1 Hz, 3H). 
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 165.6, 147.8, 145.9, 142.0, 136.2, 135.8, 135.1, 
130.3, 129.8, 129.4, 114.3, 113.2, 61.2, 33.4, 14.1. 
MS (70 eV, EI): m/z (%) = 633 (62) [M]+, 458 (54), 441 (63), 413 (100), 331 (84), 286 (49), 
259 (30), 204 (35), 175 (43), 159 (27), 127 (43), 111 (45). 
HRMS (EI) C17H14ClI2NO5S: calculated [M]+: 632.8371   found: 632.8374. 
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Synthesis of p-toluenesulfonic acid 3-benzoyl-5-bromo(pyridin-2-yl) ester (123i) 
 
N
COPh
OTs
Br
 
 
Prepared according to GP9 from p-toluenesulfonic acid 3,5-dibromo(pyridin-2-yl) ester 121i 
(1.63 g, 4 mmol), LiCl (258 mg, 6 mmol), zinc dust (390 mg, 6 mmol, 1.5 equiv, <10 micron, 
98+%, Aldrich), BrCH2CH2Br (5 mol%), Me3SiCl (2 mol%). Insertion condition: 25 °C, 12 
h; reaction with electrophile: transmetalation with CuCN·2LiCl (1 equiv.) 10 min at 0°C, 
followed by addition of benzoyl chloride at T2 = –78 °C. The reaction mixture was stirred 
afterwards for 1 h at –78 °C and warmed to 25 °C for 3 h. Purification by flash 
chromatography (SiO2, n-pentane/ ether = 1:1) afforded 123i (1.40 g, 81%) as a white solid.  
mp.: 102.5-103.1 oC.   
IR (KBr): ν (cm-1) = 3060 (m), 1659 (vs), 1598 (s), 1572 (s), 1382 (vs), 1173 (vs), 689 (vs). 
1H NMR (CDCl3, 300 MHz) δ (ppm) = 8.43 (d, 4J(H,H) = 2.7 Hz, 1H), 7.94 (d, 4J(H,H) = 
2.7 Hz, 1H), 7.54-7.71 (m, 5H), 7.43 (d, 3J(H,H) = 8.0 Hz, 2H), 7.20 (d, 3J(H,H) = 8.0 Hz, 
2H), 2.35 (s, 3H). 
13C-NMR (CDCl3, 75 MHz) δ (ppm) =190.5, 152.4, 150.5, 145.4, 142.2, 135.6, 134.0, 
133.1, 129.7, 129.4, 128.5, 128.3, 127.5, 117.9, 21.5. 
MS (70 eV, EI) m/z (%) = 369 (M+ (81Br)-C5H4, 13), 367 (M+ (79Br)-C5H4, 13), 340 (14), 
288(31), 155 (22), 91 (100). 
HRMS (EI) C19H15BrNO4S: calculated [M+H]+: 431.9900   found: 431.9923. 
 
 
Synthesis of diisopropylcarbamic acid 2-allyl-6-iodo(pyridin-3-yl) ester (123j) 
 
N
O
I
O(Pri)2N
 
 
Prepared according to GP9 from diisopropylcarbamic acid 2,6-diiodo(pyridin-3-yl) ester 121j 
(948 mg, 2 mmol), LiCl (129 mg, 3 mmol), zinc dust (216 mg, 3 mmol, 1.5 equiv, <10 
micron, 98+%, Aldrich), BrCH2CH2Br (5 mol%), Me3SiCl (2 mol%). Insertion conditions: 25 
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°C, 5 h; reaction with electrophile: allyl bromide (1.3 equiv) was added, followed by the 
addition of one drop of CuCN·2LiCl (a 1.0 M solution in THF was used, ca. 0.02 mmol, ca. 
0.5 mol %) at –20°C. The crude residue was purified by column chromatography (SiO2, n-
pentane/ ether = 3:2) afforded 123j (645 mg, 83%) as colourless oil. 
IR (KBr): ν (cm-1) = 2970 (w), 1717 (s), 1575 (w), 1422 (s), 1314 (s), 1242 (s), 1172 (m), 
1242 (m), 1153 (m), 1041 (w), 980 (w), 861 (w). 
1H NMR (CDCl3, 300 MHz): δ (ppm) = 7.55 (d, 3J(H,H)J = 8.3 Hz, 1H), 7.08 (d, 3J(H,H) = 
8.3 Hz, 1 H), 6.04-5.91 (m, 1H), 5.09 (m, 1H), 5.05 (dd, 3J(H,H) = 7.4 Hz, 2J(H,H) = 1.5 Hz, 
1H), 4.10 (broad m, 1H), 3.93 (broad m, 1H), 3.15 (m, 2H), 1.30 (d, 3J(H,H) = 6.8 Hz, 12H).      
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 154.9, 152.1, 146.4, 134.1, 133.2, 132.5, 116.6, 
111.5, 46.8, 46.8, 37.5, 21.4, 20.4. 
MS (70 eV, EI): m/z (%)= 387.3 (M+), 259.5 (16), 127.9 (100), 69.9 (3), 42.9 (41).  
HRMS (EI) C15H21IN2O4: calculated [M]+: 388.0648    found: 388.0638. 
 
 
Synthesis of  5-allyl-4-iodo-2-methyl-1-(p-toluenesulfonyl)-1H-imidazole (123k) 
 
N
N
I
Ts
 
 
Prepared according to GP9 from 4,5-diiodo-2-methyl-1H-imidazole 121k (1.95 g, 4 mmol), 
LiCl (258 mg, 6 mmol), zinc dust (390 mg, 6 mmol, 1.5 equiv, <10 micron, 98+%, Aldrich), 
BrCH2CH2Br (5 mol%), Me3SiCl (2 mol%). Insertion condition: 50 °C, 1 h; reaction with 
electrophile: allyl bromide (1.1 equiv) was added, followed by the addition of one drop of 
CuCN·2LiCl (a 1.0 M solution in THF was used, ca. 0.02 mmol, ca. 0.5 mol %) at –20 °C. 
The crude residue was purified by column chromatography (SiO2, n-pentane/ ether = 3:2) 
afforded 123k (1.28 g, 80 %) as white needles. 
mp.: 126.5-127.5 oC 
IR (KBr): ν (cm-1) = 3080 (w), 3018 (w), 2982 (w), 1642 (w), 1593 (w), 1524 (m), 1389 (m), 
1373 (s), 1292 (s), 1193 (s), 1166 (s), 1114 (s), 1085 (m), 993 (m), 903 (m), 818 (w), 670 (m), 
580 (m).  
1H NMR (CDCl3, 300 MHz): δ (ppm) = 7.96 (d, 3J(H,H) = 8.4 Hz, 2H), 7.34 (d, 3J(H,H) = 
8.0 Hz, 2H), 5.80 (m, 1H), 5.06 (m, 1H), 5.02 (dd, 3J(H,H) = 5.7 Hz and 2J(H,H) = 1.4 Hz, 
1H), 3.59 (d, 3J(H,H) = 5.9 Hz, 2H), 2.58 (s, 3H), 2.45 (s, 3H).   
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13C-NMR (CDCl3, 75 MHz): δ (ppm) = 148.5, 146.2, 135.4, 133.4, 132.3, 130.3, 130.3, 
127.2, 127.2, 116.9, 88.0, 30.7, 21.7, 16.9. 
MS (70 eV, EI): m/z (%) = 401.9 (M, 100), 246.9 (24), 154.9 (64), 119.9 (10), 94.0 (12), 90.9 
(89), 65.0 (13). 
HRMS (EI) C14H15IN2O2S: calculated [M+]: 401.9894    found: 401.9894. 
 
 
Synthesis of  (1-benzenesulfonyl-3-iodo-1H-indol-2-yl) phenyl ketone (123l) 
 
N
SO2Ph
I
COPh
 
 
Prepared according to GP9 from 2,3-diiodo-1-benzenesulfonyl-1H-indole (121l) (2.03 g, 4 
mmol), LiCl (258 mg, 6 mmol), zinc dust (390 mg, 6 mmol, 1.5 equiv, <10 micron, 98+%, 
Aldrich), BrCH2CH2Br (5 mol%), Me3SiCl (2 mol%). Insertion condition: 50 °C, 2 h; 
reaction with electrophile: transmetalation with CuCN·2LiCl (1 equiv.) 10 min at 0°C, 
followed by addition of benzoyl chloride at T2 = –78 °C. The reaction mixture was stirred 
afterwards for 1 h at –78 °C and warmed to 25 °C for 3 h. Purification by flash 
chromatography (SiO2,  n-pentane/ether = 1:1) afforded 123l (1.63 g, 83%) as a white solid.  
mp.: 144.9-147.0 oC 
IR (KBr): ν (cm-1) = 3067 (w), 1671 (m), 1595 (w), 1446 (m), 1372 (s), 1250 (m), 1174 (s), 
1148 (s), 1186 (m), 1052 (w), 951 (m), 732 (s), 720 (m), 681 (m).  
1H NMR (CDCl3, 300 MHz): δ (ppm) = 8.08-7.92 (m, 5H), 7.73-7.35 (m, 9H). 
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 189.1, 137.5, 136.9, 136.7, 135.3, 134.3, 134.0, 
131.8, 130.0, 129.2, 128.8, 127.5, 127.2, 124.9, 122.9, 114.5, 72.6. 
MS (70 eV, EI) m/z (%) = 488.9 (M, 100), 345.9(64), 218.9 (80), 190.9 (31), 105.0 (11), 77.0 
(33). 
HRMS (EI) C21H14INO3S: calculated [M+]: 486.9739   found: 486.9721. 
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Synthesis of p-toluenesulfonic acid 7-(2,2-dimethylpropionyl)-5-iodo(quinolin-8-yl) ester 
(123m) 
N
I
OTs
O
t-Bu
 
 
Prepared according to GP9 from p-toluenesulfonic acid 5,7-diiodo(quinolin-8-yl) ester 121m 
(1.10 g, 2 mmol), LiCl (172 mg, 3 mmol), zinc dust (260 mg, 3 mmol, 1.5 equiv, <10 micron, 
98+%, Aldrich), BrCH2CH2Br (5 mol%), Me3SiCl (2 mol%). Insertion conditions: 25 °C, 24 
h (Note: organozinc reagent has brown colour); reaction with electrophile: transmetalation 
with CuCN·2LiCl (1 equiv.) 10 min at 0°C, followed by addition of pivaloyl chloride at T2 = 
–50 °C. The reaction mixture was stirred afterwards for 1 h at –50 °C and warmed to 25 °C 
for 6 h. Purification by flash chromatography (SiO2,  n-pentane/ dichloromethane = 1:1) 
afforded p-toluenesulfonic acid 7-(2,2-dimethylpropionyl)-5-iodo(quinolin-8-yl) ester 123m 
(78%) as a pale yellow solid. 
mp.: 119.5-124.0 oC. 
IR (KBr): ν (cm-1) = 2968 (w), 1997 (s), 1477 (w), 1451 (w), 1372 (s), 1341 (m), 1206 (m), 
1177 (s), 1085 (s), 999 (m), 806 (m), 779 (s), 742 (s), 688 (m), 671 (s).  
1H NMR (CDCl3, 400 MHz): δ (ppm) = 8.87 (dd, 3J(H,H) = 4.1 Hz, 3J(H,H) = 1.5 Hz, 1H), 
8.34 (dd, 3J(H,H) = 8.5 Hz, 4J(H,H) = 1.5 Hz, 1H), 7.90 (d, 3J(H,H) = 8.3 Hz, 2H), 7.84 (s, 
1H), 7.53 (dd, 3J(H,H) = 8.5 Hz, 3J(H,H) = 4.1 Hz, 1H), 7.43 (d, 3J(H,H) = 8.4 Hz, 2H), 2.46 
(s, 3H), 1.12 (s, 9H).  
13C-NMR (CDCl3, 100 MHz): δ (ppm) = 208.4, 151.8., 145.1, 142.4, 142.3, 140.2, 136.0, 
134.3, 133.8, 131.2, 129.3, 128.8, 123.9, 96.3, 45.4, 26.7, 21.7. 
MS (70 eV, EI): m/z (%) = 451.9 ((M+-tBu); 100), 445.5 (47), 383.5 (21), 352.4 (12), 297.2 
(73), 270.7 (23), 155.0 (51), 91.0 (37).  
HRMS (EI) C21H20INO4S: calculated [M+]: 509.0158    found: 509.0164  
 
 
Synthesis of 2-(2-bromothiazol-4-yl)benzaldehyde (123n) 
 
N
S
Br
OHC
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Prepared according to GP9 from 2,4-dibromothiazole 121n (486 mg, 2 mmol), LiCl (172 mg, 
3 mmol), zinc dust (260 mg, 3 mmol, 1.5 equiv, <10 micron, 98+%, Aldrich), BrCH2CH2Br 
(5 mol%), Me3SiCl (2 mol%). Insertion conditions: 25 °C, 0.5 h; reaction with electrophile: 
tetrakis(triphenylphosphine)palladium (104 mg, 0.09 mmol) was added at 25 °C followed by 
addition of 2-iodobenzaldehyde (925 mg, 4 mmol) and the mixture was heated at 50 °C for 20 
h. Purification by flash chromatography (SiO2, n-pentane/diethyl ether = 1:1) afforded 2-(2-
bromothiazol-4-yl)benzaldehyde 123n (455 mg, 85 %) as a colourless solid. 
mp.: 121.1-123.5 oC. 
IR (KBr): ν (cm-1) = 3033 (w), 2790 (m), 2994 (w) 2741 (w), 1740 (s), 1452 (s), 1386 (m), 
1233 (m), 1016 (s), 740 (m). 
1H NMR (CDCl3, 400 MHz): δ (ppm) = 10.31 (s, 1H), 8.09 (s, 1H), 7.90 (dd, 3J(H,H) = 7.8 
Hz, 4J(H,H) = 1.5 Hz, 1H), 7.87 (dd, 3J(H,H) = 7.8 Hz, 4J(H,H) = 1.5 Hz, 1H), 7.80 (td, 
3J(H,H) = 7.4 Hz, 4J(H,H) = 1.1 Hz, 1H), 7.71 (tdd, 3J(H,H) = 7.6 Hz, 4J(H,H) = 1.2 Hz, 1H).   
13C-NMR (CDCl3, 100 MHz): δ (ppm) = 191.2, 165.7, 134.1, 133.9, 133.4, 130.7, 130.1, 
128.2, 124.9, 120.8. 
MS (70 eV, EI): m/z (%) = 268 (100), 266 (99), 192 (12), 105 (48), 77 (21), 51 (9). 
HRMS (EI) C10H6BrNOS: calculated [M+]: 266.9353    found: 266.9359.  
 
 
Synthesis of [2-(2,6-dibromopyrimidin-4-yl)methyl]acrylic acid ethyl ester (123o) 
 
N N
Br
Br
CO2Et
 
 
Prepared according to GP9 from 2,4,6-tribromopyrimidine 121o (628 mg, 2 mmol), LiCl (172 
mg, 3 mmol), zinc dust (260 mg, 3 mmol, 1.5 equiv, <10 micron, 98+%, Aldrich), 
BrCH2CH2Br (5 mol%), Me3SiCl (2 mol%).Insertion condition: 25 °C, 4 h (Note: organozinc 
reagent has brown colour); reaction with electrophile: ethyl (2-bromomethyl)acrylate (1.3 
equiv) was added, followed by the addition of one drop of CuCN·2LiCl (a 1.0 M solution in 
THF was used, ca. 0.02 mmol, ca. 0.4 mol %) at –78°C. The reaction mixture was stirred 
afterwards for 2 h and warmed up to 25 °C for 4 h. Purification by flash chromatography 
(SiO2, dichloromethane) afforded 2-[(2,6-dibromo-pyrimidin-4-yl)methyl]acrylic acid ethyl 
ester 123o (438 mg, 63%) as a colorless oil. 
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IR (film): ν (cm-1) = 2980 (w), 1711 (s), 1544 (s), 1510 (s), 1288 (w), 1223 (m), 1117 (w), 
778 (m). 
1H NMR (CDCl3, 400 MHz): δ (ppm) = 7.41 (s, 1H), 6.41 (s, 1H), 5.80 (s, 1H), 4.18 (q, 
3J(H,H) = 7.0 Hz, 2H), 3.72 (s, 2H), 1.20 (t, 3J(H,H) = 7.0 Hz, 3H)  
13C-NMR (CDCl3, 75 MHz): δ (ppm) = 171.6, 165.8, 153.1, 151.4, 135.4, 129.5, 123.5, 61.2, 
39.2, 14.1. 
MS (EI, 70 ev): m/z (%) = 349.9 (M+, 6), 320.8 (68), 304.9 (22), 276.9 (100), 195.7 (20), 43.8 
(17). 
HRMS (EI) C10H10Br2N2O2: calculated [M+]: 347.9109  found: 347.9100.  
 
 
Synthesis of biphenyl-4-yl-(4-iodo-2,6-dimethoxy-pyrimidin-5-yl)methanone (123p) 
 
N
N
OMe
OMeI
O
Ph
 
 
Prepared according to GP9 from 4,5-diiodo-2,6-dimethoxypyrimidine (89a) (266 mg, 1 
mmol), LiCl (86 mg, 1.5 mmol), zinc dust (130 mg, 1.5 mmol, 1.5 equiv, <10 micron, 98+%, 
Aldrich), BrCH2CH2Br (5 mol%), Me3SiCl (2 mol%). Insertion condition: 50 °C, 3 h; 
reaction with electrophile: transmetalation with CuCN·2LiCl (0.5 equiv.) 10 min at 0°C, 
followed by addition of biphenyl-4-carbonyl chloride (260 mg, 1.3 equiv, 1.2 mmol) at T2 = –
30 °C. The reaction mixture was stirred afterwards for 1 h at –30 °C and slowly warmed to 25 
°C for 14 h. Purification by flash chromatography (SiO2, pentane/ Et2O = 1:1) afforded 123p 
(333 mg, 83%) as a white solid. 
mp.:152.3-154.7 oC 
IR (KBr): ν (cm-1) =1664 (m), 1600 (m), 1570 (s), 1526 (s), 1460 (m), 1384 (s), 1369 (s), 
1311 (s), 1261 (s), 1200 (m), 1075 (s), 1008 (s), 916 (s). 
1H NMR (CDCl3, 600 MHz): δ (ppm) = 7.85 (d, J = 8.2 Hz, 2H), 7.63 (d, J = 8.2 Hz, 2H), 
7.57 (d, J = 7.1 Hz, 2H), 7.42-7.37 (m, 2H), 7.36-7.31 (m, 1H), 3.99 (s, 3H), 3.84 (s, 3H). 
13C NMR (CDCl3, 150 MHz): δ (ppm) = 190.2, 165.0, 161.1, 144.6, 137.3, 131.9, 128.0 (2 
carbons), 126.7 (2 carbons), 126.1, 125.2 (2 carbons), 125.0 (2 carbons), 124.3, 118.9, 53.3, 
52.5. 
MS (EI, 70 eV): m/z (%) = 446 (M+, 100), 345 (15), 293 (37), 181 (49), 152 (31). 
HRMS (EI) C19H15IN2O3: calculated [M+]: 446.0127   found: 446.0109. 
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Synthesis of 4-(4-bromo-2,6-dimethoxy-pyrimidin-5-yl)benzonitrile (123q) 
 
NC
N
N
OMe
OMeBr
 
 
Prepared according to GP9 from 4,5-dibromo-2,6-dimethoxypyrimidine (69b) (253 mg, 0.85 
mmol), LiCl (72 mg, 1.5 mmol), zinc dust (110 mg, 1.5 mmol, 1.5 equiv, <10 micron, 98+%, 
Aldrich), BrCH2CH2Br (5 mol%), Me3SiCl (2 mol%). Insertion condition: 25 °C, 12 h; 
reaction with electrophile: In a flame-dried round bottom flask was charged with Pd(dba)2 (24 
mg, 5 mol%), P(o-furyl)3 (20 mg, 10 mol%) and THF (1 mL). The mixture was stirred at 25 
oC for 10 min then transferred to the reaction flask which was charged with organozinc 
solution 122q. 4-Iodobenzonitrile (234 mg, 1.2 equiv, 1.02 mmol). The reaction mixture was 
refluxed for 2 h. Purification by flash chromatography (SiO2, pentane/ Et2O = 3:2) afforded 
123q (234 mg, 86%) as a white solid. 
mp.: 149.1-150.6 oC 
IR (KBr): ν (cm-1) = 2228 (w), 1587 (m), 1531 (m), 1460 (m), 1376 (s), 1324 (m), 1196 (m), 
1094 (m), 1019 (m), 992 (m), 936 (m), 832 (m), 790 (m), 741 (m). 
1H NMR (CDCl3, 300 MHz): δ (ppm) = 7.70 (d, J= 8.6 Hz, 2H), 7.40 (d, J= 8.6 Hz, 2H), 
4.04 (s, 1H), 3.92 (s, 1H).     
13C NMR (CDCl3, 75 MHz): δ (ppm) = 168.6, 163.4, 152.3, 138.4, 132.0, 131.3, 118.6, 
115.6, 112.1, 104.7, 55.6, 55.1. 
MS (EI, 70 eV): m/z (%):  321 (M+, 100), 304 (12), 289 (28), 240 (18), 225 (24), 210 (29), 
189 (23), 168 (16), 140 (38).  
HRMS (EI): C13H10N381Br: calculated [M+]: 318.9936    found: 320.9911. 
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